
Comprehensive Evaluation of the Implementation of the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property (Report Annexes)

Corporate evaluation commissioned
by the WHO Evaluation Office

CONTENTS

| | |
|--|----|
| CONTENTS | ii |
| Annex 1 DETAILED RESULTS FROM SURVEYS..... | 3 |
| Annex 2 PARTICIPATION OF STAKEHOLDERS | 56 |
| Annex 2.1: Participation of WHO Member States in the evaluation | 56 |
| Annex 2.2 Other stakeholders who contributed to the evaluation (Surveys, key informant interviews etc.) | 57 |
| Annex 2.3 Web based public survey Participants | 58 |
| Annex 2.4 Country case studies (Key informant interviews, surveys and focus group discussions) | 59 |
| Annex 3 LIST OF DOCUMENTS | 61 |
| Annex 4 DATA ANALYSIS STRUCTURE AND TEMPLATE | 80 |
| Annex 4.1 Data Analysis Structure | 80 |
| Annex 4.2 Data Analysis Template | 82 |
| Annex 5 STAKEHOLDER PROFILE..... | 83 |
| 5.1 Coding References..... | 83 |
| 5.2 Sources of Data | 85 |
| Annex 6 LIST OF EVALUATION CRITERIA AND QUESTIONS..... | 86 |

Annex 1 DETAILED RESULTS FROM SURVEYS

The graphs in this section illustrate the responses to the survey for the question indicated weighted against the Likert scale and separated by Stakeholder Groups.

Beside the Yes / No questions (closed questions), the stakeholders were asked, among others, to rate the extent which their country or organization implemented elements, sub-elements and specific activities of the GSPOA. A choice of four different responses was offered ranging from not at all (scored here 1) or to some extent (scored 2), through to a fair extent (scored 3) and to a great extent (scored 4). The results (Stakeholder Groups averages of scores related to each choice) are shown in the graphs below.

The stakeholder groups have been merged into the following four Macro-level Groups, according to GSPOA document:


- **Governments of Member States** (split according to the four World Bank income levels)
- **WHO**
- **Other International Intergovernmental Organizations (OIIO)** (i., e., ILO, IOM, OECD, UNCTAD, UNITAID, UNEP, UNIDO, WIP, WIPO, WTO)
- **Other Relevant Stakeholders (ORS)** (i., e., Civil Society (Academia, Charitable Orgs, Communities), NGOs, Regulatory Organisations, Regional Organisations, Health-related industries and Private Sector, National R&D institutions, International Research Associations, Donor Agencies, Development Partners, Public Private Partnership (PPP), Product Development Partnerships, R&D Groups, Publishers

Some sub-elements and specific activities are not relevant to some of these groups, so they are not represented in the related graphs.


Element 1: Prioritizing Research and Development Needs

Indicators

Graph 1- Has your country or organization produced, published and disseminated a report on R&D gaps, including health consequences of these gaps in (other) developing countries? [1.1.1]




Graph 2-- Has your country or organization prepared a plan for the national health-related R&D capacity-building that prioritizes research and development based on identified public health needs and R&D gaps? [1.1.2]




Graph 3 - Has your organization or country published a consensus report on global research needs and priorities for a disease or type of intervention? [1.1.3]


Statements regarding developed countries' health-related R&D policies.




Graph 4 - Do health R&D policies of developed countries reflect the health needs of developing countries? [1.2.1]



Graph 5 - Are there any gaps in research on Type II and III diseases and on specific R&D needs of Type I diseases? [1.2.2]




Graph 6 - To what extent do developed countries have a good understanding of the health needs of developing countries? [1.2.3]




Sub-Element 1.1 - Prioritization of R&D Needs


Graph 7 - To what extent did your country help to map global R&D on diseases that disproportionately affect (other) developing countries? [1.3.1]




Graph 8 - To what extent did your country help to develop methodologies and mechanisms to identify gaps in research on Type II and III diseases? [1.3.2]




Graph 9 - To what extent did your organization or country help to identify (other) developing countries' specific R&D needs in relation to Type I diseases? [1.3.3]




Graph 10 - To what extent did your country or organization disseminate information on identified gaps? [1.3.4]




Graph 11 - To what extent did your country evaluate the gaps on public health? [1.3.5]



Graph 12 To what extent did your country or organization provide an assessment at the NATIONAL LEVEL of identified gaps to guide research aimed at developing affordable and therapeutically sound products to meet public health needs? [1.3.6]




Graph 13 - To what extent did your country or organization provide an assessment at the REGIONAL LEVEL of identified gaps to guide research aimed at developing affordable and therapeutically sound products to meet public health needs? [1.3.7]




Graph 14 - To what extent did your country or organization provide an

assessment at the INTERNATIONAL LEVEL of identified gaps to guide research aimed at developing affordable and therapeutically sound products to meet public health needs? [1.3.8]




Sub-Element 1.2 - Prioritized explicit R&D strategies


Graph 15 - To what extent did your country formulate explicit prioritized strategies for research and development at country level? [1.4.1]




Graph 16 - To what extent did your country formulate explicit prioritized strategies for research and development at country level? [1.4.2]




Graph 17 - To what extent did your country formulate explicit prioritized strategies for research and development at the INTERNATIONAL level? [1.4.3]




Graph 18 - To what extent did your country set research priorities to address public health needs? [1.4.4]




Graph 19 - To what extent did your country implement public health policy based on appropriate and regular needs assessments? [1.4.5]




Graph 20 - To what extent did your country conduct research appropriate for resource-poor settings? [1.4.6]




Graph 21 - To what extent did your country conduct research on technologically appropriate products for addressing public health needs to combat diseases in (other) developing countries? [1.4.7]




Graph 22 - To what extent did your country or organization include research and development needs on health systems in a prioritized strategy? [1.4.8]




Graph 23 - To what extent did your country urge the leadership and commitment of GOVERNMENTS in determining priorities for research and development to address public health needs? [1.4.9]




Graph 24 - To what extent did your country or organization urge the leadership of REGIONAL organizations in determining priorities for research and development to address public health needs? [1.4.10]




Graph 25 - To what extent did your country or organization urge the leadership and commitment of INTERNATIONAL organizations in determining priorities for research and development to address public health needs? [1.4.11]




Graph 26 - To what extent did you urge the PRIVATE SECTOR in determining priorities for research and development to address public health needs? [1.4.12]



Graph 27 - To what extent did your country increase overall research and development efforts on diseases that disproportionately affect the (other) developing countries? [1.4.13]




Graph 28 - To what extent did these efforts lead to the development of quality products that address public health needs that are user friendly (in terms of use, prescription and management) and accessible (in terms of availability and affordability)? [1.4.14]




Sub-Element 1.3 - Encouraging R&D into traditional med


Graph 29 - To what extent did your country encourage R&D in traditional medicine in accordance with national priorities and legislation? [1.5.1]




Graph 30 - To what extent did your country take into account the relevant international instruments, including, as appropriate, those concerning traditional knowledge and the rights of indigenous peoples? [1.5.2]



Graph 31 - To what extent did your country or organization set research priorities in traditional medicine? [1.5.3]




Graph 32 - To what extent did your country or organization support (other) developing countries to build their capacity in research and development in traditional medicine? [1.5.4]




Graph 33 - To what extent did your country or organization promote international cooperation and the ethical conduct of research? [1.5.5]



Graph 34 - To what extent did your country or organization support South-South cooperation in information exchange and research activities? [1.5.6]




Graph 35 - To what extent did your country or organization support early-stage drug research and development in traditional medicine systems in (other) developing countries? [1.5.7]




Element 2: Promoting Research and Development

Indicators


Graph 36 - Does the national strategic plan of your country or organization for the health workforce and related professionals include a research and development component? [2.1.1]




Graph 37 - To what extent has your country or organization created or strengthened national initiative(s) on health-related research and development, including between public and private entities? [2.1.2]



Graph 38 - To what extent has your country or organization created or strengthened initiatives aimed at providing efficient and affordable access to publications and information such as research knowledge, results and technology? [2.1.3]




Graph 39 - To what extent have the new or strengthened initiatives aimed at enhancing capacities to analyse and manage clinical trial data been successful? [2.1.4]




Statement Regarding: Innovation capacity


Graph 40 - To what extent do the political institutions participate in the development of health research policy? [2.2.1]




Graph 41 - To what extent do the economic institutions participate in the development of health research policy? [2.2.2]




Graph 42 - To what extent do the social institutions participate in the development of health research policy? [2.2.3]




Graph 43 - How has the range of measures to promote, coordinate and finance public and private research into Type II and Type III diseases changed during 2008-2015? [2.2.4]




Graph 44 - To what extent were the measures to promote, coordinate and finance public research into Type II and Type III diseases enhanced? [2.2.5]




Graph 45 - To what extent were the measures to promote, coordinate and finance private research into Type II and Type III diseases enhanced? [2.2.6]




Graph 46 - To what extent has the range of measures to promote, coordinate and finance public and private research into the needs of (other) developing countries in relation to Type I diseases been enhanced? [2.2.7]



Graph 47 - To what extent have the levels of investment into health research increased during 2008-2015? [2.2.8]




Graph 48 - To what extent has your country or organization supported the development or improvement of national health research programmes? [2.2.9]




Sub-Element 2.1 - Promotion of R&D in health


Graph 49 - To what extent has your country or organization established, where appropriate, strategic research networks to facilitate better coordination of stakeholders in R&D? [2.3.1]




Graph 50 - To what extent has your country or organization promoted cooperation between private and public sectors on research and development? [2.3.2]




Graph 51 - To what extent has your organization provided support for national health research programmes in (other) developing countries through political action? [2.3.3]



Graph 52 - To what extent has your country provided support for national health research programmes in developing countries through long-term funding? [2.3.4]



Graph 53 - To what extent has your organization or a country supported governments in establishing health-related innovation initiatives in (other) developing countries? [2.3.5]




Sub-Element 2.2 - Promoting upstream research and product development in developing countries


Graph 54 - To what extent has your country or organization promoted upstream research in (other) developing countries? [2.4.1]




Graph 55 - To what extent has your country or organization promoted product development in (other) developing countries? [2.4.2]




Graph 56 - To what extent has your organization or country supported discovery science, i.e through voluntary open-source methods, in order to assist (other) developing countries? [2.4.3]




Graph 57 - To what extent has your organization or country promoted and improved access to compound libraries through voluntary means for the representatives from the (other) developing countries? [2.4.5]




Graph 58 - To what extent does your organization or country provide technical support to (other) developing countries for conducting upstream research and product development? [2.4.6]




Graph 59 - To what extent does your organization or country promote access of (other) developing countries to drug leads identified through the screening of compound libraries? [2.4.7]




Graph 60 - To what extent has your organization or country identified barriers, including intellectual property-related provisions, that might affect increased research on public health in (other) developing countries? [2.4.8]




Graph 61 - To what extent has your organization or country suggested ways to facilitate access to research results and tools for the (other) developing country representatives? [2.4.9]




Graph 62 - To what extent has your organization or country supported basic and applied scientific research on Type II and Type III diseases? [2.4.10]




Graph 63 - To what extent has your organization or country supported basic and applied scientific research on the specific research and development needs of (other) developing countries in relation to Type I diseases? [2.4.11]




Graph 64 - To what extent has your organization or country supported early-stage drug research and development in (other) developing countries? [2.4.12]




Graph 65 - To what extent has your country or organization built capacity to conduct clinical trials and other mechanisms for stimulating innovation, taking into account international ethical standards and the needs of (other) developing countries? [2.4.13]



Graph 66 - To what extent has your country or organization promoted public and other sources of funding for clinical trials and other mechanisms for stimulating local innovation, meeting international ethical standards and the needs of (other) developing countries? [2.4.14]




Graph 67 - To what extent has your country or organization promoted new knowledge and technologies to facilitate the development of new health products and medical devices to tackle the health problems of (other) developing countries? [2.4.15]




Sub-Element 2.3 - Health and biomedical R&D


Graph 68 - To what extent has your country or organization improved cooperation, participation and coordination of health and biomedical R&D with (other) developing countries? [2.5.1]




Graph 69 - To what extent has your country or organization stimulated and improved global cooperation and coordination in research and development, in order to optimize resources? [2.5.2]




Graph 70 - To what extent has your country or organization enhanced existing forums in order to improve the coordination and sharing of information on research and development activities? [2.5.3]




Graph 71 - To what extent has your country or organization examined the need for new mechanisms in order to improve the coordination and sharing of information on research and development activities? [2.5.4]




Graph 72 - To what extent has your country or organization encouraged further exploratory discussions on the utility of possible instruments for essential health and biomedical research and development? [2.5.5]



Graph 73 - To what extent has your country or organization supported active participation of (other) developing countries in building technological capacity? [2.5.7]




Graph 74 - To what extent has your country or organization promoted the active participation of (other) developing countries in the innovation process? [2.5.8]




Sub-Element 2.4 - Promoting greater access to knowledge and technology relevant to meet public health needs of developing countries


Graph 75 - To what extent has your country or organization been promoting greater access to knowledge in order to meet public health needs of (other) developing countries? [2.6.1]




Graph 76 - To what extent has your country or organization been promoting greater access to relevant technology in order to meet public health needs of (other) developing countries, during 2008-2015? [2.6.2]




Graph 77 - To what extent has your country or organization been promoting the creation and development of accessible public health libraries in order to enhance availability and use of relevant publications by universities, institutes and technical centres, especially in (other) developing countries? [2.6.3]




Graph 78 - To what extent has your organization or country promoted public access to the results of government-funded research? [2.6.4]



Graph 79 - To what extent has your organization or a country encouraged all government-funded researchers to submit an electronic version of their final, peer-reviewed manuscripts to an open access database? [2.6.5]




Graph 80 - To what extent has your country or organization been supporting the creation of voluntary open databases and compound libraries? [2.6.6]




Graph 81 - To what extent has your country or organization been supporting the access to drug leads identified through the screening of compound libraries? [2.6.7]




Graph 82 - To what extent has your country or organization encouraged the development and dissemination of medical inventions and know-how through appropriate licensing policies that enhance access to innovations for development of products relevant to the public health needs of (other) developing countries? [2.6.8]



Graph 83 - To what extent has your country or organization encouraged the development and dissemination of medical inventions and know-how in the form of open licensing that enhance access to innovations for development of products of relevance to the public health needs of (other) developing countries on reasonable, affordable and non-discriminatory terms? [2.6.9]




Graph 84 - To what extent has your country considered, where appropriate, the use of a research exemption to address public health needs in (other) developing countries consistent with the Agreement on Trade- Related Aspects of Intellectual Property Rights? [2.6.10]




Sub-Element 2.5 - National and regional coordinating bodies on R&D

Graph 85 - To what extent has your country or organization strengthened national and regional coordinating bodies on research and development? [2.7.1]




Graph 86 - To what extent has your country or organization developed and coordinated an R&D agenda with other countries? [2.7.2]



Element 3: Building and Improving Innovative Capacity Indicators


Graph 87 - To what extent do the national health research systems in your country or organization meet international standards? [3.1.2]




Graph 88 - To what extent have your national regulatory authorities been assessed, supported and accredited? [3.1.3] [Level Assessed]




Graph 89 - To what extent have your national regulatory authorities been assessed, supported and accredited? [3.1.3] [Level Supported]




Graph 90 - To what extent have your national regulatory authorities been assessed, supported and accredited? [3.1.3] [Level Accredited]




Graph 91 - Have any new global quality and ethical standards or other tools been created or updated in your country or organization during 2008-2015, in order to promote the quality and effective regulation of health products, such as vaccines, diagnostics and medicines, and technologies? [3.1.4] [Quality standards created or updated]



Graph 92 - Have any new global quality and ethical standards or other tools been created or updated in your country or organization during 2008-2015, in order to promote the quality and effective regulation of health products, such as vaccines, diagnostics and medicines, and technologies? [3.1.4] [Ethical standards created or updated]




Graph 93 - Does your country or organization have a national traditional medicines policy that includes research and development component? [3.1.5]




Statement Regarding: Health innovation capacities in developing countries


Graph 94 - To what extent has your country or organization addressed the need to support effective policies that promote the development of capacities in (other) developing countries related to health innovation? [3.2.1]




Graph 95 - To what extent has your country or organization made investments in the (other) developing countries' capacities relating to science and technology? [3.2.2]




Graph 96 - To what extent has your country or organization made investments in the (other) developing countries' local production of pharmaceuticals? [3.2.3]




Graph 97 - To what extent has your country or organization made investments in the developing countries' clinical trials? [3.2.4]




Graph 98 - To what extent has your country or organization made investments in (other) developing countries' regulation? [3.2.5]



Graph 99 - To what extent has your country or organization made investments in (other) developing countries' intellectual property? [3.2.6]




Graph 100 - To what extent has your country or organization made investments in the (other) developing countries' traditional medicine? [3.2.7]




Sub-Element 3.1 - Capacity to meet R&D needs for health products in developing countries


Graph 101 - To what extent has your country or organization been building capacity of the (other) developing countries to meet research and development needs for health products? [3.3.1]




Graph 102 - To what extent has your country or organization supported investment by (other) developing countries in human resources, especially in education and training, including in public health? [3.3.2]



Graph 103 - To what extent has your country or organization supported existing and new research and development groups and institutions in (other) developing countries? [3.3.3]



Graph 104 - To what extent has your country or organization supported existing and new regional centres of excellence in (other) developing countries? [3.3.4]




Graph 105 - To what extent has your country or organization strengthened health surveillance and information systems? [3.3.5]




Sub-Element 3.2 - Promotion of the development of capacities for health innovation


Graph 106 - To what extent has your country or organization framed, developed and supported effective policies that promote the development of capacities for health innovation, during 2008-2015? [3.4.1]




Graph 107 - To what extent has your country established and strengthened regulatory capacities in (other) developing countries? [3.4.2]




Graph 108 - To what extent has your country strengthened human resources in research and development in (other) developing countries through long-term national capacity-building plans? [3.4.3]




Graph 109 - To what extent has your country or organization encouraged international cooperation to develop effective policies for retention of health professionals, in (other) developing countries? [3.4.5]




Graph 110 - To what extent has your country or organization encouraged international cooperation to develop effective policies for retention of researchers, specifically, in (other) developing countries? [3.4.6]



Graph 111 - To what extent has your country established mechanisms to mitigate the adverse impact of the loss of health personnel and researchers, in (other) developing countries through migration? [3.4.7]




Graph 112 - To what extent has your country supported the strengthening of national health and research systems for human resource development, in the (other) developing countries? [3.4.8]



Sub-Element 3.3 - Supporting the promotion of innovation based on traditional medicine


Graph 113 - To what extent had your country (or organization) provided support for improving innovative capacity in accordance with the needs of (other) developing countries? [3.5.1]




Graph 114 - To what extent has your country (or organization) developed successful health innovation models in accordance with the needs of (other) developing countries? [3.5.2]




Graph 115 - To what extent had your country (or organization) intensified North-South and South-South partnerships to support capacity building in accordance with the needs of (other) developing countries? [3.5.3]



Graph 116 - To what extent has your country (or organization) established and strengthened mechanisms for ethical review in the research and development process in (other) developing countries? [3.5.4]




Graph 117 - To what extent has your country (or organization) established and strengthened mechanisms for ethical review in the clinical trials in (other) developing countries? [3.5.5]




Sub-Element 3.4 - Developing and implementing incentives for health-related innovation


Graph 118 - To what extent has your country or organization supported policies that will promote innovation based on traditional medicine within an evidence-based framework? [3.6.1]




Graph 119 - To what extent has your country established and strengthened national policies to develop, support and promote traditional medicine? [3.6.2]



Graph 120 - To what extent has your country established and strengthened regional policies to develop, support and promote traditional medicine? [3.6.3]



Graph 121 - To what extent has your country promoted policies on innovation in the field of traditional medicine? [3.6.4]




Graph 122 - To what extent has your country or organization promoted standard setting to ensure the quality, safety and efficacy of traditional medicine? [3.6.5]




Graph 123 - To what extent has your country or organization encouraged research on mechanisms for action and pharmacokinetics of traditional medicine? [3.6.7]




Graph 124 - To what extent has your country promoted South-South collaboration in traditional medicine? [3.6.8]



Graph 125 - To what extent has your country or organization formulated and disseminated guidelines on good manufacturing practices for traditional medicines? [3.6.9]




Graph 126 - To what extent did your country or organization lay down evidence-based standards for quality and safety evaluation in manufacturing of traditional medicines? [3.6.10]




Sub-Element 3.5 - Developing and implementing incentives for health-related innovation


Graph 127 - To what extent did your country or organization develop and implement incentive schemes for health-related innovation? [3.7.1]



Graph 128 - To what extent did your country or organization encourage the establishment of award schemes for health-related innovation? [3.7.2]




Graph 129 - To what extent did your country recognize innovation for purposes of career advancement for health researchers? [3.7.3]




Element 4: Transfer of Technology

Indicators


Graph 130 - Has your country or organization participated in the creation of regional collaboration initiatives aimed at increasing and facilitating transfer of health-related technology, including between public and private entities? [4.1.3]




Graph 131 - Has your country or organization participated in regional technology transfer initiatives? [4.1.4]



Graph 132 - Has your country or organization participated in the creation of global collaboration initiatives aimed at increasing and facilitating transfer of health-related technology, including between public and private entities? [4.1.5]




Graph 133 - Did your country or organization create technology transfer strategies during 2008-2015 that include health-related technologies and relevant capacity-building components? [4.1.7]




Statement Regarding: Transfer of technology related to health innovation

Graph 134 - To what extent has your country or organization supported North-South and South-South development cooperation to build and improve transfer of technology related to health innovation? [4.2.1]




Graph 135 - Does your country comply with the Article 7 of the Agreement on Trade-Related Aspects of Intellectual Property Rights, which states that the protection and the enforcement of intellectual property rights should contribute to the promotion of technological innovation and the transfer and dissemination of technology, to the mutual advantage of producers and users of technological knowledge and in a manner conducive to social and economic welfare, and to the balance of rights and obligations? [4.2.2]




Sub-Element 4.1 - Promoting transfer of technology and the production of health products in developing countries


Graph 136 - To what extent has your country or organization promoted production of health products in the (other) developing countries through technology transfer? [4.3.1]




Graph 137 - To what extent has your country or organization created new mechanisms to facilitate transfer of technology and technical support to build and improve innovative capacity for health-related R&D in the (other) developing countries? [4.3.2]




Graph 138 - To what country or organization has your country made a better use of existing mechanisms to facilitate transfer of technology and technical support to build and improve innovative capacity for health-related R&D in (other) developing countries? [4.3.3]



Graph 139 - To what extent has your country or organization promoted transfer of technology in (other) developing countries through investment and capacity building? [4.3.4]




Graph 140 - To what extent has your country or organization identified the best practices (good practices) in technology transfer in the field of health related R&D? [4.3.5]




Sub-Element 4.2 - Technology transfer for health products


Graph 141 - To what extent has your country or institution participated in North-South collaboration between the developing countries and the pharmaceutical industries? [4.4.2]




Graph 142 - To what extent has your country or organization participated in South-South collaboration between the developing countries and the pharmaceutical industries? [4.4.3]




Graph 143 - To what extent has your country or organization facilitated local networks for collaboration on R&D and transfer of technology? [4.4.4]




Graph 144 - To what extent has your country or organization facilitated regional networks for collaboration on R&D and transfer of technology? [4.4.5]



Graph 145 - To what extent has your country promoted technology transfer to least developed country members of WTO (consistent with Article 66.2 of the Agreement on Trade-Related Aspects of Intellectual Property Rights)? [4.4.6]




Graph 146 - To what extent has your country or organization promoted the necessary training to increase absorptive capacity for technology transfer? [4.4.7]




Sub-Element 4.3 - Transfer of, and access to, key health-related technologies


Graph 147 - To what extent has your country or institution developed new mechanisms to promote access to key health-related technologies? [4.5.1]




Graph 148 - To what extent has your country or institution examined feasibility of voluntary patent pools of upstream and downstream health-related technologies? [4.5.2]



Graph 149 - To what extent has your country or organization promoted the (other) developing countries' access to technologies related to Type II and III diseases? [4.5.3]




Graph 150 - To what extent has your country or organization promoted the (other) developing countries' access to the specific R&D needs related to Type I diseases? [4.5.5]




Element 5: Application and Management of intellectual Property to Contribute to Innovation and Promote Public Health

Indicators


Graph 151 To what extent has your country or organization been engaged in initiatives to strengthen the capacities to manage and apply intellectual property rights in order to contribute to innovation and promote public health? [5.1.1]




Graph 152 In the previous question, how effective was this measure?




Graph 153 To what extent has your country or organization been supporting efforts to strengthen capacities in the management and application of Intellectual Property rights in a manner oriented to public health needs of (other) developing countries? [5.1.2]




Graph 154 In the previous question, how effective was this measure?




Graph 155 To what extent has your country or organization been integrating flexibilities for protection of public health of the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights into national legislation? [5.1.3]



Graph 156 In the previous question, to what extent were the base data/norms on which action was based known and applied?




Graph 157 In question E193 (above), how effective was this measure?



Graph 158 To what extent has your organization participated in initiatives aimed at coordinating work relating to intellectual property and public health? [5.1.4]




Graph 159 In the previous question, how effective was this measure?




Statement Regarding: Incentives for the development of new health products


Graph 160 Have the international regulations on Intellectual Property created incentives to develop new health products in your country? [5.2.1]




Graph 161 In the previous question, how effective was this measure?




Graph 162 To what extent have the international incentive schemes for research and development on Type II and Type III diseases been explored and implemented in your country? [5.2.2]




Graph 163 In the previous question, how effective was this measure?




Graph 164 To what extent has your country or organization explored and implemented the international incentive schemes for R&D needs of (other) developing countries in respect of Type I diseases?[5.2.3]




Graph 165 In the previous question, how effective was this measure?




Graph 166 To what extent has your country or organization strengthened innovation capacity in (other) developing countries? [5.2.4]




Graph 167 In the previous question, how effective was this measure?




Graph 168 To what extent has your country or organization assisted to manage and apply intellectual property in (other) developing countries? [5.2.5]




Graph 169 In the previous question, how effective was this measure?



Graph 170 To what extent has your country or organization complied with the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights and instruments related to that agreement, which provide flexibilities to take measures to protect public health? [5.2.6]




Graph 171 In the previous question, how effective was this measure?




Sub-Element 5.1 - Information sharing and capacity building of health-related IP management in developing countries


Graph 172 To what extent has your country or organization shared information and built capacity in the field of Intellectual Property with respect to the promotion of public health in (other) developing countries? [5.3.1]




Graph 173 In the previous question, how effective was this measure?




Graph 174 To what extent has your country or organization shared information and built capacity in the field of Intellectual Property with respect to health-related innovation? [5.3.2]




Graph 175 In the previous question, how effective was this measure?




Graph 176 To what extent has the application and management of Intellectual Property maximized health-related innovation and promoted access to health products? [5.3.3]




Graph 177 In the previous question, how effective was this measure?




Graph 178 To what extent has the application and management of Intellectual Property met the specific R&D needs of (other) developing countries? [5.3.4]




Graph 179 To what extent has your country or organisation supported international efforts to manage and apply intellectual property in the (other) developing countries? [5.3.5]




Graph 180 In the previous question, how effective was this measure?




Graph 181 To what extent has your organization or country facilitated widespread access to administrative status of health-related patents? [5.3.6]




Graph 182 In the previous question, how effective was this measure?




Graph 183 To what extent has your organization or country stimulated collaboration between national institutions and government departments to promote information sharing relevant to public health needs? [5.3.7]




Graph 184 In the previous question, how effective was this measure?




Graph 185 To what extent has your organization or country stimulated collaboration between regional institutions and government departments to promote information sharing relevant to public health needs? [5.3.8]




Graph 186 In the previous question, how effective was this measure?




Graph 187 To what extent has your organization or country stimulated collaboration between global institutions and government departments to promote information sharing relevant to public health needs? [5.3.9]




Graph 188 In the previous question, how effective was this measure?




Graph 189 To what extent has your country or organization strengthened education and training in the application and management of Intellectual Property from a public health perspective? [5.3.10]




Graph 190 In the previous question, how effective was this measure?




Graph 191 To what extent has the provided training and education taken into account in the provisions contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights including the flexibilities recognized by the Doha Declaration on the TRIPS Agreement and Public Health and other WTO instruments related to the Agreement on Trade-Related Aspects of Intellectual Property Rights? [5.3.11]




Graph 192 In the previous question, how effective was this measure?




Graph 193 To what extent has your organization or country facilitated access to traditional medicinal knowledge for use as prior art in examination of patents? [5.3.12]




Graph 194 In the previous question, how effective was this measure?




Graph 195 In the previous question, how effective was this measure?




Graph 196 In the previous question, how effective was this measure?




Graph 197 In the previous question, how effective was this measure?




Graph 198 In the previous question, how effective was this measure?




Graph 199 To what extent has your country or institution coordinated work related to Intellectual Property and public health among the secretariats and governing bodies of relevant regional organizations to disseminate information to countries? [5.3.15]




Graph 200 In the previous question, how effective was this measure?



Graph 201 To what extent has your country or institution coordinated work related to Intellectual Property and public health among the secretariats and governing bodies of relevant international organizations to disseminate information to countries? [5.3.16]




Graph 202 In the previous question, how effective was this measure?




Sub-Element 5.2 - Providing technical support to countries regarding IP agreements


Graph 203 To what extent has your country or institution provided technical support to countries that intend to make use of the provisions contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights, in order to promote access to pharmaceutical products? [5.4.1]




Graph 204 To what extent has your country or institution provided technical support to policy processes to the countries that intend to make use of the provisions contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights, in order to promote access to pharmaceutical products? [5.4.2]




Graph 205 Has your country adapted national legislation to fully use the flexibilities contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights, including those recognized by the Doha Declaration on the TRIPS Agreement and Public Health and the WTO decision of 30 August 2003? [5.4.3]




Graph 206 To what extent has your country or organization taken into account the impact on public health when adopting or implementing more extensive Intellectual Property protection than is required by the Agreement on Trade-Related Aspects of Intellectual Property Rights? [5.4.4]




Graph 207 To what extent has your country taken into account in trade agreements the flexibilities contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights? [5.4.5]




Graph 208 Does your country have manufacturing capacity? [5.4.6A]



Graph 209 If your country has manufacturing capacity, to what extent has your country taken necessary measures to facilitate, through export, access to pharmaceutical products in countries with insufficient or no manufacturing capacity in the pharmaceutical sector in a manner consistent with the Agreement on Trade-Related Aspects of Intellectual Property Rights? [5.4.6B]




Graph 210 To what extent has your country or institution considered legislative measures to help to prevent misappropriation of health-related traditional knowledge? [5.4.7]




Sub-Element 5.3 - Promoting possible R&D incentive schemes


Graph 211 To what extent has your country or institution promoted possible incentive schemes for R&D on Type II and Type III diseases? [5.5.1]




Graph 212 To what extent has your country or institution promoted possible incentive schemes for R&D on (other) developing countries specific research and development needs in relation to Type I diseases? [5.5.2]



Graph 213 To what extent has your country or organization promoted possible incentive schemes for R&D on Type II and Type III diseases? [5.5.3]



Graph 214 To what extent has your country or organization promoted possible incentive schemes for R&D on developing countries' specific research and development needs in relation to Type I diseases? [5.5.4]



Graph 215 To what extent has your country or organization promoted a range of incentive schemes for delinking of the costs of R&D and the price of health products, for example through the award of prizes, with the objective of addressing diseases that disproportionately affect (other) developing countries? [5.5.5]



Graph 216 In summary, to what extent have the application and management of intellectual property contributed to innovation and the promotion of public health? [5]



Element 6: Improving Delivery and Access

Indicators


Graph 217 Has your country formulated official national policies on access, quality and use of essential medical products and technologies, during 2008-2015? [6.1.1]




Graph 218 Is your country implementing its official national policies on access, quality and use of essential medical products and technologies? [6.1.2]




Graph 219 Has your country designed or strengthened new comprehensive national procurement and supply systems? [6.1.3]




Graph 220 Does your country possess national strategic plans for the health workforce and related professionals including policies and management practices on incentives, regulation and retention? [6.1.6]




Graph 221 Is your country fully implementing its national strategic plans for the health workforce and related professionals, including policies and management practices on incentives, regulation and retention? [6.1.7]



Graph 222 Does your country have an adequate number of qualified or trained health-related regulatory professionals? [6.1.8]




Graph 223 To what extent are there gaps in staffing in some specific areas of specialization? [6.1.9]




Statements Regarding: Competition, pricing, and taxation of health products


Graph 224 To what extent are the pricing and taxation policies for health products in your country appropriate in order to guarantee strong health systems? [6.2.1]




Graph 225 To what extent is there competition in the field of health products in your country? [6.2.2]




Graph 226 To what extent are there functioning mechanisms to regulate the safety, quality and efficacy of medicines and other health products? [6.2.3]




Graph 227 To what extent does your country adhere to good manufacturing practices and effective supply chain management? [6.2.4]



Graph 228 To what extent has your country monitored the International agreements that have an impact on access to health products in developing countries, with respect to their development and application? [6.2.5]




Graph 229 To what extent has your country or organization monitored the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights and of the Doha Declaration on the TRIPS Agreement and Public Health that permit improved access? [6.2.6]




Sub-Element 6.1 - Increased investment in the health delivery infrastructure and financing of health products


Graph 230 To what extent has your country increased investment in the health delivery infrastructure in order to strengthen the health system? [6.3.1]




Graph 231 To what extent has your country financed health products in order to strengthen the health system? [6.3.2]




Graph 232 To what extent has your country or organization invested in developing health delivery infrastructures? [6.3.3]




Graph 233 To what extent have your country developed effective and sustainable mechanisms in the least developed countries (LDCs) in order to improve access to existing medicines, acknowledging the transitional period until 2016? [6.3.4]




Graph 234 To what extent has your country prioritized health care in national agendas? [6.3.5]




Graph 235 To what extent has your country or organization developed strategies to promote rational use of medicines? [6.3.7]




Graph 236 To what extent has the investment by your country or organization in human resource development changed in the health sector? [6.3.8]



Graph 237 To what extent has your country developed effective country poverty reduction strategies that contain clear health objectives? [6.3.9]




Graph 238 To what extent has your country or organization pooled procurement mechanisms for health products and medical devices? [6.3.10]




Sub-Element 6.2 - Regulation of health products and medical devices


Graph 239 To what extent are the mechanisms to improve ethical review and regulate the quality, safety and efficacy of health products and medical devices established and strengthened in your country or organization? [6.4.1]




Graph 240 To what extent has your country or organization developed and/or strengthened the capacity of national regulatory authorities to monitor the quality, safety and efficacy of health products? [6.4.2]




Graph 241 To what extent has your country or organization sustained ethical review standards? [6.4.3]




Graph 242 To what extent has your country or organization promoted operational research to maximize the appropriate use of new and existing products? [6.4.4]




Graph 243 To what extent has your country or organization promoted operational research to maximize the appropriate use of cost- effective and affordable products? [6.4.5]




Graph 244 To what extent has your country or organization promoted operational research in settings with a high disease burden? [6.4.6]




Graph 245 To what extent has your country or organization complied with good manufacturing practices for safety standards, efficacy and quality of health products? [6.4.7]




Graph 246 To what extent has your organization or a country strengthened the WHO prequalification programme? [6.4.8]




Graph 247 To what extent has your country or organization harmonized the processes by the regulatory authorities for drug marketing approvals? [6.4.9]




Graph 248 To what extent has your country or organization promoted ethical principles for clinical trials involving human beings as a requirement of registration of medicines and health-related technologies? [6.4.10]



Graph 249 To what extent has your country or organization made reference to the Declaration of Helsinki, and other appropriate texts, on ethical principles for medical research involving human subjects, including good clinical practice guidelines? [6.4.11]




Graph 250 To what extent has your country or organization supported collaborative efforts to strengthen the regulation and implementation of clinical trials using appropriate standards for evaluation and approval of medicines? If so, please describe. [6.4.12]




Sub-Element 6.3 - Improve availability and affordability of needed health products


Graph 251 To what extent has your country or organization promoted competition to improve availability and affordability of health products consistent with public health policies and needs? [6.5.1]




Graph 252 To what extent has your country supported the production and introduction of generic versions of essential medicines, in developing countries? [6.5.2]




Graph 253 To what extent has your country developed national legislation and/ or policies that encourage generic production and entry, including a regulatory exception² or Bolar-type provision, and that are consistent with the Agreement on Trade-Related Aspects of Intellectual Property Rights and instruments related to that agreement? [6.5.3]




Graph 254 To what extent has your country or organization framed policies to improve access to safe and effective essential medicines at affordable prices, consistent with international agreements? [6.5.4]




Graph 255 To what extent has your country or organization implemented policies to improve access to safe and effective essential medicines at affordable prices, consistent with international agreements? [6.5.5]



Graph 256 To what extent has your country reduced or eliminated import tariffs on health products and medical devices during 2008-2015? [6.5.6]




Graph 257 To what extent has your country monitored supply and distribution chains and procurement practices to minimize cost and increase access? [6.5.7]




Graph 258 To what extent has your country or organization encouraged pharmaceutical companies and health-related industries to consider policies, including differential pricing policies, that are conducive to promoting access to quality, safe, efficacious and affordable health products in developing countries, consistent with national law? [6.5.8]




Graph 259 To what extent has your country improved affordability of health products? [6.5.10]




Graph 260 To what extent has your country supported WHO's ongoing work on pharmaceutical pricing? [6.5.11]




Graph 261 To what extent has your country prevented the abuse of Intellectual Property rights by right holders? [6.5.12]




Graph 262 To what extent has your country restrained trade or affected the international transfer of technology, in the field of health products? [6.5.13]



Graph 263 To what extent has your country or organization increased information among policy-makers, users, doctors and pharmacists regarding generic products? [6.5.14]



Graph 264 In summary, to what extent have delivery and access been improved? [6]




Element 7: Promoting Sustainable Financing Mechanisms

Indicators

Graph 265 Has your country or organization, during 2008-2010, submitted reports of expert working group on R&D and financing? [7.1.1]




Graph 266 To which extent has the sustainable health-related R&D funding increased during 2008-2015? [7.1.3]




Statement Regarding: Financing to make health products available in developing countries


Graph 267 To what extent has your country or organization secured further funding on a sustainable basis to support a long-term R&D effort for products to meet the health needs of (other) developing countries? [7.2.1]



Graph 268 Has your country or organization identified and analyzed the most serious gaps in financing for health products and R&D to meet the health needs of (other) developing countries? [7.2.2]




Graph 269 To what extent has your organization or country made maximum use of, or complemented the current initiatives - thereby contributing to the flow of resources into innovation and implementation? [7.2.3]




Sub-Element 7.1 - Secure adequate and sustainable financing for R&D, and improve coordination of its use


Graph 270 To what extent has your country or organization secured adequate financing for R&D in order to address the health needs of (other) developing countries? [7.3.1]




Graph 271 To what extent has your country or organization improved coordination of the use of R&D financing in order to address the health needs of (other) developing countries? [7.3.2]




Graph 272 To what extent has your country or organization established a results-oriented and time-limited expert working group under the auspices of WHO to examine current financing and coordination of research and development? [7.3.3]




Graph 273 To what extent has your country or organization linked this expert working group with other relevant groups to examine current financing and coordination of research and development? [7.3.4]



Graph 274 To what extent has your country or organization created proposals for new and innovative sources of financing to stimulate R&D related to Type II and Type III diseases? [7.3.5]




Graph 275 To what extent has your country or organization created proposals for new and innovative sources of financing to address the specific research and development needs of developing countries in relation to Type I diseases? [7.3.6]




Graph 276 To what extent has your country considered channeling additional funds to health-oriented research organizations, in both the private and public sector of developing countries? [7.3.7]



Graph 277 To what extent has your country promoted good financial management to maximize the effectiveness of these health-oriented research organizations, in both the private and public sector of (other) developing countries (as recommended by resolution WHA58.34)? [7.3.8]




Graph 278 Has your country or organization created a database of possible sources of financing for R&D? [7.3.9]




Sub-Element 7.2 - Maximize use of financing


Graph 279 To what extent has your country or organization facilitated the maximum use of existing financing in order to develop and deliver safe, effective and affordable health products and medical devices? [7.4.1]




Graph 280 To what extent has your country or organization used financing through public private and product development partnerships to develop and deliver safe, effective and affordable health products and medical devices? [7.4.2]



Graph 281 To what extent has your country or organization documented and disseminated the best (good) practices in public private and product development partnerships? [7.4.3]




Graph 282 To what extent has your country or organization developed tools during 2008-2009 for periodic assessment of performance of public private and product development partnerships? [7.4.4]




Graph 283 To what extent has your country or organization supported public private and product development partnerships in (other) developing countries? [7.4.5]



Graph 284 Has your organization or country supported other appropriate research and development initiatives in (other) developing countries? [7.4.6]




Graph 285 In summary, to what extent have sustainable financing mechanisms been promoted? [7]




Element 8: Establishing Monitoring and Reporting Systems

Indicators


Graph 286 Has your country or organization reported regularly on progress towards the implementation of the strategy during 2009-2015? [8.1.1]




Graph 287 To what extent has your country or organization created new or strengthened existing initiatives at national level to promote the implementation of the strategy, during 2009-2015? [8.1.2]




Graph 288 To what extent has your country or organization created new or strengthened existing initiatives at regional level to promote the implementation of the strategy, during 2009-2015? [8.1.3]



Graph 289 To what extent has your country or organization created new or strengthened existing initiatives at global level to promote the implementation of the strategy, during 2009-2015? [8.1.4]



Graph 290 Has your country or organization submitted reports on the compliance with Element 8, during 2009-2015? [8.1.5]




Statement Regarding: Performance and progress monitoring


Graph 291 Has your country or organization been subject to comprehensive evaluation of the strategy, during 2009-2015? [8.2.1]




Graph 292 To what extent has your country or organization measured performance and progress towards objectives contained in the strategy and plan of action, during 2009-2015? [8.2.2]




Graph 293 To what extent has your country or organization, during 2009-2015, established systems to monitor performance and progress of the implementation of each element of the global strategy and plan of action? [8.2.3]




Graph 294 To what extent has your country or organization, during 2009-2015, monitored and reported periodically to WHO's governing bodies on the gaps and needs related to health products and medical devices in your country? [8.2.4]




Graph 295 To what extent has your country or organization monitored the impact of Intellectual Property rights on the development of, and access to, health care products, during 2009-2015? [8.2.5]




Graph 296 To what extent has your country or organization reported on the impact of Intellectual Property rights on the development of, and access to, health care products, to the Health Assembly, during 2009-2015? [8.2.6]




Graph 297 To what extent has your country or organization monitored and reported on the impact of incentive mechanisms on innovation of health products and medical devices, during 2009-2015? [8.2.7]



Graph 298 To what extent has your country or organization monitored and reported on the impact of incentive mechanisms on access to health products and medical devices, during 2009-2015? [8.2.8]



Graph 299 To what extent has your country or organization monitored and reported on investment in research and development to address the health needs of (other) developing countries, during 2009-2015? [8.2.9]



Annex 2 PARTICIPATION OF STAKEHOLDERS

Annex 2.1: Participation of WHO Member States in the evaluation*

| High Income group | Upper Middle Income group |
|--|--|
| Argentina Australia Bahamas Bahrain Brunei Darussalam Canada Chile Czech Republic Estonia Hungary Iceland Japan Netherlands Oman Poland Qatar Russian Federation Seychelles Spain Switzerland Trinidad and Tobago United States of America Venezuela (Bolivarian Republic of) | Belarus Bosnia and Herzegovina Brazil Costa Rica Fiji Jordan Lebanon Maldives Peru Serbia South Africa Thailand |
| Lower Middle Income Group | Low Income Group |
| Bangladesh Bhutan Cameroon Cote d'Ivoire Egypt Guatemala Kiribati Morocco Myanmar Nigeria Philippines Sao Tome and Principe Senegal Sri Lanka Tajikistan Timor-Leste Zambia | Afghanistan Benin Burkina Faso Burundi Democratic Republic of the Congo Haiti Liberia Madagascar Malawi Niger Rwanda South Sudan Togo Uganda United Republic of Tanzania Zimbabwe |

* Countries in **bold** letters are case study countries.

Annex 2.2 Other stakeholders who contributed to the evaluation (Surveys, key informant interviews etc.)

| Stakeholder Group | Offices |
|--------------------|---|
| WHO | Headquarters and Regional Offices |
| WIPO | Headquarters |
| UNCTAD | Headquarters |
| WTO | Headquarters |
| Other Stakeholders | African Union |
| | European Commission |
| | South Centre |
| | UNITAID |
| | Medicines for Malaria Venture |
| | The ASEAN Network for Drugs, Diagnostics, Vaccines and Traditional Medicines Innovation (ASEAN-NDI) |
| | International Federation of the Pharmaceutical Manufacturers & Associations (IFPMA) |
| | European Federation of Pharmaceutical Industries and Associations (EFPIA) |
| | GSK |
| | MERCK |
| | ROCHE |
| | World Federation of Hemophilia |
| | World Hypertension League |
| | Population Council |
| | International Union of Basic and Clinical Pharmacology |
| | World Federation of Occupational Therapists |
| | Pink Ribbon Red Ribbon |
| | Médecins Sans Frontières |

Annex 2.3 Web based public survey Participants

| Country of respondents (Alphabetical order) | Stakeholder groups |
|---|--|
| Afghanistan | Civil society |
| Albania | Academia, Civil society |
| Argentina | Academia, General public |
| Barbados | Government employee |
| Belgium | International research association, Academia |
| Belize | Civil society |
| Canada | Academia, Nongovernmental organization |
| Colombia | Nongovernmental organization |
| Costa Rica | Academia |
| Democratic People's Republic of Korea | Development partner |
| France | Academia |
| Germany | Academia, National Research Institution |
| India | Charitable foundation, National research institution, Nongovernmental organization, General public, Academia, International research association |
| Indonesia | Academia |
| Libya | General public |
| Mali | Nongovernmental organization |
| Mexico | General public |
| Netherlands | Nongovernmental organization, National research institution |
| Nigeria | National research institution, Academia |
| Pakistan | Academia, Drug regulatory authority |
| Portugal | General public |
| Russian Federation | Academia |
| Sierra Leone | Development partner |
| Spain | Civil society |
| Sri Lanka | Academia |
| Switzerland | Private sector, Nongovernmental organization, General public |
| Uganda | Nongovernmental organization |
| United Kingdom | Civil society, Academia |
| United States of America | Academia, Development Partner, International research association, General public |
| Zambia | International research association |

Annex 2.4 Country case studies (Key informant interviews, surveys and focus group discussions)

At the country level, the evaluators met the representatives of the following organizations and stakeholder groups.

| Country | Organization |
|-------------|---|
| Afghanistan | Ministry of Public Health |
| Bangladesh | Bangladesh Directorate General of Drugs Administration, Incepta Pharmaceuticals Ltd, WHO |
| Brazil | Ministry of Health, National & Regional Regulatory Organization, Fiocruz, National Health Surveillance Agency (ANVISA), Médecins Sans Frontières (MSF), Brazilian Network for the Integration of Peoples – REBRIP, FARMABRASIL Group, INTERFARMA. |
| Cameroon | Ministry of Public Health, Ministry of Technology Development and Innovation, Coordinating Organization for the Fight against Endemic Diseases in Central Africa Region (OCEAC), Observatoire Nationale de Santé Publique, Strategic Purchasing for System Performance, Research Foundation for Tropical Diseases and Environment, Health Research for Development Results Group (HEREG), Research Foundation for Health and Development (ReForHD), Research Laboratory 'LRHCS', Groupe Spiral International, UNFPA, WHO Representative's Office. Centre de Recherche sur les Filarioses et autres Maladies Tropicales Négligées, Institut pour la Recherche, le Développement Socio-Economique et de Comportements, Centre Pasteur du Cameroun, Strategic Purchasing for System Performance Monitoring and Evaluation Consulting Group (2SPerMeCG), University of Yaoundé, Organization Catholique pour la Santé au Cameroun, Plan International Cameroon, Clinton Health Initiative Cameroon, Direction de la promotion et de la protection de la famille (MINPROFF), Positive Génération, National Regulatory Organisation, Harmattan and PUCAC Publishers, Catholic University of Central Africa, Leading distributor of pharmaceuticals in Cameroon (LABOREX), Biopharma, National Institute of Medicinal Plants, Universal Health Coverage Network, Municipality Access Initiatives |
| Guatemala | Ministry of Health, National Science and Technology Commission, Institute of Nutrition of Central America and Panama (INCAP), Ministère de l'Enseignement Supérieur de la Recherche Scientifique et de la Formation des Cadres (MESRSFC), Instituto para la Investigación Científica y la Educación Acerca de las Enfermedades Genéticas y Metabólicas Humanas (INVEGEM), PAHO Representative's Office |
| Jordan | Ministry of Health, Ministry of Planning, High Population Council, High Education Council, High Council for Science and Technology, High Health Council, Jordanian Food and Drug Administration, Jordanian Association of Pharmaceutical Manufacturers, ABT Association, Eastern Mediterranean Network for Social Health (EMPHNET), Arabic Society for Protection of Intellectual Rights, WHO Representative's Office. |
| Morocco | Ministry of Health, Ministère de l'Enseignement Supérieur de la Recherche Scientifique et de la Formation des Cadres (MESRSFC), Centre Antipoison et de Pharmacovigilance du Maroc, Sanofi, Novo Nordisk Pharma S.A.S., Les entreprises du médicaments au Maroc (LEMM), WHO Representative's Office |
| Philippines | Department of Health, Food and Drug Administration, Philippine Council for Health Research and Development (PCHRD), Bureau of International Health Cooperation, Health Human Resource Development Bureau, Philippine Institute of Traditional and Alternative Health Care |
| Qatar | Ministry of Public Health, Ministry of Foreign Affairs, Ministry of Economy and Commerce- Intellectual Property Department, Qatar Development Fund, Qatar Foundation, Supreme Council of Health, Weill Cornell Medical College, Hamad Medical Cooperation, Office of technology transfer – Sidra, World Innovation Summit for Health, Qatar Red Crescent |
| Rwanda | Ministry of Health |

| Country | Organization |
|--------------|---|
| South Africa | Department of Health, Department of Trade and Industry, Department of Science & Technology, South African Medical Research Council, Biovac Institute |
| Sri Lanka | Ministry of Health, Education Training and Research, Medical University Colombo, National Institute of Health Sciences, Postgraduate Institute of Medicine, Bandaranayake Memorial Ayurveda Institute, Gammal Interpharma Ltd, Health Education Bureau, National Health Research Council, Institute of Indigenous Medicine, National Health Research Council, individual consultants. |
| Switzerland | Federal Office of Public Health, Swiss Agency for Development and Cooperation, Swiss Academy of Sciences (SNAT), Swiss Tropical and Public Health Institute |
| Thailand | Ministry of Public Health, Office of the National Policy on Medicine System Development, FDA, National Health Security Office, Government Pharmaceutical Organization, Thai Pharmaceutical Manufacturer Association, Health Intervention and Technology Assessment Program (HITAP), FTA Watch, Health Systems Research Institute, Expert in R&D and patent system, Siam Bioscience Co., Ltd., Biolab Co., Ltd., WHO Representative's Office |
| USA | Department of Health and Human Services (HHS/OGA), USAID, Global Health Association of American Universities Technology Managers, Global Health Technologies (GHT) Coalition (associated with PATH), National Institutes of Health (NIH), PhRMA, US Trade Representative (USTR), Bill and Belinda Gates Foundation, Foundation of the National Institutes of Health (FNIH), PATH. |

Annex 3 LIST OF DOCUMENTS

The following documents and websites were reviewed:

| Title | Source | Page Count |
|--|---|------------|
| Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property English | http://www.who.int/phi/publications/Global_Strategy_Plan_Action.pdf | 52 |
| Evaluation: annual report 8 May 2015 | http://apps.who.int/gb/ebwha/pdf_files/EB137/B137_7-en.pdf?ua=1 | 9 |
| Trade, growth and intellectual property - Strategy for the protection and enforcement of intellectual property rights in third countries | http://trade.ec.europa.eu/doclib/docs/2014/july/tradoc_152643.pdf | 19 |
| Using Intellectual Property Rights to Stimulate Pharmaceutical Production in Developing Countries: A Reference Guide (UN 2011) | http://unctad.org/en/Docs/diaepcb2009d19_en.pdf | 204 |
| Progress reports; Report by the Secretariat 1 April 2016 | http://apps.who.int/gb/ebwha/pdf_files/WHA69/A69_43-en.pdf | 18 |
| Medicines Regulation, Regulatory Harmonization, Global Initiatives | http://www.who.int/medicines/areas/policy/IPC_dec2012_Seiter_reg.pdf | 27 |
| WHO support for medicines regulatory harmonization in Africa: focus on East African Community | http://www.who.int/medicines/publications/druginformation/DI_28-1_Africa.pdf | 5 |
| The Value and Benefits of ICH to Drug Regulatory Authorities - Advancing Harmonization for Better Health | http://www.ich.org/fileadmin/Public_Web_Site/ABO/UT_ICH/Vision/Value_Benefits_for_Regulatory_2010.pdf | 36 |
| Regulatory Harmonization and Convergence | http://www.fda.gov/BiologicsBloodVaccines/InternationalActivities/ucm271079.htm | web |
| Life Sciences Innovation Forum | http://www.apec.org/Home/Groups/Committee-on-Trade-and-Investment/Life-Sciences-Innovation-Forum | web |
| Executive Board - 137th Session Geneva, 27 And 28 May 2015 | http://apps.who.int/gb/ebwha/pdf_files/EB137-REC1/B137_REC1-en.pdf#page=1 | 90 |
| Executive Board - 136th Session Geneva, 26 January–3 February 2015 | http://apps.who.int/gb/ebwha/pdf_files/EB136-REC1/B136_REC1-en.pdf#page=1 | 141 |
| Executive Board - Special Session On The Ebola Emergency Geneva, 25 January 2015 | http://apps.who.int/gb/ebwha/pdf_files/EBSS3-REC1/EBSS3_REC1-en.pdf#page=1 | 99 |
| Monitoring and evaluation framework for the Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property | http://www.who.int/phi/implementation/ME_framework_and_implementation_final.pdf?ua=1 | 28 |
| National Assessment Tool to Assist Member States in Implementing The Global Strategy And Plan Of Action On Public Health, Innovation And Intellectual Property | http://www.who.int/phi/implementation/monitoring/national_phi_assessment_tool_gspa_oct14.pdf?ua=1 | 17 |
| WHO promotes, values and encourages health innovation | http://www.who.int/phi/2016_05health_innovation-brochure.pdf?ua=1 | 2 |
| Promoting Access to Medical Technologies and Innovation | https://www.wto.org/english/res_e/booksp_e/pamtiwhowipowtweb13_e.pdf | 259 |
| Elements of a global strategy and plan of action Progress to date in the Intergovernmental Working Group 8 December 2006 | http://apps.who.int/gb/phi/pdf/igwg1/phi_igwg1_5-en.pdf | 18 |
| Intergovernmental Working Group on Public Health, Innovation and Intellectual Property Report of the first session Geneva, 4–8 December 2006 / 25 January 2007 | http://apps.who.int/gb/phi/pdf/igwg1/A_PHI_IGWG1_6-en.pdf | 36 |
| Review of recommendations of the Commission on Intellectual Property Rights, Innovation and Public Health: WHO's response; 4 December 2006 | http://apps.who.int/gb/phi/pdf/igwg1/phi_igwg1_id1-en.pdf | 6 |

| Title | Source | Page Count |
|---|---|------------|
| Status of implementation of resolution WHA59.24; 4 December 2006 | http://apps.who.int/gb/phi/pdf/igwg1/phi_igwg1_id2-en.pdf | 4 |
| Intergovernmental Working Group on Public Health, Innovation and Intellectual Property / List of participants | http://apps.who.int/gb/phi/pdf/igwg1/phi_igwg1_%20div2rev1.pdf | 18 |
| Officers of the Intergovernmental Working Group on Public Health, Innovation and Intellectual Property | http://apps.who.int/gb/phi/pdf/igwg1/phi_igwg1_div4-en.pdf | 1 |
| New Proposal To Extend WHO Action Plan On Innovation, IP Rights /27/01/2015 | http://www.ip-watch.org/2015/01/27/new-proposal-to-extend-who-action-plan-on-innovation-ip-rights/ | web |
| WHO Submission to the UN SG High Level Panel on Access to Medicines | http://www.ip-watch.org/weblog/wp-content/uploads/2016/03/WHO_HLP_Submission_7Mar2016.pdf | 20 |
| Public health, innovation and intellectual property rights English | http://www.who.int/intellectualproperty/documents/thereport/ENPublicHealthReport.pdf?ua=1 | 218 |
| Essential medicines | http://who.int/topics/essential_medicines/en/ | web |
| Essential medicines Africa | http://www.afro.who.int/en/clusters-a-programmes/hss/essential-medicines.html | web |
| Essential medicines Americas | http://www.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=1160&Itemid=1176&lang=en | web |
| Essential medicines South-East Asia | http://www.searo.who.int/entity/medicines/en/ | web |
| Essential medicines Europe | http://www.euro.who.int/en | web |
| Essential medicines Eastern Mediterranean | http://www.emro.who.int/emp/ | web |
| Essential medicines Western Pacific | http://www.wpro.who.int/topics/essential_medicines/en/ | web |
| Tropical diseases by Regions | http://who.int/topics/tropical_diseases/en/ | web |
| HIV/AIDS by Regions | http://who.int/topics/hiv_aids/en/ | web |
| Hepatitis by Region | http://who.int/topics/hepatitis/en/ | web |
| Vaccines by Regions | http://who.int/topics/vaccines/en/ | web |
| Pharmaceutical products by Regions | http://who.int/topics/pharmaceutical_products/en/ | web |
| National strategy and plan of action for pharmaceutical manufacturing development in Ethiopia (2015–2025) | http://www.who.int/phi/publications/Ethiopia_strategy_local_production.pdf?ua=1 | 37 |
| Launch of Ethiopian National Strategy and Plan of Action for Pharmaceutical Manufacturing Development and Improving Access 14 July 2015 | http://www.who.int/phi/news/1838PHIrev150915.pdf?ua=1 | 16 |
| National Assessment Report Sri Lanka | http://www.who.int/phi/implementation/monitoring/Sri_Lanka-report.pdf?ua=1 | 73 |
| Development of a Regional Framework on Public Health, Innovation and Intellectual Property; Report of a Regional Consultation SEARO, New Delhi, India, 5-6 April 2011 | http://www.searo.who.int/entity/intellectual_property/documents/5april2011.pdf | 104 |
| Stakeholders Workshop Report: National Position on the Consultative Expert Working Group's Report on Research and Development – Financing and Coordination Held at the Kenya Medical Research Institute (Kemri) Training Centre, Nairobi - 30th August 2012 | http://www.haiafrica.org/pdfs/Kenya%20CEWG%20Position%20Paper.pdf | 30 |
| TDR Website | http://www.who.int/tdr/en/ | web |
| TDR 2015 Results Report | http://www.who.int/tdr/publications/year/2016/TDR-2015-results-report.pdf?ua=1 | 52 |
| TDR Strategic Plan 2012 -2015 | http://apps.who.int/iris/bitstream/10665/75138/1/TDR_STRAT_12.2_eng.pdf?ua=1 | 11 |
| Global strategy and plan of action on public health, innovation and intellectual property The Sixty-first World Health Assembly | http://www.wpro.who.int/health_research/policy_documents/global_strategy_may2008.pdf | 2 |
| Travel Report Beyer Egypt 2014 | Hard copy examined | 3 |
| Euro Mediterranean Report 2015 | Hard copy examined | 184 |

| Title | Source | Page Count |
|---|---|------------|
| WHO updates patent information on sofosbuvir and ledipasvir for the treatment of Hepatitis C Virus | http://www.who.int/phi/implementation/ip_trade/ip_patent_landscapes/en/ | web |
| Research and Development to Meet Health Needs in Developing Countries: Strengthening Global Financing and Coordination | http://www.who.int/phi/CEWG_Report_5_April_2012.pdf | 226 |
| Technology transfer | http://www.who.int/phi/implementation/tech_transfer/en/ | web |
| Access to HIV Treatment, Other Essential Medicines And Intellectual Property / National Consultations Republic Of Moldova 18-19 November 2014 | http://www.md.undp.org/content/moldova/en/home/library/effective_governance/accesul-la-tratamentul-hiv-sida--alte-medicamente-eseniale-i-pro.html | 21 |
| Martin Shkreli, CEO reviled for drug price gouging, arrested on securities fraud charges | http://www.reuters.com/article/us-usa-crime-shkreli-idUSKBN0U01IM20151217 | 3 |
| Technical Assistance, Cambodia | Hard copy examined | 12 |
| Overview on technical cooperation programmes relating to the implementation of the TRIPS Agreement / review files for 2005 - 2015 | http://www.who.int/phi/wto_communications/en/ | web |
| Facilitating access to patent information | http://www.who.int/phi/patent_info/en/ | web |
| The role of intellectual property in local production in developing countries Opportunities and challenges | http://www.who.int/phi/publications/int_prop_local_prod_opportunities_challenges/en/ | web |
| The role of intellectual property in local production in developing countries Opportunities and challenges / Additional Links | http://www.who.int/phi/publications/category/en/ | web |
| Increasing access to HIV treatment in middle-income countries | http://www.who.int/phi/publications/WHO_Increasing_access_to_HIV_treatment.pdf?ua=1 | 56 |
| Kenya National Assessment in the Context of Global Strategy and Plan of Action on Public Health, Innovation and Intellectual | Hard copy examined | 3 |
| Tanzania Innovation and Access to Health Technologies National Assessment Report | Hard copy examined | 123 |
| Promoting access to medical innovation | Supplied by client | 4 |
| The Changing Landscape of Medical Innovation: How Have Business Models Responded? Global Challenges Brief | http://www.wipo.int/export/sites/www/meetings/en/2013/who_wipo_ip_med_ge_13/pdf/brief.pdf | 5 |
| Research Brochure | Hard copy examined | |
| WIPO Re:Search Sharing Innovation in the Fight Against Neglected Tropical Diseases (Guiding Principles) | http://www.wipo.int/export/sites/www/research/docs/guiding_principles.pdf | 9 |
| Global Challenge Brief Sharing Innovation in the Fight Against Neglected Tropical Diseases | http://www.wipo.int/edocs/pubdocs/en/wipo_pub_gc_8.pdf | 5 |
| Innovative licensing expands access to HIV treatments | http://www.wipo.int/wipo_magazine/en/2012/06/article_0005.html | 5 |
| WIPO Patent Search Report on Pandemic Influenza Preparedness (PIP)-Related Patents and Patent Applications | http://www.wipo.int/export/sites/www/patentscope/en/programs/patent_landscapes/documents/patent_landscapes/influenza_full_report_01_04_2011.pdf | 45 |
| Strategic Review of WIPO Re:Search | http://www.wipo.int/export/sites/www/research/en/docs/wipo_research_external_review.pdf | 52 |
| WRS Members 01/2015 | List | 2 |
| Update on the implementation of the MoU with Bill & Melinda Gates Foundation | Hard copy examined | 10 |
| WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property: the Contribution of Switzerland | http://www.swisstph.ch/fileadmin/user_upload/Pdfs/Reports/2011/Lorenz_et_al._WHO_Global_Strat_Plan_Action_Public_Health_2011.pdf | 62 |
| Preparatory note for the Open-ended meeting "Follow-up of the report of the CEWG" "Follow-up of the report of the CEWG" (Dates: 2 - 4 May 2016) | Hard copy examined | 8 |
| SDC Engagement in Product Development Partnerships: When Public Meets Private | https://www.shareweb.ch/site/Health/portfolio/Documents/SDC%20ENGAGEMENT%20IN%20PRODUCT%20DEVELOPMENT%20PARTNERSHIPS.pdf | 8 |

| Title | Source | Page Count |
|--|---|------------|
| Swiss Health Foreign Policy | http://www.bag.admin.ch/themen/internationales/13102/index.html?lang=en | 44 |
| Obligations of low income countries in ensuring equity in global health financing | http://bmcomedethics.biomedcentral.com/articles/10.1186/s12910-015-0055-3 | 8 |
| Global report for research on infectious diseases of poverty | http://tbevidence.org/wp-content/uploads/2012/04/TDR-Global-report-research-on-infect-dis-of-poverty.pdf | 184 |
| Incentivizing Access and Innovation for Essential Medicines: A Survey of the Problem and Proposed Solutions | http://link.springer.com/chapter/10.1057%2F9781137349088_13 | web |
| East African Community Regional Pharmaceutical Manufacturing Plan of Action (2012 - 2016) | http://eacgermany.org/wp-content/uploads/2014/10/EACRPMPOA.pdf | 50 |
| The Proliferation of Anti-counterfeiting Legislation in the East African Community: Addressing Public Health, Copyright and Developmental Concerns | http://www.haiafrica.org/index.php?option=com_content&view=article&id=36:hai-africa-and-iqsensato-launch-a-pilot-monitoring-tool-to-assess-the-implementation-of-the-who-global-strategy-on-essential-health-research&catid=41:intellectual-property&access-to-essential-medicine | web |
| Rwanda Intellectual Property Policy | http://www.wipo.int/edocs/lexdocs/laws/en/rw/rw03en.pdf | 29 |
| Country Cooperation Strategy for WHO and Afghanistan 2009–2013 | http://apps.who.int/iris/bitstream/10665/113236/1/CCS_Afghanistan_2010_EN_14480.pdf | 72 |
| Country Cooperation Strategy at a glance Afghanistan | http://apps.who.int/iris/bitstream/10665/136852/1/ccsbrief_afg_en.pdf | 2 |
| Country Cooperation Strategy Rwanda | http://apps.who.int/iris/bitstream/10665/205893/1/CCS_Rwa_2014_18.pdf | 2 |
| Good Review Practices: Guidelines for National And Regional Regulatory Authorities. WHO Technical Report Series, No. 992, 2015, Annex 9 | http://apps.who.int/medicinedocs/documents/s21902en/s21902en.pdf | 20 |
| Medical devices regulations | http://www.who.int/medical_devices/safety/en/ | web |
| The Essential List of Regulatory Authorities in Asia | http://www.raps.org/Regulatory-Focus/News/Databases/2015/04/06/21908/The-Essential-List-of-Regulatory-Authorities-in-Asia/ | web |
| Regulatory conferences: Getting regulatory requirements in sync | http://www.ifpma.org/subtopics/regulatory-conferences/ | web |
| Overview of the Current Global Regulatory Landscape | http://www.ncbi.nlm.nih.gov/books/NBK174229/ | 128 |
| Health technology assessment bodies | http://www.ema.europa.eu/ema/index.jsp?curl=pages/partners_and_networks/general/general_content_000476.jsp& | web |
| System for Evaluation of the National Regulatory Authorities for Medicines | http://www.paho.org/hq/index.php?option=com_content&view=article&id=1615%3A2009-sistema-evaluacion-autoridades-reguladoras-nacionales-medicamentos&catid=1267%3Aquality-drug-regulation&Itemid=1179&lang=en | web |
| Essential Medicines and Biologicals | http://www.paho.org/hq/index.php?option=com_content&view=category&layout=blog&id=1160&Itemid=327&lang=en | web |
| Regulatory agencies seek expansion of Pan American cooperation | http://www.paho.org/hq/index.php?option=com_content&view=article&id=10262%3A2014-regulatory-agencies-look-for-expansion-of-pan-american-cooperation&catid=1443%3Aweb-bulletins&Itemid=135&lang=en | web |
| PAHO recognizes COFEPRIS as a National Regulatory Authority of Regional Reference | http://www.paho.org/hq/index.php?option=com_content&view=article&id=6967%3A2012-paho-recognizes-cofepris-as-national-regulatory-authority-regional-reference&catid=1443%3Aweb-bulletins&Itemid=135&lang=en | web |

| Title | Source | Page Count |
|---|---|------------|
| The First IGAD Regional Medicines Regulatory Authorities Conference on Regulatory Coordination and Harmonization | http://www.igad.int/index.php?option=com_content&view=article&id=1186:the-first-igad-regional-medicines-regulatory-authorities-conference-on-regulatory-coordination-and-harmonization&catid=44:economic-cooperation&Itemid=127 | web |
| Directory of health technology assessment agencies worldwide | http://www.ispor.org/htadirectory/index.aspx | web |
| Approaches to Healthcare Quality Regulation in Latin America and the Caribbean | http://pdf.usaid.gov/pdf_docs/Pnade604.pdf | 62 |
| Asia-pacific-regional-regulatory-partnership-malaria-elimination | https://www.duke-nus.edu.sg/core/page/asia-pacific-regional-regulatory-partnership-malaria-elimination-meeting | web |
| REGULATORY ISSUES: Ensuring Fair Evaluation of and Access to Tuberculosis Treatment | http://www.treatmentactiongroup.org/sites/g/files/g450272/f/201512/TB%20Regulatory%20Guide.pdf | 10 |
| Strengthening Regulatory Frameworks to Fuel Health Technology Innovation | http://www.nbr.org/downloads/pdfs/CHA/PHS_2012_Technology_Regulation.pdf | 16 |
| International Coalition of Medicines Regulatory Authorities (ICMRA) | https://www.tga.gov.au/international-coalition-medicines-regulatory-authorities-icmra | web |
| Regulation of Medical Devices: a Regional approach | http://www.imdrf.org/docs/imdrf/final/meetings/imdrf-meet-150324-tokyo-presentation-paho.pdf | 19 |
| More Trade for Better Health? International Trade and Tariffs on Health Products. | https://www.wto.org/english/res_e/reser_e/ersd201217_e.pdf | 38 |
| Special Compulsory Licences for Export of Medicines: Key Features of WTO Members' Implementing Legislation | https://www.wto.org/english/res_e/reser_e/ersd201507_e.pdf | 75 |
| WTO secretariat technical cooperation in the trips area - Note by the Secretariat - 20150803 | Hard copy examined | 12 |
| Technical cooperation activities: information from other intergovernmental organizations - World Health organization (who) - 20151012 | Hard copy examined | 8 |
| Report on the implementation of article 66.2 of the trips agreement - Japan - Revision 20151005 | Hard copy examined | 14 |
| Report on the implementation of article 66.2 of the trips agreement - Japan Annex 1 | Hard copy examined | 14 |
| Report on the implementation of article 66.2 of the trips agreement - Japan Annex 2 | Hard copy examined | 27 |
| Report on the implementation of article 66.2 of the trips agreement - Japan Annex 3 | Hard copy examined | 28 |
| Report on the implementation of article 66.2 of the trips agreement - Japan Annex 4 | Hard copy examined | 36 |
| Report on the implementation of article 66.2 of the trips agreement - Japan Annex 5 - Revision 1 | Hard copy examined | 26 |
| Report on the implementation of article 66.2 of the trips agreement - Japan Annex 6 | Hard copy examined | 5 |
| Report on the implementation of article 66.2 of the trips agreement - Japan Annex 7 | Hard copy examined | 118 |
| Strategic and business plan for the African Network for Drugs and Diagnostics Innovation (ANDI) | http://www.who.int/tdr/publications/documents/sbp_andi.pdf | 76 |
| ANDI Draft Strategy for Intellectual Property Management | Hard copy examined | 8 |
| STRATEGIC BUSINESS PLAN - Association of Southeast Asian Nations Network for Drugs, Diagnostics, Vaccines and Traditional Medicine Innovation December 2012 | Hard copy examined | 201 |
| GE Healthcare - Working with the Medical Technology Industry to Improve Health Outcomes | Hard copy examined | 20 |
| The Innovative Medicines Initiative: A European Response to the Innovation Challenge | Hard copy examined | 8 |

| Title | Source | Page Count |
|--|---|------------|
| Europe 2020 - Flagship Initiative Innovation Union - Research & Innovation policy | https://ec.europa.eu/research/innovation-union/pdf/innovation-union-communication-brochure_en.pdf | 48 |
| MOU - UNECA and WHO The Establishment, Development, Promotion and Management of the African Network for Drugs and Diagnostics Innovation (ANDI) | Hard copy examined | 23 |
| Draft Editorial for special issue of WHO Bulletin on BRICS in June 2014. Last date of submission is 25th April 2014. Supporting public health-oriented local production in Africa is a smart investment | Hard copy examined | 2 |
| Cuban experience with local production of medicines, technology transfer and improving access to health - Draft | Hard copy examined | 76 |
| WHO guidelines on quality risk management | Hard copy examined | 32 |
| Promoting Access, Quality and Technology Transfer between Africa and China | http://www.wpro.who.int/china/mediacentre/releases/2015/20150327/en/ | 72 |
| WHO Prequalification - Building quality-assured manufacturing capacity in Nigeria | http://apps.who.int/medicinedocs/documents/s21721en/s21721en.pdf | 6 |
| Pharmaceuticals & Healthcare Report - Jordan - Q3 2014 | Hard copy examined | 107 |
| Pharmaceuticals & Healthcare Report - Kenya - Q3 2014 | Hard copy examined | 106 |
| Pharmaceuticals & Healthcare Report - Tanzania - Q3 2014 | Hard copy examined | 70 |
| Pharmaceuticals & Healthcare Report - Uganda - Q3 2014 | Hard copy examined | 61 |
| Report Of The Meeting To Develop Regional And National Good Manufacturing Practices (GMP) Road Map For The Ecowas Region | Hard copy examined | 7 |
| Progress reports - Report by the Secretariat 17 Nov 2011 | Hard copy examined | 10 |
| To Support the Progressive Transformation of The West African Pharmaceutical Manufacturers Association | Hard copy examined | 12 |
| UNIDO Independent Final Evaluation GLOBAL ACTIVITIES (2015) | https://www.unido.org/fileadmin/user_media_upgrade/Resources/Evaluation/Final_Evaluation_GENERIC_DRUGS__2015.pdf | 104 |
| A stepwise approach for pharmaceutical companies in developing countries to attain WHO GMP standards | http://apps.who.int/medicinedocs/documents/s22464en/s22464en.pdf | 13 |
| A framework for risk-based identification of essential medicine products for local manufacturing in low- and middle-income countries | Hard copy examined | 21 |
| SADC - Final Report - Feasibility study on Regional Manufacturing of Medicines and Health Commodities (January 2016) | Hard copy examined | 104 |
| Concept Note of the Chinese Pharmaceutical Investment Delegation to Kenya and Ethiopia | Hard copy examined | 7 |
| Inter-Agency Agreement between WHO and UNCTAD - July 2012 | Hard copy examined | 32 |
| Pharma China Web edition - Chinese Firms Lure Cream of Indian Drug Formulation Experts with High Pay | Hard copy examined | 2 |
| A Landscape of North-South and South-South Initiatives for Local Pharmaceutical Production and Related Technology Transfer | https://www.researchgate.net/publication/262373958_A_Landscape_of_North-South_and_South-South_Initiatives_for_Local_Pharmaceutical_Production_and_Related_Technology_Transfer | 89 |

| Title | Source | Page Count |
|--|---|------------|
| Assessment of Pharmaceutical Wholesale Market in Ghana - An Incentive Survey | http://apps.who.int/medicinedocs/documents/s22306en/s22306en.pdf | 35 |
| Hubs to spread technology and save lives | http://www.who.int/bulletin/volumes/93/5/15-020515/en/ | 2 |
| KENYA GMP ROADMAP - A Stepwise Approach for the Pharmaceutical Industry to Attain WHO GMP Standards | http://docplayer.net/18626224-Kenya-gmp-roadmap-a-stepwise-approach-for-the-pharmaceutical-industry-to-attain-who-gmp-standards.html | 90 |
| Private Sector Pharmaceutical Supply and Distribution Channels in Africa - A Focus on Ghana, Malawi and Mali | http://docplayer.net/20738557-Private-sector-pharmaceutical-supply-and-distribution-channels-in-africa.html | 78 |
| Public vaccine manufacturing capacity in the Latin American and Caribbean region: Current status and perspectives | Hard copy examined | 12 |
| Workshop on the Development of a Business Plan for the Operationalization of the Pharmaceutical Manufacturing Plan for Africa (PMPA) | Hard copy examined | 9 |
| Antecedents, environmental moderators and consequences of market orientation: A study of pharmaceutical firms in Ghana | Hard copy examined | 15 |
| Commodities for better health in Africa – time to invest locally | http://www.who.int/bulletin/volumes/92/6/14-140566/en/ | 2 |
| Avmi - Vaccine Manufacturing And Procurement In Africa (Vmpa) Study Stakeholder Consultation: Positioning And Alignment Meeting | Hard copy examined | 2 |
| Who Expert Committee On Specifications For Pharmaceutical Preparations - Forty-Fifth Report | http://apps.who.int/iris/bitstream/10665/44079/1/WHO_TRS_961_eng.pdf | 440 |
| Technical Cooperation Activities: Information From Other Intergovernmental Organizations World Health Organization (Who) - 5 Aug 2013 | Hard copy examined | 4 |
| Technical Cooperation Activities: Information From Other Intergovernmental Organizations World Health Organization (Who) Addendum | Hard copy examined | 6 |
| Enhancing Access to Treatment: Intellectual Property Protection and HIV/AIDS - The State of Egypt | Hard copy examined | 102 |
| Enhancing Access to Treatment: Intellectual Property Protection and HIV/AIDS - The Kingdom of Jordan | Hard copy examined | 99 |
| Enhancing Access to Treatment: Intellectual Property Protection and HIV/AIDS - The Emirate of Kuwait | Hard copy examined | 56 |
| Enhancing Access to Treatment: Intellectual Property Protection and HIV/AIDS - The Kingdom of Morocco | Hard copy examined | 113 |
| A proposal prepared for PhRMA and IPASA: Campaign to Prevent Damage to Innovation from the Proposed Draft National IP Policy in South Africa | Hard copy examined | 9 |
| Enhancing Access to Treatment: Intellectual Property Protection and HIV/AIDS - The State of Pakistan | Hard copy examined | 110 |
| Enhancing Access to Treatment: Intellectual Property Protection and HIV/AIDS - The State of Qatar | Hard copy examined | 82 |
| Improving Access To Essential Medicines And Basic Health Technologies For NCDs – Towards A Set Of Who Proposed Actions | Hard copy examined | 14 |
| Research and Development Coordination and Financing - Report of the Expert Working Group (2010) | http://apps.who.int/medicinedocs/documents/s22473en/s22473en.pdf | 98 |
| Creating a global observatory for health R&D | http://science.sciencemag.org/content/345/6202/1302.full | 4 |
| Global strategy and plan of action on public health, innovation and intellectual property - Report by the Secretariat 15 May 2015 | Hard copy examined | 6 |

| Title | Source | Page Count |
|--|---|------------|
| The Global Innovation and Access Platform for the Global Strategy and Plan of Action - WHO HQ/PAHO joint programme | Hard copy examined | 2 |
| Implementation Of The Global Strategy And Plan Of Action On Public Health, Innovation, And Intellectual Property | Hard copy examined | 4 |
| Developing and sustaining human resources in the health supply chain in Ethiopia: barriers and enablers | http://www.rrh.org.au/articles/subviewnew.asp?ArticleID=3613 | 11 |
| Trade and Health: Towards building a National Strategy | http://apps.who.int/iris/bitstream/10665/183934/1/9789241565035_eng.pdf?ua=1 | 149 |
| Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research | Hard copy examined | 184 |
| Health topics – Intellectual property | http://who.int/topics/intellectual_property/en/ | web |
| Health topics – Non-communicable diseases | http://who.int/topics/noncommunicable_diseases/en/ | web |
| Consultative Expert Working Group on Research and Development: Financing and Coordination | http://www.who.int/phi/cewg/en/ | web |
| UN High-level Panel – comment by Marcus Low | Hard copy examined | 2 |
| WHO Essential Medicines and Health Products: Annual Report 2015 | http://www.who.int/entity/medicines/publications/emp_annual-report2015/en/index.html | 48 |
| Essential Medicines and Health Products: Biennial Report 2012-2013 | http://www.who.int/entity/medicines/publications/biennial_report2012-2013/en/index.html | 12 |
| Essential Medicines Biennial Report: The Pharmaceutical Scene in 2008–2009 | http://www.who.int/entity/medicines/areas/access/biennial_report08_09/en/index.html | 12 |
| Essential Medicines Biennial Report: The Pharmaceutical Scene in 2006–2007 | http://www.who.int/entity/medicines/areas/access/biennial_report06_07/en/index.html | 8 |
| Essential Medicines Annual Report 2006 English Pdf, 513kb | http://www.who.int/entity/medicines/publications/WHO_pharma_annual_report_En.pdf?ua=1 | 15 |
| Essential Medicines Annual Report 2005 English Pdf, 2.34mb | http://www.who.int/entity/medicines/publications/AnnualReport05En.pdf?ua=1 | 6 |
| Essential Medicines Annual Report 2004 English Pdf, 4.08mb | http://www.who.int/entity/medicines/publications/AnnualReport2004EN.pdf?ua=1 | 4 |
| Annual report 2013: prequalification of medicines: a vital service | http://apps.who.int/prequal/info_general/documents/annual_reports/2013/WHO-PQP_AnnualReport2013.pdf?ua=1 | 28 |
| WHO Prequalification: Progress Report. June, 2013 | http://apps.who.int/iris/bitstream/10665/97496/1/9789241506175_eng.pdf?ua=1&ua=1 | 16 |
| WHO Prequalification of Medicines Programme (PQP): Annual Report 2012. - Globalizing Quality | http://apps.who.int/medicinedocs/documents/s20293en/s20293en.pdf?ua=1 | 28 |
| WHO Prequalification of Medicines Programme (PQP): Facts and Figures for 2011 | http://apps.who.int/medicinedocs/documents/s19976en/s19976en.pdf?ua=1 | 4 |
| WHO Prequalification of Medicines Programme (PQP): Facts and Figures for 2010 | http://apps.who.int/medicinedocs/documents/s18635en/s18635en.pdf?ua=1 | 4 |
| WHO Prequalification of Medicines Programme (PQP): Facts and Figures for 2009 | http://apps.who.int/medicinedocs/documents/s19977en/s19977en.pdf?ua=1 | 3 |
| WHO Prequalification of Medicines Programme (PQP): Quality Medicines for Everyone. 2008 | http://apps.who.int/medicinedocs/documents/s19978en/s19978en.pdf?ua=1 | 4 |
| WHO Prequalification of Medicines: Programme Update for 2006 | http://apps.who.int/iris/bitstream/10665/69934/1/WHO_PSM_QSM_2007.4_eng.pdf?ua=1&ua=1 | 16 |
| WHO Prequalification Programme: Programme Activities in 2005 | http://apps.who.int/medicinedocs/documents/s14087e/s14087e.pdf?ua=1 | 10 |
| MEDICAL INNOVATION FOR NEGLECTED PATIENTS: Important Progress Over Past Ten Years, But “Fatal Imbalance” Persists | Hard copy examined | 12 |
| Innovative Partnerships for Drug Discovery against Neglected Diseases | http://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0001221 | 4 |

| Title | Source | Page Count |
|--|---|------------|
| Analysis of pan-African Centres of excellence in health innovation highlights opportunities and challenges for local innovation and financing in the continent | http://bmcinthealthhumrights.biomedcentral.com/articles/10.1186/1472-698X-12-11 | 15 |
| Preliminary Findings from Health Technology R&D Needs Assessment | Hard copy examined | 65 |
| R&D Needs Assessment draft article | Hard copy examined | 8 |
| African trials registry launches child strategy | Hard copy examined | 1 |
| Health research prioritization at WHO - an overview of methodology and high level analysis of WHO led health research priority setting exercises | Hard copy examined | 35 |
| WHO's role and responsibilities in health research, Secretariat's report | http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_22-en.pdf | 26 |
| An R&D Blueprint For Action To Prevent Epidemics | http://www.who.int/csr/research-and-development/WHO-R_D-Final10.pdf (This one is a very important new initiative from WHO) | 48 |
| New Technology Needs for Non-communicable Diseases in Developing Countries: a landscaping study | http://www.resultsfordevelopment.org/sites/resultsfordevelopment.org/files/R4D%20-%20RD%20for%20NCDs%20final.pdf | 60 |
| Summary Report: Consultation on Advancing Technological Innovation for Older Persons in Asia | http://www.who.int/kobe_centre/mediacentre/summary_report_innovation_feb2013.pdf | 83 |
| Study on China Africa cooperation on LP | Hard copy examined | 2 |
| Implementation of GSPOA- Sri Lanka- Book | http://apps.who.int/medicinedocs/en/d/Js22068en/ | 73 |
| Inventory of Existing Online Databases Containing Traditional Knowledge Documentation Data | http://www.wipo.int/edocs/mdocs/tk/en/wipo_grtkf_ic_3/wipo_grtkf_ic_3_6-main1.pdf | 40 |
| Annex to Doc232 | http://www.wipo.int/edocs/mdocs/tk/en/wipo_grtkf_ic_3/wipo_grtkf_ic_3_6-annex1.doc | 35 |
| 2013 (EB134/53) - Progress reports | 2013 (EB134/53) - Progress reports | 27 |
| 2011 (EB130/35 Add.3) - Progress report | 2011 (EB130/35 Add.3) - Progress report | 5 |
| 2010 (EB126.6) Public health, innovation and intellectual property: global strategy and plan of action | 2010 (EB126.6) Public health, innovation and intellectual property: global strategy and plan of action | 6 |
| 2010 (EB126.6 Add.1) Public health, innovation and intellectual property: Report of the Expert Working Group on Research and Development Financing | 2010 (EB126.6 Add.1) Public health, innovation and intellectual property: Report of the Expert Working Group on Research and Development Financing | 19 |
| Monitoring and Evaluation Framework (see EB Report paragraph 3) | Monitoring and Evaluation Framework (see EB Report paragraph 3) | 13 |
| Technology transfer activities (see EB Report paragraphs 7 and 13) | Technology transfer activities (see EB Report paragraphs 7 and 13) | 3 |
| Collaboration with WIPO and WTO (see EB Report paragraph 9) | Collaboration with WIPO and WTO (see EB Report paragraph 9) | 2 |
| Regional and national networks for innovation: the African Network for Drugs and Diagnostics Innovation (see EB Report paragraphs 10 and 11) | Regional and national networks for innovation: the African Network for Drugs and Diagnostics Innovation (see EB Report paragraphs 10 and 11) | 5 |
| WHO Meeting on Norms and Standards for Research Ethics Committees (see EB Report paragraph 21) | WHO Meeting on Norms and Standards for Research Ethics Committees (see EB Report paragraph 21) | 20 |
| Implementation of the draft WHO Strategy on Research for Health and harmonization with the Global Strategy and Plan of Action | Implementation of the draft WHO Strategy on Research for Health and harmonization with the Global Strategy and Plan of Action | 5 |
| Planning Meeting with Regional Advisers on Medicines for the Implementation of the GSPA-PHI | Planning Meeting with Regional Advisers on Medicines for the Implementation of the GSPA-PHI | 11 |
| Implementation Discussion - AFRO | AFRO | 1 |
| Implementation Discussion - AMRO/PAHO | AMRO/PAHO | 3 |
| Implementation Discussion - EMRO | EMRO | 50 |
| Innovative framework to support the implementation of the global strategy developed by COHRED (See EB Report paragraph 26) | Innovative framework to support the implementation of the global strategy developed by COHRED (See EB Report paragraph 26) | 9 |

| Title | Source | Page Count |
|--|---|------------|
| WHO activities to implement the global strategy and plan of action on public health, innovation and intellectual property, including the quick start programme - Quick Start Activities | http://www.who.int/phi/GS_implementQS.pdf?ua=1 | 10 |
| CEWG - Report by the Secretariat | http://apps.who.int/gb/CEWG/pdf/A_CEWG_3-en.pdf | 20 |
| Report of the regional committee discussions by the Director-General | http://apps.who.int/gb/CEWG/pdf/A_CEWG_2-en.pdf | 12 |
| Report of the regional committee discussions by the Director-General - Annex | http://apps.who.int/gb/CEWG/pdf/A_CEWG_2Add1-en.pdf | 4 |
| Report of the open-ended meeting of Member States on the follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination, Geneva, 26–28 November 2012 | http://apps.who.int/gb/CEWG/pdf/A_CEWG_4-en.pdf | 5 |
| Report of the Consultative Expert Working Group on Research and Development: Financing and Coordination | http://apps.who.int/gb/CEWG/pdf/A65_24-en.pdf | 198 |
| Follow up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination | http://apps.who.int/gb/ebwha/pdf_files/WHA65/A65_R22-en.pdf | 2 |
| Open-ended meeting of Member States to assess progress and continue discussions on the remaining issues in relation to monitoring, coordination and financing for health research and development. - Progress Report | http://apps.who.int/gb/CEWG/rdmcf/pdf/A_RDMCF_2-en.pdf | 10 |
| Response to Operative Paragraph 2(1) of WHA Resolution 63.28 | http://www.who.int/phi/ewg_response_wha63_28/en/ | 1 |
| all the proposals considered by the EWG including their source | http://www.who.int/phi/proposals_considered_including_their_source.pdf?ua=1 | 3 |
| Doc258 - Proposal from Algeria | http://www.who.int/entity/phi/Algeria.pdf?ua=1 | 12 |
| Doc258 - Proposal from Bangladesh, Barbados, Bolivia, and Suriname - Proposal 1 | http://www.who.int/entity/phi/Bangladesh_Barbados_Bolivia_Suriname_ChagasPrize.pdf?ua=1 | 7 |
| Doc258 - Proposal from Bangladesh, Barbados, Bolivia, and Suriname - Proposal 2 | http://www.who.int/entity/phi/Bangladesh_Barbados_Bolivia_Suriname_DonorPrize.pdf?ua=1 | 5 |
| Doc258 - Proposal from Bangladesh, Barbados, Bolivia, and Suriname - Proposal 3 | http://www.who.int/entity/phi/Bangladesh_Barbados_Bolivia_Suriname_R_DTreaty.pdf?ua=1 | 7 |
| Doc258 - Proposal from Bangladesh, Barbados, Bolivia, and Suriname - Proposal 4 | http://www.who.int/entity/phi/Bangladesh_Barbados_Bolivia_Suriname_TBPrize.pdf?ua=1 | 7 |
| Doc258 - Proposal from Bangladesh, Bolivia, and Suriname | http://www.who.int/entity/phi/Bangladesh_Bolivia_Suriname_CancerPrize.pdf?ua=1 | 3 |
| Doc258 - Proposal from Brazil | http://www.who.int/entity/phi/Brazil.pdf?ua=1 | 6 |
| Doc258 - Proposal from Burkina Faso | http://www.who.int/entity/phi/BurkinaFasoeng.pdf?ua=1 | 11 |
| Doc258 - Proposal from Costa Rica | http://www.who.int/entity/phi/CostaRica_En.pdf?ua=1 | 3 |
| Doc258 - Proposal from Mexico | http://www.who.int/entity/phi/Mexico_En.pdf?ua=1 | 2 |
| Doc258 - Proposal from Monaco | http://www.who.int/entity/phi/Monaco_En.pdf?ua=1 | 2 |
| Doc258 - Proposal from Nigeria | http://www.who.int/entity/phi/Nigeria.pdf?ua=1 | 2 |
| Doc258 - Proposal from Serbia | http://www.who.int/entity/phi/Serbia.PDF?ua=1 | 2 |
| Doc258 - Proposal from South Africa | http://www.who.int/entity/phi/SouthAfrica.pdf?ua=1 | 4 |
| Doc258 - Proposal from Syria | http://www.who.int/entity/phi/Syria_En.doc?ua=1 | 3 |
| Doc258 - Proposal from Sophie Bloemen - Health Action International, Netherlands | http://www.who.int/entity/phi/HAI.pdf?ua=1 | 6 |
| Doc258 - Proposal from Michelle Childs - Médecins Sans Frontières, France | http://www.who.int/entity/phi/MSF.pdf?ua=1 | 7 |
| Doc258 - Proposal from Alicia Greenidge - International Federation of Pharmaceutical Manufacturers Association, Switzerland | http://www.who.int/entity/phi/IFPMA.pdf?ua=1 | 5 |

| Title | Source | Page Count |
|---|---|------------|
| Doc258 - Proposal from Aidan Hollis - University of Calgary, Canada, also on behalf of Thomas Pogge, Peter Singer, Carl Nathan, Amitava Banerjee, Paul Grootendorst, and Rudolf V. Van Puymbroeck | http://www.who.int/entity/phi/HIF.pdf?ua=1 | 10 |
| Doc258 - Proposal from Caroline Joiner - US Chamber of Commerce, USA | http://www.who.int/entity/phi/USChamberofCommerce.pdf?ua=1 | 4 |
| Doc258 - Proposal from James Love - Knowledge Ecology International, Switzerland | http://www.who.int/entity/phi/KEI.pdf?ua=1 | 7 |
| Doc258 - Proposal from Warren Mitchell - AIDS Vaccine Advocacy Coalition, USA | http://www.who.int/entity/phi/AVAC.pdf?ua=1 | 4 |
| Doc258 - Proposal from Itaru Nitta - Green Intellectual Property Project, Switzerland | http://www.who.int/entity/phi/GreenIP.pdf?ua=1 | 10 |
| Doc258 - Proposal from Peter Singer and Abdallah Daar - McLaughlin-Rotman Centre for Global Health, University Health Network and University of Toronto, Canada | http://www.who.int/entity/phi/MRC.pdf?ua=1 | 8 |
| Doc258 - Proposal from Rebecca Stevens - Novartis, Switzerland | http://www.who.int/entity/phi/Novartis.pdf?ua=1 | 5 |
| Doc258 - Proposal from Wayne D. Taylor - The Cameron Institute, Canada | http://www.who.int/entity/phi/CameronInstitute.pdf?ua=1 | 4 |
| Doc258 - Proposal from Ellen 't Hoen - UNITAID, Switzerland | http://www.who.int/entity/phi/UNITAID.pdf?ua=1 | 5 |
| Doc258 - Proposal from Charles W. Wessner - US National Academies of Science, USA | http://www.who.int/entity/phi/SBIR.pdf?ua=1 | 2 |
| Research and Development - Coordination and Financing - Report of the World Health Organization Expert Working Group on Research and Development Financing | http://www.who.int/phi/documents/ewg_report/en/ | 98 |
| The WHO strategy on research for health | http://www.who.int/phi/WHO_Strategy_on_research_for_health.pdf?ua=1 | 62 |
| 2010 (WHA63.21 - Resolution) WHO's role and responsibilities in health research | http://apps.who.int/gb/ebwha/pdf_files/WHA63-REC1/WHA63_REC1-P2-en.pdf?ua=1 | 63 |
| 2010 (WHA63.22) WHO's role and responsibilities in health research: Draft WHO strategy on research for health | http://apps.who.int/gb/ebwha/pdf_files/WHA63-REC1/WHA63_REC1-P4-en.pdf?ua=1 | 76 |
| Report on financial and administrative implications for the Secretariat of resolutions proposed for adoption by the Executive Board or Health Assembly | http://apps.who.int/gb/ebwha/pdf_files/WHA63/A63_22Add1-en.pdf?ua=1 | 2 |
| 2009 (EB124.12 Add.2) Bamako Global Ministerial Forum on Research for Health | http://apps.who.int/gb/archive/pdf_files/EB124/B124_12Add2-en.pdf?ua=1 | 6 |
| 2011 (WHA 64.5) Pandemic influenza preparedness: sharing of influenza viruses and access to vaccines and other benefits | http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_R5-en.pdf?ua=1 | 2 |
| 2011 (WHA 64.14) Global health sector strategy on HIV/AIDS, 2011–2015 | http://apps.who.int/gb/ebwha/pdf_files/WHA64/A64_R14-en.pdf?ua=1 | 2 |
| The United Nations Secretary-General's High-Level Panel on Access to Medicines Report - Promoting Innovation and Access to Health Technologies | http://www.unsgaccessmeds.org/final-report/ | 70 |
| [e-drug] Health Action International Response to UN HLP Report on Access to Medicines | Hard copy examined | 1 |
| [e-drug] MSF response to UNSG HLP on Access to Medicines report | Hard copy examined | 1 |
| [e-drug] Oxfam policy briefing on the UN HLP | Hard copy examined | 1 |
| Report of the UN Secretary-General's High-Level Panel on human rights and medicines: Oxfam's response | http://policy-practice.oxfam.org.uk/publications/report-of-the-un-secretary-generals-high-level-panel-on-human-rights-and-medicines-620085 | 10 |
| MSF wants the Naked Truth on R&D as new report launched | Hard copy examined | 3 |

| Title | Source | Page Count |
|--|---|------------|
| MSF R&D Report: Lives on the Edge | http://www.msfacecess.org/content/rd-report-lives-edge | 56 |
| [e-drug] Oxfam GB comment on HLP report | Hard copy examined | 1 |
| WHO Progress Report 2012 | http://apps.who.int/gb/ebwha/pdf_files/WHA65/A65_26-en.pdf page 9 | |
| WHO Progress Report 2014 | http://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_40-en.pdf page 17 | |
| Commission Staff Working Document Investing in Health Accompanying the Document Communication from the Commission to The European Parliament, the Council, the European Economic and Social Committee and the Committee of the Regions Towards Social Investment for Growth and Cohesion - including implementing the European Social Fund 2014-2020 | http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52013SC0043&from=EN | 23 |
| OECD Health Policy Studies Pharmaceutical Pricing Policies in a Global Market | Hard copy examined | 215 |
| Website of African Network for Drugs and Diagnostics Innovation (ANDI) - Mandate | http://www.andi-africa.org/index.php/about-us/mandate | web |
| National strategy for pharmaceutical manufacturing development in Ethiopia, 2015–2025 | http://www.who.int/phi/publications/Ethiopia_strategy_local_production.pdf | 37 |
| Joint Procurement of medical countermeasures | http://ec.europa.eu/health/preparedness_response/joint_procurement_en | web |
| Innovative Financing Mechanism for Global Health Innovation Charles W. Wessner, Ph.D, Director of Technology & Innovation, US National Academies of Science With support from the Global Forum for Health Research, Geneva | http://www.who.int/phi/SBIR.pdf | 2 |
| The role of NGOs in global health research for development | https://health-policy-systems.biomedcentral.com/articles/10.1186/1478-4505-3-3 | 21 |
| Comparative Review of Innovative Financing Proposals for Health R&D | https://www.google.hu/?gws_rd=ssl#q=www.who.int%2Fphi%2FCompreviewEWGDec09.doc | 42 |
| Local Production for Access to Medical Products: Developing a Framework to Improve Public Health | http://www.who.int/phi/publications/Local_Production_Policy_Framework.pdf | 78 |
| Technical Cooperation Activities: Information from Other Intergovernmental Organizations | http://www.who.int/phi/WHO_Report_to_WTO_2014_final_W603A1.pdf?ua=1 | 6 |
| An Innovative Approach to R&D for neglected patients ten years of experience & lessons learned by DNDi | http://www.dndi.org/wp-content/uploads/2009/03/DNDi_Modelpaper_2013.pdf | 24 |
| Strategy 2010–2016 Swiss Tropical and Public Health Institute | Hard copy examined | 15 |
| Global Biomedical R&D Fund and Mechanisms for Innovations of Public Health Importance | Hard copy examined | 4 |
| Improving access: overcoming barriers Roche's commitment to sustainable healthcare | http://www.roche.com/dam/jcr:a9c0006a-fed9-4864-a8c9-8ffec6ca508/en/access_to_healthcare.pdf | 28 |
| Swissmedic, Swiss Agency for Therapeutic Products IdAG Gesundheitsaussenpolitik, 20. June 2016 | Hard copy examined | 10 |

List of Documents Supplied as Part of Country Case Studies

| |
|---|
| Using Intellectual Property Rights |
| Department of Science and Technology – Republic of South Africa Bioeconomy Strategy 2013 |
| Department of Health Province of Kwazulu-Natal Health Research & Knowledge Management - RESEARCH BULLETIN JULY 2016 |
| MomConnect |
| Grants Innovation and Product Development Presentation South African Medical Research Council |
| South Africa Country Operational Plan 2016 - USA-PEPFAR |

| |
|--|
| South Africa- Right to Care - Programme Overview |
| South Africa-Saving Blood Saving Lives Project |
| Afghanistan National Health Policy 2015-2020 |
| Country Cooperation Strategy for WHO and Afghanistan 2009–2013 |
| EAC Regional Pharmaceutical Manufacturing Plan of Action 2012-2016 |
| Health Action International (HAI) Africa, IQ sensate – Summary of Pilot Monitoring Tool to Assess the Implementation of the WHO Global Strategy on Essential Health Research |
| Obligations of low income countries in ensuring equity in global health financing BMC Medical Ethics |
| Rwanda Intellectual Property Policy 2009 |
| WHO COUNTRY COOPERATION STRATEGY 2009-2013 Rwanda |
| WHO COUNTRY COOPERATION STRATEGY Rwanda 2014-2018 |
| WHO EMRO - New assessment highlights gaps in health service provision in Afghanistan - Afghanistan-news |
| Joint Preparatory NCDs Assessment Mission to Jordan 31st May – 6th June 2015 - Final Report |
| 2014 Q3 Jordan Pharmaceuticals and Healthcare Report |
| Jordan 2025 A National Vision and Strategy part1 |
| Jordan 2025 A National Vision and Strategy part2 |
| Jordan Factsheet Tobacco Control, 2015 |
| INTELLECTUAL PROPERTY REGIME, INFRASTRUCTURE AND RELATED PROCEDURES - Enhancing Access to Treatment: Intellectual Property Protection and HIV/AIDS - The Kingdom of Jordan |
| National response for prevention and control of NCDs2015 |
| National response for prevention and control of NCDs 2016 |
| Maternal Mortality Study |
| Policy Directions Jordan National Health Sector Strategy (2015-2019) |
| Jordan Ministry of Health Strategic Plan 2013-2017 |
| Non-communicable Diseases in the Eastern Mediterranean Region Jordan Country Profile2014 |
| Projecting the Prevalence of Major Non-Communicable Diseases / Risk Factors for the Jordanian Youth Population for the Years 2007 - 2050 |
| Promoting Access to Medical Technologies and Innovation |
| Swiss Health Foreign Policy |
| Strategy 2010–2016 Swiss Tropical and Public Health Institute |
| SDC Engagement In Product Development Partnerships |
| Preparatory note for the Open-ended meeting “Follow-up of the report of the CEWG” |
| Global Biomedical R&D Fund and Mechanisms for Innovations of Public Health Importance |
| WHO Global Strategy and Plan of Action on Public Health, Innovation and Intellectual Property: the Contribution of Switzerland |
| An Innovative Approach to R&D for neglected patients ten years of experience & lessons learned by DNDi |
| Improving access: overcoming barriers Roche’s commitment to sustainable healthcare |
| Swissmedic, Swiss Agency for Therapeutic Products IdAG Gesundheitsaussenpolitik, 20. June 2016 |
| Response of the Association of University Technology Managers to Q112 in the GSPOA Survey |
| AUTM In the Public Interest: Nine Points to Consider in Licensing University Technology |
| AUTM Statement of Principles and Strategies for the Equitable Dissemination of Medical Technologies |
| UN High-Level Panel on Access to Medicines BVGH contribution |
| FNIH 2011 Annual Report |
| FNIH 2012 Annual Report |
| FNIH 2013 Annual Report |
| FNIH 2014 Annual Report |
| FNIH 2015 Annual Report |
| From idea to impact: How the US government can improve coordination of global health research and development |
| Achieving a bold vision for global health: Policy solutions to advance global health R&D |
| USAID Health-Related Research and Development |
| Progress Report An Update on the 2011–2015 Health Research Strategy |
| GHTC A Pipeline of Promise Global Health Research and Product Development Process |
| GFINDER Neglected Disease Research and Development: The Ebola Effect |
| GHTC Briefing Paper, Volume 1: Developing technologies to address poverty-related and neglected diseases and conditions |
| GHTC Briefing Paper, Volume 2: Financing health research and development |
| GHTC Briefing Paper, Volume 3: Improving the affordability, availability, and acceptability of health technologies |
| GHTC Briefing Paper, Volume 4: Addressing regulatory challenges throughout the product development process |
| GHTC Briefing Paper, Volume 5: Working with partners to strengthen local research and manufacturing capacity |
| The Hatch-Waxman Act and Market Exclusivity for Generic Manufacturers: An Entitlement or an Incentive |
| Hatch-Waxman, Generics, and Patents: Balancing Prescription Drug Innovation, Competition, and Affordability |

| |
|---|
| Laing & Kaplan Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines An Overview of Key Concepts, Issues and Opportunities for Future Research |
| African Vaccine Initiative (AVI) – A new approach towards Vaccine Self-sufficiency in Africa - A background presentation to AVI |
| NBER 2014 Cockburn - Patents and the Global Diffusion of New Drugs |
| International Biomedical Research: The Role of the National Institutes of Health - A White Paper Prepared for the NIH Directors |
| PATH's Guiding Principles for Private Sector Collaboration |
| Bringing new health technologies within reach for everyone |
| Email of links supplied by PATH 2016 AUG 02 |
| PATH Annual Report 2015 |
| PhARMA email from Ayelet Haran 2016 JUL 28 |
| Email from Robert Emrey – re: USAID documents |
| A Decade of Progress - The President's Malaria Initiative Tenth Annual Report to Congress April 2016 |
| USAID'S VISION FOR HEALTH SYSTEMS STRENGTHENING |
| US Government: Global Health Initiative Promoting Partnerships to Advance GHI Objectives 2013 |
| The Office of the United States Trade Representative - 2016 Special 301 Report |

List of Documents and Websites Supplied as Part of the Survey

Element 1

| |
|---|
| http://www.bt.com.bn/news-national/2011/09/24/1-gdp-be-allotted-research |
| http://www.ubd.edu.bn/faculties-and-institutes/iber/ |
| http://www.ubd.edu.bn/faculties-and-institutes/iber/ |
| http://vufind.uniovi.es/Record/oai:doaj.org/article:83f54affe03044f3ab7798dc7a1e9386 |
| http://www.isciii.es/ISCIII/es/contenidos/fd-investigacion/fd-financiacion/convocatorias-ayudas-accion-estrategica-salud.shtml |
| https://www.sm.ee/sites/default/files/content-editors/eesmargid_ja_tegevused/Tervis/strategy_research_and_innovation_for_health.pdf |
| https://www.sm.ee/sites/default/files/content-editors/eesmargid_ja_tegevused/Tervis/Aruanded/rta_2009-2020_2012_eng.pdf |
| http://government.ru/docs/7257/ |
| http://www.ins.gob.pe/repositorioaps/0/2/ier/mater_prior/Resumen%20Ejecutivo%20Proceso%20de%20Prioridades%20de%20Investigacion%2011_05_15%20v4R.pdf |
| http://bvsms.saude.gov.br/bvs/publicacoes/agenda_nacional_prioridades_2ed_3imp.pdf |
| www.pchrd.dost.gov.ph |
| http://qfrd.org/QNRS_2012/QNRS_2012.pdf |
| http://www.qnrf.org/Portals/0/Download/QNRS%202014.pdf |
| https://www.moph.gov.qa/about/departments/research |
| http://www.sidra.org/wp-content/uploads/PDFs/sidras-five-year-strategic.pdf |
| https://www.hamad.qa/EN/education-and-research/Medical-Research/About%20MRC/Pages/Vision-and-Mission.aspx |
| http://www.nimr.or.tz/wp-content/uploads/2013/10/National-Health-Research-Priorities-2013-2018.pdf |
| http://srf.gov.io/National-priorities |
| http://www.observatoriorh.org/guatemala/sites/observatoriorh.org/guatemala/files/webfiles/publicaciones/Subcomisiones/Areas_y_Prioridades_de_Investigacion_para_la_Salud_2014.pdf |
| http://www.vyzkum.cz/FrontClanek.aspx?idsekce=653383 |
| https://www.ministeriodesalud.go.cr/index.php/investigacion-y-tecnologia-en-salud/plan-nacional-de-ciencia-tecnologia-en-salud/file |
| https://www.ministeriodesalud.go.cr/index.php/sobre-ministerio/politicas-y-planos-en-salud/politicas-en-salud/2746-politica-nacional-de-salud-2015/file |
| http://www.who.int/phi/wto_communications/en/ |
| http://www.who.int/reproductivehealth/topics/maternal_perinatal/pph-carbetocin/en/ |
| http://www.who.int/phi/implementation/consultation_imnadr/en/ |
| http://www.who.int/research-observatory/en/ |
| http://www.worldhypertensionleague.org/ |
| http://www.mmv.org/research-development/interactive-rd-portfolio |
| http://www.mmv.org/research-development/target-product-profiles-target-candidate-profiles |
| http://www.mmv.org/research-development |

Element 2

| |
|---|
| http://www.bt.com.bn/news-national/2014/03/11/budget-boost-research-and-development-funds |
| http://www.bt.com.bn/news-national/2012/04/15/rkn10-spotlight-innovation-and-r-d |
| https://home.trc.gov.om/Default.aspx?alias=home.trc.gov.om/arabic |
| http://mohcsr.gov.om/ |
| http://www.rimais.net/ |
| http://eulachealth.eu/es/ |
| http://www.ras.ru/scientificactivity/plan2025.aspx |
| http://www.msmsu.ru/userdata/manual/doc/nauka/strategiya%20razvitiya%20med%20nauki.pdf |
| http://adala.justice.gov.ma/production/html/Fr/190513.htm |
| http://www.sante.gov.ma/Pages/Dossiers.aspx |
| http://www.conicyt.cl/fonis/ |
| http://web.minsal.cl/portal/url/item/c4034eddbbc96ca6de0400101640159b8.pdf |
| http://web.minsal.cl/portal/url/item/c4034eddbbc96ca6de0400101640159b8.pdf |
| http://www.campack-cm.com/minresi/images/communique/organigramme%20minresi%202012.pdf |
| http://www.gknt.gov.by/opencms/opencms/ru/zakonadatelstvo/z2/ |
| http://www.gknt.gov.by/opencms/opencms/ru/zakonadatelstvo/z2/ |
| www.pchrd.dost.gov.ph |
| http://www.isqua.org/Events/previous-conferences/doha-2015/post-conference |
| http://www.qnl.qa/ |
| http://www.qnrf.org/ |
| www.mesr.gouv.sn |
| www.sante.gouv.sn |
| http://drp.muhas.ac.tz/Documents/Research_Information/The%20National%20Research%20and%20Development%20Policy.pdf |
| http://www.r4d.ch/News/Pages/160406_newr4dprojects_OC2.aspx |
| https://www.shareweb.ch/site/Health/publiclibrary/Public%20Library/Strategic%20Framework%202015%E2%80%932019%20SDC%20Global%20Programme%20Health.pdf |
| http://www.accesstomedicineindex.org/novartis-ag |
| http://www.accesstomedicineindex.org/roche-holding-ag |
| http://www.swisstph.ch |
| http://www.srf.gov.io |
| http://journals.ju.edu.jo/JMJ |
| http://journals.ju.edu.jo/JJPS |
| http://srtf.hcst.gov.io/ |
| http://hcst.gov.io/ |
| http://www.mspas.gob.gt/files/Descargas/LeyPresupuesto2014/17bis/Plan%20estrategico%20MSPAS%202014-2019%20version%20040414.pdf |
| http://www.vyzkum.cz/FrontClanek.aspx?idsekce=743635 |
| http://www.who.int/csr/research-and-development/en/ |
| http://www.worldhypertensionleague.org/ |
| http://www.gsk.com/media/280806/clinical-trials-in-the-developing-world-policy.pdf |
| http://www.gsk.com/media/280827/disclosure-of-clinical-trial-information-policy.pdf |
| http://www.gsk.com/en-gb/research/ |
| http://www.gsk.com/en-gb/research/open-innovation/diseases-of-the-developing-world/ |

Element 3

| |
|---|
| http://www.oxfordbusinessgroup.com/news/investing-innovation-brunei-darussalam |
| https://itif.org/publications/2011/12/05/innovation-trade-and-technology-policies-asia-pacific-economies-scorecard |
| http://www.idi.mineco.gob.es/stfls/MICINN/Investigacion/FICHEROS/Estrategia_espanola_ciencia_tecnologia_Innovacion.pdf |
| http://government.ru/docs/7257/ |
| http://www.rusnano.com/investment/strategy |
| http://www.rusnano.com/infrastructure/rusnanoprize |
| http://www.portal.ins.gob.pe/es/cnpb/cnpb-c2/productos-cnpb/relacion-productos-cnpb |
| http://www.ompic.org.ma/fr/content/partenariats-au-niveau-international |
| http://www.enssup.gov.ma/fr |
| http://www.csefrs.ma |
| http://www.sante.gov.ma/Pages/Dossiers.aspx |
| http://www.gknt.gov.by/opencms/opencms/ru/zakonadatelstvo/z2/ |

| |
|---|
| www.pchrd.dost.gov.ph |
| https://ghcc.moph.gov.qa/Uploads/da60c709-f968-422f-8dc6-3b6efc3774cf.pdf |
| https://ghcc.moph.gov.qa/Uploads/add24c82-b73c-4e85-99b7-b1ae4e6e155f.pdf |
| http://www.nhsq.info/app/media/4053 |
| www.mesr.gouv.sn |
| www.sante.gouv.sn |
| http://www.sbf.admin.ch/themen/01370/01390/01420/index.html?lang=en |
| http://www.indepth-network.org/ |
| https://www.novartis.com/about-us/corporate-responsibility/expanding-access-healthcare/our-work-africa |
| www.mspas.gob.gt |
| www.medicamentos.com.gt |
| www.tulasalud.org |
| senacyt.concyt.gob.gt/portal/ |
| http://www.nudz.cz/en/ |
| https://www.tacr.cz/index.php/en/international-collaboration.html |
| https://avobloguje.wordpress.com/avo/ |
| http://www.avcr.cz/en/ |
| http://www.who.int/phi/implementation/monitoring/national_phi_assessment_tool_gspa_oct14.pdf?ua=1 |

Element 4

| |
|---|
| https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&cad=rja&uact=8&ved=0ahUKEwj1uo6E75fNAhUBul8KHfxHCmsQFggMAI&url=http%3A%2F%2Fwww.uis.unesco.org%2FStatisticalCapacityBuilding%2FWorkshop%2520Documents%2FST%2520Workshop%2520dox%2FVietnam%25202011%2FBRUNEI%2520NATIONAL%2520%2520PRESENTATION%2520V1%2520.pptx&usq=AFQjCNH5s4sp25ORakCpGdrt1RJ4LesNrg&sig2=saTebklzC8vzCcZhCffj8w&bvm=bv.124088155.d.c2l |
| https://www.rosminzdrav.ru/news/2016/03/15/2844-ministr-veronika-skvortsova-vystupila-na-kruglom-stole-rossiyskaya-vaktsina-protiv-eboly-pervye-uroki-i-vzglyad-v-budushee |
| https://www.rosminzdrav.ru/news/2016/01/15/2728-ministr-veronika-skvortsova-posetila-fnts-epidemiologii-i-mikrobiologii-im-pochetnogo-akademika-n-f-gamalei-gde-poluchena-rossiyskaya-vaktsina-protiv-eboly |
| https://www.rosminzdrav.ru/news/2016/02/15/2782-v-zheneve-proshla-prezentatsiya-rossiyskoy-vaktsiny-ot-eboly |
| http://www.financenews.press.ma/site/economie/13844-industrie-pharmaceutique-ayman-cheikh-lahlou-a-coeur-ouvert |
| http://aujourd'hui.ma/societe/sothema-biocad-trois-nouveaux-medicaments-contre-le-cancer |
| http://telquel.ma/2016/04/15/sothema-250-millions-dirhams-anticancereux_1492332 |
| http://www.sante.gov.ma/Documents/2016/02/PPN-Fr-2015.pdf |
| http://www.mcinet.gov.ma/~mcinetgov/fr/content/pharmacie |
| http://laviieco.com/news/economie/le-portugais-tecnimede-double-le-capital-de-sa-filiale-marocaine-atlas-pharm-29733.html |
| www.pchrd.dost.gov.ph |
| http://qatar-weill.cornell.edu/media/reports/2015/wcm-q-workshop-targets-diabetes-related-infections.html |
| http://www.qf-arf.org/ |
| http://eservices.moph.gov.qa/qpsw/media.jsp |
| http://www.crdglobal.org/grants-and-grantees/current-funding-opportunities/2014/06/09/2014-u.s-qatar-mena-research-initiative |
| www.snte.gouv.sn |
| www.mesr.gouv.sn |
| www.rars.org |
| http://www.ihl.or.tz/projects/biomedical1 |
| http://www.csr.ch/ |
| http://www.csr.ch/organisation.php?historique |
| http://www.ifda.jo/EchoBusV3.0/SystemAssets/PDF/AR/LawsAndRegulation/Drug/RegisterSection/10_316.pdf |
| http://www.invegem.org/ |
| https://i2qb3.umg.edu.gt/quienes-somos/servicios-2/laboratorio-de-biologia-molecular-2/ |
| http://senacyt.concyt.gob.gt/portal/ |
| http://www.enterprise-europe-network.cz/en/publications/transfer-papers/innovative-treatment-of-obstructive-sleep-apnea-by-mad-r?FfGenericListItem_page=5 |
| http://www.enterprise-europe-network.cz/en/publications/transfer-papers/using-the-conductive-ink-not-only-in-medicine?FfGenericListItem_page=3 |
| http://www.enterprise-europe-network.cz/en/publications/transfer-papers/small-size-hemp-processing-technology?FfGenericListItem_page=2 |
| http://www.enterprise-europe-network.cz/en/publications/transfer-papers?FfGenericListItem_page=6 |

| |
|---|
| http://www.who.int/phi/programme_technology_transfer/en/ |
| http://www.gsk.com/media/280902/technology-transfer-vaccines-policy.pdf |
| http://www.gsk.com/media/280860/ip-atm-developing-countries-policy.pdf |
| http://www.gsk.com/media/383996/technology-transfer-capacity-building-and-developing-countries.pdf |
| http://www.gsk.com/en-gb/research/open-innovation/diseases-of-the-developing-world/ |
| http://www.sciencedirect.com/science/journal/0264410X/29/supp/S1 |
| http://www.who.int/influenza_vaccines_plan/objectives/objective2/en/ |

Element 5

| |
|---|
| http://www.inta.org/INTABulletin/Pages/Brunei_IP_Office_DG_Interview_7019.aspx |
| http://www.ompic.org.ma/fr |
| http://www.ompic.org.ma/sites/default/files/Strategie_OMPIC_2020_Fr.pdf |
| http://www.wipo.int/wipolex/fr/text.jsp?file_id=315988 |
| http://pravo.by/main.aspx?guid=3871&p0=C21200205&p1=2 |
| www.pchrd.dost.gov.ph |
| http://www.qf.org.qa/news/qf-sets-up-intellectual-property-and-technology-transfer-office |
| https://cdn.qf.com.qa/app/media/18455 |
| www.mesr.gouv.sn |
| www.bsda.sn |
| http://www.haiafrica.org/index.php?option=com_content&view=article&id=273:a-briefing-paper-on-the-utilization-of-trips-flexibilities-in-the-eac-region&catid=78:news |
| http://senacyt.concyt.gob.gt/portal/ |
| digi.usac.edu.gt |
| http://www.uvg.edu.gt/investigacion/ces/index.html |
| http://www.paho.org/gut/ |
| http://www.bc.cas.cz/en/ |
| http://www.who.int/phi/implementation/ip_trade/ip_patent_landscapes/en/ |
| http://www.who.int/phi/wto_communications/en/ |
| http://www.gsk.com/media/280860/ip-atm-developing-countries-policy.pdf |
| http://www.wipo.int/research/en/ |
| http://www.gsk.com/en-gb/media/press-releases/2016/gsk-expands-graduated-approach-to-patents-and-intellectual-property-to-widen-access-to-medicines-in-the-world-s-poorest-countries/ |
| https://www.southcentre.int/category/publications/research-papers/ , with particular reference to # 61, 49, 47, 42, 41 and 35. ¹ |

Element 6

| |
|---|
| https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=3&cad=rja&uact=8&ved=0ahUKEwiBj7WcsKTNAhVBqpQKHe0AClgQFgg2MAI&url=http%3A%2F%2Fwww.who.int%2Fphi%2Fpublications%2FIncreasing_Access_to_Diagnostic_s_Through_Technology_Transfer.pdf&v6u=https%3A%2F%2Fs-v6exp1-ds.metric.gstatic.com%2Fgen_204%3Fip%3D103.4.190.222%26ts%3D1465799384231185%26auth%3Dusv5inbhvwrwvqu2xymgq5qmtgpmrfe7%26rndm%3D0.606398484185543&v6s=1&v6t=50477&usg=AFQjCNG98-ldSDz0MpTJ875fRUh0X32KwA&sig2=d_3-4RLEMCgyskMNPoH2Gg |
| https://www.boe.es/buscar/act.php?id=BOE-A-1986-10499 |
| https://www.boe.es/diario_boe/txt.php?id=BOE-A-2015-8343 |
| http://publication.pravo.gov.ru/Document/View/0001201601040062 |
| https://www.rosminzdrav.ru/open/supervision/format |
| http://bvcenadim.digemid.minsa.gob.pe/ |
| http://diprece.minsal.cl/le-informamos/auge/ |
| http://www.minsal.cl/leyricarte/ |
| http://www.minsal.cl/programa-nacional-de-inmunizaciones/ |

¹ #61 (Guidelines on Patentability and Access to Medicines);
 #49 (Public-private Partnerships in Global Health: Putting Business before Health?);
 #47 (Access to Medicines and Intellectual Property: The contribution of the World Health Organization);
 #42 (Rethinking Global Health: A Binding Convention for R&D for Pharmaceutical Products);
 #41 (Pharmaceutical Innovation, Incremental Patenting and Compulsory Licensing);
 #35 (The Right to Health and Medicines: The Case of Recent Negotiations on the Global Strategy on Public Health, Innovation and Intellectual Property).

| |
|---|
| http://web.minsal.cl/programas-alimentarios-nacionales/ |
| www.moph.gov.lb |
| www.pchrd.dost.gov.ph |
| http://www.sch.gov.qa/app/media/24 |
| http://www.nhsq.info/strategy-goals-and-projects/affordable-services/healthcare-infrastructure-master-plan |
| http://www.nhsq.info/strategy-goals-and-projects/skilled-national-workforce |
| http://www.nhsq.info/strategy-goals-and-projects/comprehensive-world-class-healthcare/community-pharmacies-strategy |
| http://www.gnrf.org/LinkClick.aspx?fileticket=e4cpWNKMmj0%3d&tabid=120&portalid=0&mid=494 |
| www.pna.sn |
| http://nexus.som.yale.edu/ph-tanzania/?q=node/111 |
| https://www.swissmedic.ch/ueber/01398/03317/index.html?lang=de |
| http://www.swisstph.ch/about-us/departments/medicines-research.html |
| www.medicusmundi.ch |
| https://www.swissmedic.ch/ueber/01398/03317/index.html?lang=de |
| https://www.novartis.com/about-us/corporate-responsibility/expanding-access-healthcare/novartis-access |
| https://www.eda.admin.ch/deza/en/home/themen/gesundheit.html |
| http://www.sukl.eu/index.php?lang=2 |
| https://www.celnisprava.cz/cz/dalsi-kompetence/ochrana-spolecnosti-a-zivotniho-prostredi/Stranky/leky-leciva.aspx |
| http://www.who.int/phi/publications/category/en/ |
| http://www.worldhypertensionleague.org/ |
| http://www.gsk.com/media/280905/tiered-pricing-for-vaccines-policy.pdf |
| http://www.gsk.com/en-gb/responsibility/health-for-all/ |
| http://www.gsk.com/en-gb/responsibility/health-for-all/access-to-healthcare/ |

Element 7

| |
|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4256544/ |
| http://www.un.org/esa/agenda21/natlinfo/countr/brunei/social.htm |
| https://www.hse.ru/data/2012/06/06/1252970299/%D0%9F%D0%BE%D0%BB%D1%8F%D0%BA%D0%BE%D0%B2_%D0%A1%D0%93_26.05.12.pdf |
| https://portal.concytec.gob.pe/ |
| http://www.pravo.by/main.aspx?guid=3871&p0=v19302105&p2={NRPA} |
| http://www.pravo.by/main.aspx?guid=3871&p0=C21001326 |
| www.pchrd.dost.gov.ph |
| http://www.un.org/esa/ffd/ffd3/wp-content/uploads/sites/2/2015/10/Tanzania-Health-Financing-Brief-update_FINAL.pdf |
| http://www.who.int/tdr/publications/r_d_report/en/ |
| http://www.invegem.org/ |
| http://senacyt.concyt.gob.gt/portal/ |
| http://www.msmt.cz/research-and-development-1 |
| http://www.vyzkum.cz/Default.aspx?lang=en |
| http://www.who.int/phi/implementation/research/en/ |
| https://www.ghitfund.org/about/mediacenter/pressdetail/detail/165 |
| http://unitingtocombatntds.org/ |
| http://www.gsk.com/en-gb/media/press-releases/2015/gsk-extends-its-price-freeze-commitment-to-ten-years-for-countries-graduating-from-gavi-support/ |

Element 8

| |
|---|
| http://www.ubd.edu.bn/research/ |
| http://www.csps.org.bn/reports.html |
| http://www.roszdravnadzor.ru/drugs |
| http://www.sante.gov.ma/Pages/Dossiers.aspx |
| http://www.sante.gov.ma/Publications/Etudes_enquete/Pages/default.aspx |
| www.pchrd.dost.gov.ph |
| www.sante.gouv.sn |
| www.mesr.gouv.sn |
| www.dsrse.sn |
| http://www.mineco.gob.gt/sites/default/files/mineco_memoria_de_actividades_ano_2015-.pdf |
| https://www.rpi.gob.gt/descargas/informe2015.pdf |
| http://www.worldhypertensionleague.org/ |

| |
|---|
| http://unitingtocombatntds.org/report/fourth-report-reaching-unreached |
| http://www.gsk.com/en-gb/behind-the-science/innovation/inside-the-open-lab/ |
| http://www.gsk.com/en-gb/media/press-releases/2014/gsk-joins-with-research-councils-in-uk-and-south-africa-to-tackle-non-communicable-diseases-in-africa/ |
| http://www.who.int/phi/implementation/monitoring/en/ |
| http://www.who.int/phi/implementation/ME framework and implementation final.pdf?ua=1 |
| http://69.90.223.32:9090/oms/ |
| http://www.who.int/phi/implementation/monitoring/national phi assessment tool gspa oct14.pdf?ua=1 |
| http://www.who.int/phi/implementation/monitoring/Sri Lanka-report.pdf?ua=1 |
| http://prais.paho.org/rscpaho/#/home |

Other generic websites

| |
|---|
| http://www.nhsq.info/homepage |
| http://www.worldhypertensionleague.org/ |

Annex 4 DATA ANALYSIS STRUCTURE AND TEMPLATE

Annex 4.1 Data Analysis Structure

To make NVivo operational, a hierarchical system of nodes (points of reference) were defined. All GSPOA Elements, Sub-Elements, Specific Actions, as well as statement and indicators specified in the GSPOA were split out into as many nodes as were necessary to capture the various nuances. For example, page 11 of the GSPOA, sub-element 3.4 states:


“(3.4) Supporting policies that will promote innovation based on traditional medicine within an evidence-based framework in accordance with national priorities, taking into account the relevant provisions of relevant international instruments: (a) establish and strengthen national and regional policies to develop, support and promote traditional medicine.”

In order to capture evidence that both “national and regional policies” had been established or strengthened, two nodes were created (3.6.2 and 3.6.3) to capture the actions identified in sub-element 3.4a.


Nodes were also created for source countries; these served the purpose of identifying the correct WHO Regions and World Bank country income groups (high, upper middle, lower middle and low).

After all data had been coded in NVivo, the assigned Evaluators ran queries to extract data by NVivo node, differentiated by Region and World Bank country income groups. The triangulation of data for each node resulted in a node-specific summary that highlighted, if possible, differences and similarities across regions and income groups. Once completed, the node-specific summaries were aggregated into a summary at the sub-element and indicator level.

NVivo Node Structure



Analysis Flow



Annex 4.2 Data Analysis Template

WHO GSPOA ELEMENT LEVEL DATA ANALYSIS

Data Analyst: [Please specify your name]

ELEMENT #:

ELEMENT Title:

ELEMENT Synthesis:

| Node Analysis | | |
|--------------------------------|--------------|-----------------------|
| Node: # | Region | Evidentiary Substance |
| All Income Levels | All Regions | • |
| | African | • |
| | Americas | • |
| | Eastern Med. | • |
| | European | • |
| | SE Asia | • |
| | West Pacific | • |
| High Income Level [B1] | African | • |
| | Americas | • |
| | Eastern Med. | • |
| | European | • |
| | SE Asia | • |
| Upper Middle Income Level [B2] | African | • |
| | Americas | • |
| | Eastern Med. | • |
| | European | • |
| | SE Asia | • |
| Lower Middle Income Level [B3] | African | • |
| | Americas | • |
| | Eastern Med. | • |
| | European | • |
| | SE Asia | • |
| Low Income Level [B4] | African | • |
| | Americas | • |
| | Eastern Med. | • |
| | European | • |
| | SE Asia | • |
| Node Synthesis: | | |


Annex 5 STAKEHOLDER PROFILE

The opinions of all stakeholder groups identified in the Inception Report were represented to varying degrees in the data collected and analyzed. However, the coverage could have been enhanced with greater participation by the members of Public-Private-Partnerships (PPPs), Product Development Partnership), R&D Groups (C-12) and Other International Organisations (C-13) in the survey. While the participation in the survey by many stakeholder groups was low, the opinions of most stakeholder groups were collected by way of significant Key Informant Interviews, Focus Groups, and the documents collected during the country case studies. The number of survey participants who accessed the survey website, but did not participate (38%, n=93) raises questions about the degree to which the various stakeholders that had been identified were actually aware of the GSPOA and/or the role they had been expected to play in it.


5.1 Coding References

The following graph illustrates the comparison of how many references across all data sources were coded to the macro stakeholder groups indicated.

Graph 300 Coding References by Stakeholder Group



Graph 301 Coding References by Element



The following table show the extent of coverage of data by GSPOA Element and stakeholder group. Each convergent cell reflects the number of references in the overall data set that were coded to the stakeholder group identified (in the horizontal), and the GSPOA Element identified (in the vertical)

Table 1: Coding References by Element and Stakeholder Group

| | High Income | Upper Middle Income | Lower Middle Income | Low Income | WHO | Civil Society | Academia | Charitable Orgs | Communities | NGOs | Regulatory Organisations | Regional Organisations | Health-related Industries and Private Sector | National R&D Institutions | International Research Associations | Donor Agencies | Development Partners | PPP, Product Development Partnerships R&D | Product Development Partnerships | Public Private Partnership (PPP) | R&D Groups | Other International Organisations | ILO | IOM | OECD | UNCTAD | UNEP | UNIDO | WFP | WTO | Publishers | Other Relevant Stakeholder (ORS) | Other International Intergovernmental Organisations | Total |
|---|-------------|---------------------|---------------------|-------------|-------------|---------------|------------|-----------------|-------------|------------|--------------------------|------------------------|--|---------------------------|-------------------------------------|----------------|----------------------|---|----------------------------------|----------------------------------|------------|-----------------------------------|-----------|-----------|-----------|-----------|----------|-----------|------------|------------|------------|----------------------------------|---|-------|
| 1: ELEMENT 1 Prioritizing research and development needs | 251 | 244 | 282 | 183 | 230 | 8 | 16 | 18 | 0 | 13 | 6 | 26 | 22 | 31 | 4 | 0 | 4 | 17 | 7 | 16 | 7 | 0 | 4 | 0 | 5 | 2 | 0 | 12 | 35 | 28 | 2 | 4 | 15 | 1491 |
| 2: ELEMENT 2 Promoting research and development | 248 | 203 | 240 | 165 | 162 | 15 | 25 | 30 | 2 | 23 | 11 | 44 | 38 | 21 | 8 | 1 | 7 | 18 | 0 | 1 | 0 | 0 | 5 | 2 | 0 | 4 | 0 | 6 | 37 | 33 | 3 | 6 | 14 | 1373 |
| 3: ELEMENT 3 Building and improving innovative capacity | 266 | 240 | 285 | 184 | 171 | 15 | 16 | 11 | 0 | 19 | 30 | 40 | 33 | 18 | 29 | 1 | 6 | 6 | 0 | 0 | 0 | 0 | 7 | 10 | 3 | 14 | 0 | 6 | 30 | 35 | 17 | 6 | 30 | 1527 |
| 4: ELEMENT 4 Transfer of technology | 210 | 161 | 189 | 178 | 137 | 12 | 8 | 5 | 0 | 12 | 4 | 38 | 47 | 9 | 6 | 3 | 5 | 4 | 0 | 0 | 0 | 1 | 1 | 4 | 1 | 10 | 0 | 3 | 31 | 16 | 9 | 4 | 37 | 1145 |
| 5: ELEMENT 5 Application and management of intellectual property (IP) to contribute to innovation and promote public health | 294 | 251 | 297 | 201 | 136 | 5 | 15 | 5 | 0 | 12 | 12 | 36 | 40 | 5 | 22 | 0 | 4 | 4 | 0 | 0 | 0 | 0 | 3 | 6 | 0 | 17 | 0 | 10 | 201 | 78 | 1 | 4 | 9 | 1669 |
| 6: ELEMENT 6 Improving delivery and access | 400 | 409 | 406 | 323 | 281 | 20 | 9 | 10 | 5 | 25 | 39 | 46 | 21 | 15 | 11 | 4 | 4 | 4 | 7 | 0 | 7 | 0 | 9 | 3 | 2 | 17 | 0 | 21 | 101 | 97 | 16 | 5 | 21 | 2336 |
| 7: ELEMENT 7 Promoting sustainable financing mechanisms | 186 | 153 | 164 | 123 | 178 | 5 | 9 | 20 | 0 | 18 | 2 | 21 | 23 | 11 | 10 | 8 | 7 | 3 | 0 | 1 | 0 | 0 | 12 | 1 | 0 | 4 | 0 | 6 | 38 | 19 | 13 | 7 | 14 | 1055 |
| 8: ELEMENT 8 Establishing monitoring and reporting systems | 87 | 103 | 95 | 68 | 91 | 2 | 3 | 2 | 0 | 11 | 2 | 14 | 5 | 5 | 9 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 0 | 7 | 18 | 10 | 0 | 2 | 5 | 546 |
| Total | 1942 | 1764 | 1957 | 1426 | 1385 | 82 | 101 | 101 | 7 | 134 | 106 | 264 | 230 | 115 | 99 | 17 | 39 | 57 | 14 | 18 | 14 | 1 | 43 | 26 | 11 | 69 | 0 | 71 | 489 | 316 | 61 | 38 | 145 | |
| Governments | | 7090 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

5.2 Sources of Data

The following table shows that all stakeholder groups presented contributed to at least one line of evidence. Each convergent cell reflects the number of references in the overall data set that were coded to the stakeholder group identified (in the horizontal) from the Line of Evidence identified (in the vertical).

Table 2: Sources of Data by Lines of Evidence and Stakeholder Group²

| | High Income | Upper Middle Income | Lower Middle Income | Low Income | WHO | Civil Society | Academia | Charitable Orgs | Communities | NGOs | Regulatory Organisations | Regional Organisations | Health-related industries | National R&D institutions | International Research Associations | Donor Agencies | Development Partners | PPP, Product Development Partnerships | Product Development Partnerships, R&D Groups | Public Private Partnership (PPP) | R&D Groups | Other International Organisations | ILO | IOM | OECD | UNCTAD | UNEP | UNIDO | WIPO | WTO | Publishers | Other Relevant Stakeholder (ORS) | Other International Intergovernmental Organizations (OIG) | Total |
|--------------------------|-------------|---------------------|---------------------|------------|-----|---------------|----------|-----------------|-------------|------|--------------------------|------------------------|---------------------------|---------------------------|-------------------------------------|----------------|----------------------|---------------------------------------|--|----------------------------------|------------|-----------------------------------|-----|-----|------|--------|------|-------|------|-----|------------|----------------------------------|---|-------|
| Document Reviews | 125 | 119 | 127 | 114 | 153 | 4 | 3 | 1 | 1 | 14 | 2 | 18 | 15 | 4 | 7 | 3 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 5 | 0 | 5 | 22 | 9 | 16 | 2 | 15 | 789 |
| Case Study Documents | 25 | 21 | 3 | 8 | 7 | 4 | 4 | 10 | 0 | 4 | 0 | 2 | 3 | 7 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 104 |
| Survey | 24 | 9 | 16 | 16 | 7 | 5 | 21 | 1 | 0 | 16 | 0 | 3 | 5 | 4 | 4 | 0 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 13 | 0 | 151 | |
| Key Informant Interviews | 29 | 40 | 36 | 14 | 8 | 4 | 3 | 1 | 0 | 3 | 6 | 0 | 4 | 8 | 1 | 2 | 1 | 0 | 7 | 1 | 7 | 0 | 1 | 2 | 1 | 2 | 0 | 3 | 9 | 10 | 0 | 0 | 1 | 204 |
| Focus Groups | 6 | 5 | 9 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 4 | 1 | 0 | 0 | 39 |
| Total | 209 | 194 | 191 | 153 | 175 | 17 | 32 | 14 | 2 | 38 | 9 | 24 | 28 | 25 | 13 | 7 | 5 | 1 | 7 | 1 | 7 | 2 | 3 | 3 | 2 | 9 | 0 | 8 | 35 | 24 | 18 | 15 | 16 | |
| Governments | 747 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |

² **Note:** The count of sources in the rows for *Documents* and *Country Case Study Documents* reflect documents where the stakeholder group in question was referenced. For example, if a single document references the WHO, WIPO, and WTO, it is counted in all three respective columns above. The number in the row for *Surveys* represents the number of respondents to the survey from the stakeholder group in question. Both the *Key Informant Interviews* and *Focus Groups* rows reflect the number of “meetings” held with representatives from the stakeholder group in question.

Annex 6 LIST OF EVALUATION CRITERIA AND QUESTIONS

Notes:

- Civil Society: includes concerned communities, charitable foundations, and academia.
- Regulatory: includes regulatory organizations of either national or regional focus.
- Regional: includes organizations with a focus on multiple countries within a specific region.
- Health and Private: refers to "Health-related industries" and private sector.
- National R&D: includes national research institutions
- International R&R: includes international research associations
- Partnerships: includes PPP, PDP, and R&D groups
- Dev Partners: Development Partners
- The survey question numbers (SRV#) differ from the incremental question numbers (Q#) in that they are prefixed by a letter to indicate to which element they belong.

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|---|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | ELEMENT 1: PRIORITIZING RESEARCH AND DEVELOPMENT NEEDS | | | | | | | | | | | | | | | | | | | | | | |
| 1 | A2 | To what extent did your country help to develop methodologies and mechanisms to identify gaps in research on Type II and III diseases? If so, please explain which ones and describe their effect. ³ [1.3.2] | 1.3.2 | Action | C | L10 | 7 | 26 (1.1) (a) | x | x | | | | | | | | | | | | | | |
| 2 | A3 | To what extent did your organization or country help to identify (other) developing countries' specific R&D needs in relation to Type I diseases? Please elaborate and explain their effect. ⁴ [1.3.3] | 1.3.3 | Action | C | L10 | 7 | 26 (1.1) (a) | x | x | | | | | | | | | | | | | | |

³ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries. [1.3.2]

⁴ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|---|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 3 | A4 | To what extent did your country or organization disseminate information on identified gaps? If so, how? [1.3.4] | 1.3.4 | Action | D | L2/O | 7 | 26 (1.1) (b) | x | x | | | | | | | | | | | | | | |
| 4 | A5 | To what extent did your country evaluate the gaps on public health? If so, which ones? [1.3.5] | 1.3.5 | Action | D | L2/O | 7 | 26 (1.1) (b) | x | x | | | | | | | | | | | | | | |
| 5 | A6 | To what extent did your country or organization provide an assessment at the NATIONAL LEVEL of identified gaps to guide research aimed at developing affordable and therapeutically sound products to meet public health needs? If so, which ones? [1.3.6] | 1.3.6 | Action | D | L2/O | 7 | 26 (1.1) (c) | x | x | | | | | | | | | | | | | | |
| 6 | A7 | To what extent did your country or organization provide an assessment at the REGIONAL LEVEL of identified gaps to guide research aimed at developing affordable and therapeutically sound products to meet public health needs? If so, which ones? [1.3.7] | 1.3.7 | Action | D | L2/O | 7 | 26 (1.1) (c) | x | x | | | | | | | | | | | | | | |
| 7 | A8 | To what extent did your country or organization provide an assessment at the INTERNATIONAL LEVEL of identified gaps to guide research aimed at developing affordable and therapeutically sound products to meet public health needs? If so, which ones? [1.3.8] | 1.3.8 | Action | D | L2/O | 7 | 26 (1.1) (c) | x | x | | | | | | | | | | | | | | |
| 8 | A9 | To what extent did your country set research priorities to address public health needs? If so, please describe these priorities? [1.4.4] | 1.4.4 | Action | D | L2/O | 7 | 26 (1.2)a | | x | | | | x | | | | | | | | | | |
| 9 | A10 | To what extent did your country implement public health policy based on appropriate and regular needs assessments? If yes, please explain. [1.4.5] | 1.4.5 | Action | N | L11 | 7 | 26 (1.2)a | | x | | | | x | | | | | | | | | | |
| 10 | A11 | To what extent did your country conduct research appropriate for resource-poor settings? If yes, please explain. [1.4.6] | 1.4.6 | Action | D | L2/O | 7 | 26 (1.2)b | x | x | x | | | | x | x | | | | x | | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|---|--------|-----------------|--|-------------|-------|----------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 11 | A12 | To what extent did your country conduct research on technologically appropriate products for addressing public health needs to combat diseases in (other) developing countries? If yes, please describe. [1.4.7] | 1.4.7 | Action | D | L2/O | 7 | 26(1.2)b | x | x | x | | | | x | x | | | | x | | | | |
| 12 | A13 | To what extent did your country or organization include research and development needs on health systems in a prioritized strategy? If yes, please describe how. [1.4.8] | 1.4.8 | Action | N | L11 | 7 | 26(1.2)c | x | x | x | | | | | x | | | | x | | | | |
| 13 | A14 | To what extent did your country urge the leadership and commitment of GOVERNMENTS in determining priorities for research and development to address public health needs? If yes, please explain. [1.4.9] | 1.4.9 | Action | D | L2/O | 7 | 26(1.2)d | x | x | | | | | x | | | | | | | | | |
| 14 | A15 | To what extent did your country or organization urge the leadership of REGIONAL organizations in determining priorities for research and development to address public health needs? If yes, please explain. [1.4.10] | 1.4.10 | Action | D | L2/O | 7 | 26(1.2)d | x | x | | | | | x | | | | | | | | | |
| 15 | A16 | To what extent did your country or organization urge the leadership and commitment of INTERNATIONAL organizations in determining priorities for research and development to address public health needs. If yes, please explain. [1.4.11] | 1.4.11 | Action | D | L2/O | 7 | 26(1.2)d | x | x | | | | | x | | | | | | | | | |
| 16 | A17 | To what extent did you urge the PRIVATE SECTOR in determining priorities for research and development to address public health needs? If yes, please explain. [1.4.12] | 1.4.12 | Action | D | L2/O | 7 | 26(1.2)d | x | x | | | | | x | | | | | | | | | |
| 17 | A18 | To what extent did your country increase overall research and development efforts on diseases that disproportionately affect the (other) developing countries? If yes, please elaborate. [1.4.13] | 1.4.13 | Action | N | L11 | 7 | 26(1.2)e | x | x | x | | | | x | x | | | | x | | | | |
| 18 | A19 | To what extent did these efforts lead to the development of quality products that address public health needs that are user friendly (in terms of use, | 1.4.14 | Action | C | L10 | 7 | 26(1.2)e | x | x | x | | | | x | x | | | | x | | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|--|-------|-----------------|--|-------------|-------|-------------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | prescription and management) and accessible (in terms of availability and affordability)? If they did, please describe which ones and what was their effect. [1.4.14] | | | | | | | | | | | | | | | | | | | | | | |
| 19 | A20 | To what extent did your country or organization set research priorities in traditional medicine? If yes, please explain. [1.5.3] | 1.5.3 | Action | N | L11 | 8 | 26(1.3) a | x | x | x | | | | | x | | | | x | | | | |
| 20 | A21 | To what extent did your country or organization support (other) developing countries to build their capacity in research and development in traditional medicine? If yes, please explain how and with what results. [1.5.4] | 1.5.4 | Action | D | L2/O | 8 | 26(1.3) b | x | x | x | | | | x | x | | | | x | | | | |
| 21 | A22 | To what extent did your country or organization promote international cooperation and the ethical conduct of research? If yes, please explain. [1.5.5] | 1.5.5 | Action | D | L2/O | 8 | 26(1.3.) c | x | x | | | | | | | | | | | | | | |
| 22 | A23 | To what extent did your country or organization support South–South cooperation in information exchange and research activities? If so, please explain. [1.5.6] | 1.5.6 | Action | D | L2/O | 8 | 26(1.3) d | x | x | | | | x | | | | | | | | | | |
| 23 | A24 | To what extent did your country or organization support early-stage drug research and development in traditional medicine systems in (other) developing countries? If yes, please explain. [1.5.7] | 1.5.7 | Action | D | L2/O | 8 | 26(1.3) e | x | x | | | | | | | | | | | | | | |
| 24 | A25 | Has your country or organization produced, published and disseminated a report on R&D gaps, including health consequences of these gaps in (other) developing countries? If yes, please indicate title(s) and date(s). [1.1.1] | 1.1.1 | Indicator | D | L1/O | 21 | Ind 1st bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 25 | A26 | Has your country prepared a plan for the national health-related R&D capacity-building that prioritizes research and development based on identified public health needs and R&D gaps? If yes, please indicate title(s) and date(s). [1.1.2] | 1.1.2 | Indicator | D | L1/O | 21 | Ind 2nd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|---|-------|-----------------|--|-------------|-------|----------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 26 | A27 | Has your organization or country published a consensus report on global research needs and priorities for a disease or type of intervention? If yes, please indicate title(s) and date(s). [1.1.3] | 1.1.3 | Indicator | D | L1/O | 21 | Ind 3rd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 27 | A28 | To what extent did your country or organization help to map global R&D on diseases that disproportionately affect (other) developing countries? Please explain how and what was their effect. [1.3.1] | 1.3.1 | Sub-element | C | L10 | 7 | 26 (1.1) | x | x | | | | | | | | | | | | | | |
| 28 | A29 | To what extent did your country formulate explicit prioritized strategies for research and development at country level? If so, which ones? [1.4.1] | 1.4.1 | Sub-element | D | L2/O | 7 | 26 (1.2) | x | x | x | | | x | x | x | | | | x | | | | |
| 29 | A30 | To what extent did your country or organization formulate explicit prioritized strategies for research and development at the REGIONAL level? If so, which ones? [1.4.2] | 1.4.2 | Sub-element | D | L2/O | 7 | 26 (1.2) | x | x | x | | | x | x | x | | | | x | | | | |
| 30 | A31 | To what extent did your country formulate explicit prioritized strategies for research and development at the INTER-REGIONAL level? If so, which ones? [1.4.3] | 1.4.3 | Sub-element | D | L2/O | 7 | 26 (1.2) | x | x | x | | | x | x | x | | | | x | | | | |
| 31 | A32 | To what extent did your country encourage R&D in traditional medicine in accordance with national priorities and legislation? If yes, please explain how. [1.5.1] | 1.5.1 | Sub-element | N | L11 | 8 | 26(1.3) | x | x | x | | | x | x | x | | | | x | | | | |
| 32 | A33 | To what extent did your country take into account the relevant international instruments, including, as appropriate, those concerning traditional knowledge and the rights of indigenous peoples? If yes, please explain. [1.5.2] | 1.5.2 | Sub-element | N | L11 | 8 | 26(1.3) | x | x | x | | | x | x | x | | | | x | | | | |
| 33 | A34 | Do health R&D policies of developed countries (your country) reflect the health needs of developing countries? If so, how? [1.2.1] | 1.2.1 | Statement | N | L11 | 7 | 25 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 34 | A35 | Are there any gaps in research on Type II and III diseases and on specific R&D needs of Type I | 1.2.2 | Statement | D | L1/O | 7 | 25 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|---|------|---|-------|-----------------|--|-------------|-------|---------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | diseases? If so, which are they? ⁵ [1.2.2] | | | | | | | | | | | | | | | | | | | | | | |
| 35 | A36 | To what extent do developed countries (your country) have a good understanding of the health needs of developing countries? If so, how did you develop this understanding? [1.2.3] | 1.2.3 | Statement | D | L2/O | 7 | 25 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 36 | A37 | In summary, to what extent have research and development needs been prioritized?[1] | 1 | Element | D | L2 | | | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 37 | A38 | Please elaborate in respect to the prioritized research and development needs in your country. [1] | 1 | Open-ended | D | O | | | | | | | | | | | | | | | | | | |
| ELEMENT 2. PROMOTING RESEARCH AND DEVELOPMENT | | | | | | | | | | | | | | | | | | | | | | | | |
| 38 | B39 | To what extent has your country or organization promoted cooperation between private and public sectors on research and development? Please bring examples of public-private cooperation projects and describe their effect. [2.3.2] | 2.3.2 | Action | C | L10 | 8 | 28.(2.1) a | x | x | | | | | | | | | | | | | | |
| 39 | B40 | To what extent has your organization provided support for national health research programmes in (other) developing countries through political action? If yes, please describe the political action taken and what effect did it have. [2.3.3] | 2.3.3 | Action | C | L10 | 8 | 28(2.1) b | x | x | | | | x | | | | | | | | | | |
| 40 | B41 | To what extent has your country provided support for national health research programmes in developing countries through long- term funding? If yes, please describe the funding mechanisms and their effect. [2.3.4] | 2.3.4 | Action | C | L10 | 8 | 28(2.1) b | x | x | | | | x | | | | | | | | | | |
| 41 | B42 | To what extent has your organization or a country supported governments in establishing health-related innovation initiatives in (other) developing countries? If yes, please describe these initiatives. | 2.3.5 | Action | D | L2/O | 8 | 28(2.1) c | x | x | | | | x | | | | | | | | | | |

⁵ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|--|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | [2.3.5] | | | | | | | | | | | | | | | | | | | | | | |
| 42 | B43 | To what extent has your organization or country supported <u>discovery science</u> , i.e. through <u>voluntary open-source methods</u> , in order to assist (other) developing countries? If yes, please describe your initiatives. [2.4.3] | 2.4.3 | Action | D | L2/O | 8 | 28(2.2) a | x | x | | | | | | | | | | | | | | |
| 43 | B44 | To what extent has your organization or country promoted and improved access to compound libraries through voluntary means for the representatives from the (other) developing countries? If yes, please describe how and what was the effect. [2.4.5] | 2.4.5 | Action | C | L10 | 9 | 28(2.2) b | x | x | | | | | | | | | | | | | | |
| 44 | B45 | To what extent does your organization or country provide technical support to (other) developing countries for conducting upstream research and product development? If so, with which effect? [2.4.6] | 2.4.6 | Action | C | L10 | 9 | 28(2.2) b | x | x | | | | | | | | | | | | | | |
| 45 | B46 | To what extent does your organization or country promote access of (other) developing countries to drug leads identified through the screening of compound libraries? If yes, please describe how and with which effect? [2.4.7] | 2.4.7 | Action | C | L10 | 9 | 28(2.2) b | x | x | | | | | | | | | | | | | | |
| 46 | B47 | To what extent has your organization or country identified barriers, including intellectual property-related provisions that might affect increased research on public health in (other) developing countries? If so, please describe them and elaborate whether these barriers are national, regional or international? [2.4.8] | 2.4.8 | Action | D | L2/O | 9 | 28(2.2) c | x | x | | | | | | | | | | | x | x | | |
| 47 | B48 | To what extent has your organization or country suggested ways to facilitate access to research results and tools for the (other) developing country | 2.4.9 | Action | C | L10 | 9 | 28(2.2) c | x | x | | | | | | | | | | | x | x | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|---|--------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | representatives? If so, please describe how and what was their effect. [2.4.9] | | | | | | | | | | | | | | | | | | | | | | |
| 48 | B49 | To what extent has your organization or country supported basic and applied scientific research on Type II and Type III diseases? If so, please describe how. ⁶ [2.4.10] | 2.4.10 | Action | D | L2/O | 9 | 28(2.2) d | x | x | | | | | | | | | | | | | | |
| 49 | B50 | To what extent has your organization or country supported basic and applied scientific research on the specific research and development needs of (other) developing countries in relation to Type I diseases? If so, please describe how. ⁷ [2.4.11] | 2.4.11 | Action | D | L2/O | 9 | 28(2.2) d | x | x | | | | | | | | | | | | | | |
| 50 | B51 | To what extent has your organization or country supported early-stage drug research and development in (other) developing countries? If so, please describe how. [2.4.12] | 2.4.12 | Action | D | L2/O | 9 | 28(2.2) e | x | x | x | x | | | x | x | x | x | x | | | | | |
| 51 | B52 | To what extent has your country built capacity to conduct clinical trials and other mechanisms for stimulating innovation, taking into account international ethical standards and the needs of (other) developing countries? If so, please describe how. [2.4.13] | 2.4.13 | Action | N | L11 | 9 | 28(2.2)f | x | x | x | x | | | x | | | | x | x | | | | |
| 52 | B53 | To what extent has your country promoted public and other sources of funding for clinical trials and other mechanisms for stimulating local innovation, meeting international ethical standards and the needs of (other) developing countries? If yes, please describe how If yes, please describe how and what | 2.4.14 | Action | C | L10 | 9 | 28(2.2)f | x | x | x | x | | | x | | | | x | x | | | | |

⁶ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

⁷ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|--|--------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | was their effect. [2.4.14] | | | | | | | | | | | | | | | | | | | | | | |
| 53 | B54 | To what extent has your country or organization promoted new knowledge and technologies to facilitate the development of new health products and medical devices to tackle the health problems of (other) developing countries? If yes, please describe your efforts and what was their effect. [2.4.15] | 2.4.15 | Action | C | L10 | 9 | 28(2.2) g | x | x | x | | | | x | x | x | | x | | | | | |
| 54 | B55 | To what extent has your country or organization stimulated and improved global cooperation and coordination in research and development, in order to optimize resources? If yes, please describe your experience and its effect. [2.5.2] | 2.5.2 | Action | C | L10 | 9 | 28(2.3) a | x | x | | | | | | | | | | | | | | |
| 55 | B56 | To what extent has your country or organization enhanced existing forums in order to improve the coordination and sharing of information on research and development activities? If yes, please describe your experience and its effect. [2.5.3] | 2.5.3 | Action | C | L10 | 9 | 28(2.3) b | x | x | | | | | | | | | | | | | | |
| 56 | B57 | To what extent has your country or organization examined the need for new mechanisms in order to improve the coordination and sharing of information on research and development activities? If yes, please describe how and why and its effects? [2.5.4] | 2.5.4 | Action | C | L10 | 9 | 28(2.3) b | x | x | | | | | | | | | | | | | | |
| 57 | B58 | To what extent has your country or organization encouraged further exploratory discussions on the utility of possible instruments for essential health and biomedical research and development? If yes, please describe how and with which outcomes? [2.5.5] | 2.5.5 | Action | D | L2/O | 9 | 28(2.3) c | | x | | x | | | | | | | | | | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|---|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 58 | B59 | To what extent has your country or organization encouraged further exploratory discussions specifically on the utility of essential health and biomedical R&D treaty? If yes, please describe how and with which outcomes? [2.5.6] | 2.5.6 | Action | D | L2/O | 9 | 28(2.3) c | | x | | x | | | | | | | | | | | | |
| 59 | B60 | To what extent has your country or organization supported active participation of (other) developing countries in building technological capacity? If yes, please describe how and with which outcomes? [2.5.7] | 2.5.7 | Action | C | L10 | 9 | 28(2.3) d | x | x | | | | | | | | | | | | | | |
| 60 | B61 | To what extent has your country or organization promoted the active participation of (other) developing countries in the innovation process? If yes, please describe how and with which outcomes? [2.5.8] | 2.5.8 | Action | C | L10 | 9 | 28(2.3) e | x | x | | | | | | | | | | | | | | |
| 61 | B62 | To what extent has your country or organization been promoting the creation and development of accessible public health libraries in order to enhance availability and the use of relevant publications by universities, institutes and technical centres, especially in (other) developing countries? If yes, please describe how and with which outcomes. [2.6.3] | 2.6.3 | Action | C | L10 | 9 | 28(2.4) a | x | x | x | x | | | x | x | x | | | | | | | |
| 62 | B63 | To what extent has your organization or country promoted public access to the results of government-funded research? If yes, please describe how and with which results. [2.6.4] | 2.6.4 | Action | D | L2/O | 10 | 28(2.4) b | x | x | x | | | | | x | x | | | | | | | |
| 63 | B64 | To what extent has your organization or a country encouraged all government-funded researchers to submit an electronic version of their final, peer-reviewed manuscripts to an open access database? If yes, please describe how and with what results. [2.6.5] T | 2.6.5 | Action | C | L10 | 10 | 28(2.4) b | x | x | x | | | | | x | x | | | | | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|--|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 64 | B65 | To what extent has your country or organization been supporting the creation of voluntary open databases and compound libraries? If yes, please describe your experience and its effects. [2.6.6] | 2.6.6 | Action | C | L10 | 10 | 28(2.4) c | x | x | | | | | x | | | | | | x | | | |
| 65 | B66 | To what extent has your country or organization been supporting the access to drug leads identified through the screening of compound libraries? If yes, please describe how and its effects. [2.6.7] | 2.6.7 | Action | C | L10 | 10 | 28(2.4) c | x | x | | | | | x | | | | | | x | | | |
| 66 | B67 | To what extent has your country or organization encouraged the development and dissemination of medical inventions and know-how through appropriate licensing policies that enhance access to innovations for development of products relevant to the public health needs of (other) developing countries? If yes, please describe how and what was the effect. [2.6.8] | 2.6.8 | Action | C | L10 | 10 | 28(2.4) d | x | x | x | | | | | x | | | | | | | | |
| 67 | B68 | To what extent has your country or organization encouraged the development and dissemination of medical inventions and know-how in the form of open licensing that enhance access to innovations for development of products of relevance to the public health needs of (other) developing countries on reasonable, affordable and non- discriminatory terms? If yes, please describe your experience and what was its effect. [2.6.9] | 2.6.9 | Action | C | L10 | 10 | 28(2.4) d | x | x | x | | | | | x | | | | | | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|--|--------|-----------------|--|-------------|-------|-------------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 68 | B69 | To what extent has your country considered, where appropriate, the use of a “research exception” to address public health needs in (other) developing countries consistent with the Agreement on Trade-Related Aspects of Intellectual Property Rights? If yes, please describe. ⁸ [2.6.10] | 2.6.10 | Action | N | L11 | 10 | 28(2.4) e | | x | | | | | | | | | | | | | | |
| 69 | B70 | To what extent has your country or organization developed and coordinated an R&D agenda with other countries? Please describe your experience in doing so. [2.7.2] | 2.7.2 | Action | D | L2 | 10 | 28(2.5) a | x | x | | | | x | | | | | | | | | | |
| 70 | B71 | To what extent has your country or organization facilitated the dissemination and use of research and development outcomes? Please describe your how and when, and with what effects. [2.7.3] | 2.7.3 | Action | C | L10 | 10 | 28(2.5) b | x | x | | | | x | | | | | | | | | | |
| 71 | B72 | Does the national strategic plan (of your country) for the health workforce and related professionals include a research and development component? [2.1.1] | 2.1.1 | Indicator | D | L1 | 22 | Ind 1st bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 72 | B73 | To what extent has your country created or strengthened national initiative(s) on health-related research and development, including between public and private entities? If yes, please describe. [2.1.2] | 2.1.2 | Indicator | D | L2 | 22 | Ind 2nd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 73 | B74 | To what extent has your country created or strengthened initiatives aimed at providing efficient and affordable access to publications and information such as research knowledge, results and technology? If yes, please describe these | 2.1.3 | Indicator | C | L10 | 22 | Ind 3rd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

⁸ REFERENCE: The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international agreement administered by the World Trade Organization (WTO) that sets down minimum standards for many forms of intellectual property (IP) regulation as applied to nationals of other WTO Members. Full text can be found here: https://www.wto.org/english/tratop_e/trips_e/t_agm1_e.htm

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|--|-------|-----------------|--|-------------|-------|----------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | initiatives and their effects. [2.1.3] | | | | | | | | | | | | | | | | | | | | | | |
| 74 | B75 | To what extent have new or strengthened initiatives aimed at enhancing capacities to analyse and manage clinical trial data been successful? If yes, please describe these initiatives and their effects. [2.1.4] | 2.1.4 | Indicator | C | L10 | 22 | Ind 4th bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 75 | B76 | How many peer-reviewed publications has your institution published where the institution of the main author is in (another) developing country? Please list them. [2.1.5] | 2.1.5 | Indicator | D | L3 | 22 | Ind 5th bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 76 | B77 | How many peer-reviewed publications has your institution published where the institution of the secondary author is in (another) developing country? Please list them. [2.1.6] | 2.1.6 | Indicator | D | L3 | 22 | Ind 5th bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 77 | B78 | To what extent has your country or organization supported the development or improvement of national health research programmes? If yes, then how and with what effects? [2.2.9] | 2.2.9 | Sub-element | C | L10 | 8 | 28(2.1) | x | x | | | | x | | | | | | | | | | |
| 78 | B79 | To what extent has your country or organization established, where appropriate, strategic research networks to facilitate better coordination of stakeholders in R&D? Please describe these networks, and their effects. [2.3.1] | 2.3.1 | Sub-element | C | L10 | 8 | 28(2.1) | x | x | | | | x | | | | | | | | | | |
| 79 | B80 | To what extent has your country or organization promoted <u>upstream research</u> in (other) developing countries? If yes, please describe these initiatives and their effects. [2.4.1] | 2.4.1 | Sub-element | C | L10 | 8 | 28(2.2) | x | x | x | x | | | x | x | | | | x | x | x | | |
| 80 | B81 | To what extent has your country or organization promoted <u>product development</u> in (other) developing countries? If yes, please describe these | 2.4.2 | Sub-element | C | L10 | 8 | 28(2.2) | x | x | x | x | | | x | x | | | | x | x | x | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|--|-------|-----------------|--|-------------|-------|---------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | initiatives and their effects. [2.4.2] | | | | | | | | | | | | | | | | | | | | | | |
| 81 | B82 | To what extent has your country improved cooperation, participation and coordination of health and biomedical R&D with (other) developing countries? If yes, please describe your experience and their effects. [2.5.1] | 2.5.1 | Sub-element | C | L10 | 9 | 28(2.3) | x | x | | x | | | | | | | | | | | | |
| 82 | B83 | To what extent has your country or organization been promoting greater access to knowledge in order to meet public health needs of (other) developing countries? If yes, please describe them and their effects. [2.6.1] | 2.6.1 | Sub-element | C | L10 | 9 | 28(2.4) | x | x | x | x | | x | x | x | | | | | x | | | |
| 83 | B84 | To what extent has your country or organization been promoting greater access to relevant technology in order to meet public health needs of (other) developing countries, during 2008-2015? If yes, please describe how and with what outcomes. [2.6.2] | 2.6.2 | Sub-element | C | L10 | 9 | 28(2.4) | x | x | x | x | | x | x | x | | | | | x | | | |
| 84 | B85 | To what extent has your country or organization strengthened national and regional coordinating bodies on research and development? Please describe your experience with these organizations, and their effects. [2.7.1] | 2.7.1 | Sub-element | C | L10 | 10 | 28(2.5) | x | x | | | | x | | | | | | | | | | |
| 85 | B86 | To what extent do the political institutions in your country participate in the development of health research policy? If so, please elaborate how. [2.2.1] | 2.2.1 | Statement | D | L2/O | 8 | 27 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 86 | B87 | To what extent do the economic institutions in your country participate in the development of health research policy? If so, please elaborate how. [2.2.2] | 2.2.2 | Statement | D | L2/O | 8 | 27 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 87 | B88 | To what extent do the social institutions in your country participate in the development of health research policy? [2.2.3] | 2.2.3 | Statement | D | L2/O | 8 | 27 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|----|------|--|-------|-----------------|--|-------------|-------|---------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 88 | B89 | How has the range of measures to promote, coordinate and finance public and private research in your country into Type II and Type III diseases changed during 2008-2015? Please elaborate. ⁹ [2.2.4] | 2.2.4 | Statement | D | L2/O | 8 | 27 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 89 | B90 | To what extent were the measures to promote, coordinate and finance public research in your country into Type II and Type III diseases enhanced?[1] If, yes, please describe the effect of these measures. [2.2.5] | 1 | Statement | D | I2 | 8 | 27 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 90 | B91 | To what extent were the measures to promote, coordinate and finance private research in your country into Type II and Type III diseases enhanced? If, yes, please describe the effect of these measures. ¹⁰ [2.2.6] | 2.2.6 | Statement | C | L10 | 8 | 27 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 91 | B92 | To what extent has the range of measures to promote, coordinate and finance public and private research into the needs of (other) developing countries in relation to Type I diseases been enhanced? If, yes, please describe the effects of these measures. ¹¹ [2.2.7] | 2.2.7 | Statement | D | L4/O | 8 | 27 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 92 | B93 | To what extent have the levels of investment into health research increased in your country 2008-2015? Please describe the change, if applicable? [2.2.8] | 2.2.8 | Statement | C | L10 | 8 | 28 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 93 | B94 | In summary, to what extent has research and | 2 | Element | D | L2 | | | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

⁹ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

¹⁰ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries

¹¹ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | development been promoted? [2] | | | | | | | | | | | | | | | | | | | | | | |
| 94 | B95 | Please elaborate in respect to the promotion of research and development in your country. [2] | 2 | Open | D | O | | | | | | | | | | | | | | | | | | |
| | | ELEMENT 3. BUILDING AND IMPROVING INNOVATIVE CAPACITY | | | | | | | | | | | | | | | | | | | | | | |
| 95 | C97 | To what extent has your country or organization supported investment by (other) developing countries in human resources, especially in education and training, including in public health? If so, please describe how and with what results. [3.3.2] | 3.3.2 | Action | C | L10 | 10 | 30(3.1) a | | x | | | | | | | | | x | | | | | |
| 96 | C98 | To what extent has your country or organization supported existing and new research and development groups and institutions in (other) developing countries? If so, please describe how and with what results. [3.3.3] | 3.3.3 | Action | C | L10 | 10 | 30(3.1) b | | x | | | | | x | x | x | | x | | | | | |
| 97 | C99 | To what extent has your country or organization supported existing and new regional centres of excellence in (other) developing countries? If so, please describe how, with what results. [3.3.4] | 3.3.4 | Action | C | L10 | 10 | 30(3.1) b | | x | | | | | x | x | x | | x | | | | | |
| 98 | C100 | To what extent has your country or organization strengthened health surveillance and information systems? If so, please describe how and with what effects. [3.3.5] | 3.3.5 | Action | C | L10 | 10 | 30(3.1) c | x | x | x | x | | | | x | x | | | | | | | |
| 99 | C101 | To what extent has your country established and strengthened regulatory capacities in (other) developing countries? If so, please describe how and its effects. [3.4.2] | 3.4.2 | Action | C | L10 | 11 | 30(3.2) a | x | x | | | x | | | | | | | | | | | |
| 100 | C102 | To what extent has your country strengthened human resources in research and development in (other) developing countries through long-term national capacity-building plans? If so, please describe how and with what results. [3.4.3] | 3.4.3 | Action | C | L10 | 11 | 30(3.2) b | | x | | | | | | x | x | | x | | | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 101 | C103 | To what extent has your country or organization encouraged international cooperation to develop effective policies for retention of health professionals, in (other) developing countries? If so, please describe how and with what effects [3.4.5] | 3.4.5 | Action | C | L10 | 11 | 30(3.2) c | x | x | | | | | | | | | | | | | | |
| 102 | C104 | To what extent has your country or organization encouraged international cooperation to develop effective policies for retention of researchers, specifically, in (other) developing countries? If so, please describe how and with what effects. [3.4.6] | 3.4.6 | Action | C | L10 | 11 | 30(3.2) c | x | x | | | | | | | | | | | | | | |
| 103 | C105 | To what extent has your country established mechanisms to mitigate the adverse impact of the loss of health personnel and researchers, in (other) developing countries through migration? If so, please describe how and with what effects. [3.4.7] | 3.4.7 | Action | C | L10 | 11 | 30(3.2) d | | x | | | | | | | | | | | | | | |
| 104 | C106 | To what extent has your country supported the strengthening of national health and research systems for human resource development, in the (other) developing countries? If so, please describe how. [3.4.8] | 3.4.8 | Action | C | L10 | 11 | 30(3.2) d | | x | | | | | | | | | | | | | | |
| 105 | C107 | To what extent had your country (or organization) developed successful health innovation models in accordance with the needs of (other) developing countries? If so, please describe the needs and how the intervention(s) helped to develop successful models. [3.5.2] | 3.5.2 | Action | N | L11 | 11 | 30(3.3) a | x | x | x | | | | x | x | x | | x | | x | | x | x |
| 106 | C108 | To what extent had your country (or organization) intensified North–South and South–South partnerships to support capacity building in accordance with the needs of (other) developing countries? If so, please describe the needs and how the intervention(s) helped. [3.5.3] | 3.5.3 | Action | N | L11 | 11 | 30(3.3) b | x | x | x | | | | x | x | x | | | | | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 107 | C109 | To what extent has your country (or organization) established and strengthened mechanisms for ethical review in the research and development process in (other) developing countries? If so, please describe how and with what effects. [3.5.4] | 3.5.4 | Action | C | L10 | 11 | 30(3.3) c | x | x | x | | | | | x | | | | | | | | |
| 108 | C110 | To what extent has your country (or organization) established and strengthened mechanisms for ethical review in the clinical trials in (other) developing countries? If so, please describe how and with what effects. [3.5.5] | 3.5.5 | Action | C | L10 | 11 | 30(3.3) c | x | x | x | | | | | x | | | | | | | | |
| 109 | C111 | To what extent has your country established and strengthened national policies to develop, support and promote traditional medicine? If so, please describe how and with what effects. [3.6.2] | 3.6.2 | Action | C | L10 | 11 | 30(3.4) a | x | x | x | | | | | | | | | | | | | |
| 110 | C112 | To what extent has your country established and strengthened regional policies to develop, support and promote traditional medicine? If so, please describe how and with what effects. [3.6.3] | 3.6.3 | Action | C | L10 | 11 | 30(3.4) a | x | x | x | | | | | | | | | | | | | |
| 111 | C113 | To what extent has your country promoted policies on innovation in the field of traditional medicine? If so, please describe how and with what effects. [3.6.4] | 3.6.4 | Action | C | L10 | 11 | 30(3.4) b | x | x | x | | | | | x | x | | | | | | | |
| 112 | C114 | To what extent has your country or organization promoted standard setting to ensure the quality, safety and efficacy of traditional medicine? If so, please describe how and with what effects. [3.6.5] | 3.6.5 | Action | C | L10 | 11 | 30(3.4) c | x | x | x | | x | x | x | x | x | | x | | | | | |
| 113 | C115 | To what extent has your country or organization funded the research necessary to establish standards for the quality, safety and efficacy of traditional medicine? If so, please describe how and with what effects. [3.6.6] | 3.6.6 | Action | C | L12 | 11 | 30(3.4) c | x | x | x | | x | x | x | x | x | | x | | | | | |
| 114 | C116 | To what extent has your country or organization encouraged research on mechanisms for action and pharmacokinetics of traditional medicine? If so, | 3.6.7 | Action | C | L10 | 11 | 30(3.4) d | x | x | x | | | | x | x | x | | | | | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|--------|-----------------|--|-------------|-------|-------------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | please describe how and with what effects. [3.6.7] | | | | | | | | | | | | | | | | | | | | | | |
| 115 | C117 | To what extent has your country promoted South–South collaboration in traditional medicine? If so, please describe the initiatives and their effects. [3.6.8] | 3.6.8 | Action | C | L10 | 11 | 30(3.4) e | x | x | x | | | x | | x | x | | | | | | | |
| 116 | C118 | To what extent has your country or organization formulated and disseminated guidelines on good manufacturing practices for traditional medicines? If so, please elaborate on the effects. [3.6.9] | 3.6.9 | Action | C | L10 | 11 | 30(3.4)f | x | x | | | x | | x | | | | | | | | | |
| 117 | C119 | To what extent did your country or organization lay down evidence-based standards for quality and safety evaluation in manufacturing of traditional medicines? If so, please describe and with what effects. [3.6.10] | 3.6.10 | Action | C | L10 | 11 | 30(3.4)f | x | x | | | x | | x | | | | | | | | | |
| 118 | C120 | To what extent did your country encourage the establishment of award schemes for health-related innovation? If so, please describe them and with what effects. [3.7.2] | 3.7.2 | Action | C | L10 | 12 | 30(3.5) a | x | x | x | | | | | x | x | | x | | x | | | |
| 119 | C121 | To what extent did your country recognize innovation for the purposes of career advancement for health researchers? [3.7.3] | 3.7.3 | Action | D | L2/O | 12 | 30(3.5) b | x | x | x | | | | | x | x | | x | | | | | |
| 120 | C122 | Have any new health-related research centres been created or the existing ones strengthened in your country during 2008-2015 through comprehensive institutional development and support? If so, how many, and which ones? [3.1.1] | 3.1.1 | Indicator | D | L1/O | 25 | Ind 1st bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 121 | C123 | To what extent do the national health research systems in your country meet international standards? If so, please explain. [3.1.2] | 3.1.2 | Indicator | N | L11 | 25 | Ind 2nd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 122 | C124 | To what extent have your national regulatory authorities been assessed, supported and accredited? If none, please elaborate. [3.1.3] | 3.1.3 | Indicator | D | L5/O | 25 | Ind 3rd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|-------|-----------------|--|-------------|-------|----------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 123 | C125 | Have any new global quality and ethical standards or other tools been created or updated in your country during 2008-2015, in order to promote the quality and effective regulation of health products, such as vaccines, diagnostics and medicines, and technologies? If so, please list. [3.1.4] | 3.1.4 | Indicator | D | L6/O | 25 | Ind 4th bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 124 | C126 | Does your country have a national traditional medicines policy that includes research and development component? If so, please describe this policy. [3.1.5] | 3.1.5 | Indicator | D | L1/O | 25 | Ind 5th bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 125 | C127 | To what extent has your country or organization been building capacity of the (other) developing countries to meet research and development needs for health products? If so, please describe how and with what effects. [3.3.1] | 3.3.1 | Sub-element | C | L10 | 10 | 30(3.1) | | x | x | x | | | x | x | | | | | | | | |
| 126 | C128 | To what extent has your country or organization framed, developed and supported effective policies that promote the development of capacities for health innovation, during 2008-2015? If yes, when with what effects? [3.4.1] | 3.4.1 | Sub-element | C | L10 | 10 | 30(3.2) | x | x | | | x | | | x | | | | | | | | |
| 127 | C129 | To what extent had your country (or organization) provided support for improving innovative capacity in accordance with the needs of (other) developing countries? If so, please describe how. [3.5.1] | 3.5.1 | Sub-element | N | L11 | 11 | 30(3.3) | x | x | x | | | | x | x | | | | | x | | x | x |
| 128 | C130 | To what extent has your country supported policies that will promote innovation based on traditional medicine within an evidence-based framework? If so, please describe how and with what effects. [3.6.1] | 3.6.1 | Sub-element | C | L10 | 11 | 30(3.4) | x | x | x | x | x | x | x | x | | | | | | | | |
| 129 | C131 | To what extent did your country develop and implement incentive schemes for health-related innovation? If so, please describe them and their effects. [3.7.1] | 3.7.1 | Sub-element | C | L10 | 11 | 30(3.5) | x | x | x | | | | | x | | | | | x | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|-------|-----------------|--|-------------|-------|---------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 130 | C132 | To what extent has your country or organization addressed the need to support effective policies that promote the development of capacities in (other) developing countries related to health innovation? If so, please describe how, and with what results. [3.2.1] | 3.2.1 | Statement | C | L10 | 10 | 29 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 131 | C133 | To what extent has your country or organization made investments in the (other) developing countries' capacities relating to science and technology? If so, please describe how and with what effects [3.2.2] | 3.2.2 | Statement | C | L10 | 10 | 29 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 132 | C134 | To what extent has your country or organization made investments in the (other) developing countries' local production of pharmaceuticals? If so, please describe how and with what effects. [3.2.3] | 3.2.3 | Statement | C | L10 | 10 | 29 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 133 | C135 | To what extent has your country or organization made investments in the developing countries' clinical trials? If so, please describe how and with what effects. [3.2.4] | 3.2.4 | Statement | C | L10 | 10 | 29 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 134 | C136 | To what extent has your country or organization made investments in (other) developing countries' regulation? If so, please describe how and with what effects. [3.2.5] | 3.2.5 | Statement | C | L10 | 10 | 29 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 135 | C137 | To what extent has your country or organization made investments in (other) developing countries' intellectual property? If so, please describe how and with what effects. [3.2.6] | 3.2.6 | Statement | C | L10 | 10 | 29 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 136 | C138 | To what extent has your country or organization made investments in the (other) developing countries' traditional medicine? If so, please describe how, with what results. [3.2.7] | 3.2.7 | Statement | C | L10 | 10 | 29 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 137 | C139 | In summary, to what extent has innovative capacity been built? [3] | 3 | Element | D | L2 | | | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----------------------------------|------|---|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 138 | C140 | Please elaborate in respect to innovative capacity that has been built in your country. [3] | 3 | Open | D | O | | | | | | | | | | | | | | | | | | |
| ELEMENT 4: TRANSFER OF TECHNOLOGY | | | | | | | | | | | | | | | | | | | | | | | | |
| 139 | D142 | To what extent has your country created new mechanisms to facilitate transfer of technology and technical support to build and improve innovative capacity for health-related R&D in the (other) developing countries? If so, please elaborate on your efforts and the effects. [4.3.2] | 4.3.2 | Action | C | L10 | 12 | 32(4.1) a | x | x | | | | | x | x | x | | | | x | x | | x |
| 140 | D143 | To what extent has your country made a better use of existing mechanisms to facilitate transfer of technology and technical support to build and improve innovative capacity for health-related R&D in (other) developing countries? If so, please elaborate on your efforts and the effects. [4.3.3] | 4.3.3 | Action | C | L10 | 12 | 32(4.1) a | x | x | | | | | x | x | x | | | | x | x | | x |
| 141 | D144 | To what extent has your country or organization promoted transfer of technology in (other) developing countries through investment and capacity building? If so, please explain the effects. [4.3.4] | 4.3.4 | Action | C | L10 | 12 | 32(4.1) b | x | x | | | | | x | | | | | | | | | |
| 142 | D145 | To what extent has your country identified the best practices (good practices) in technology transfer in the field of health related R&D? If so, please explain. [4.3.5] | 4.3.5 | Action | D | L2/O | 12 | 32(4.1) c | x | x | x | x | | | x | | | | x | | | | | |
| 143 | D146 | To what extent has your country or institution participated in North–South collaboration between the developing countries and the pharmaceutical industries? [4.4.2] | 4.4.2 | Action | D | L2/O | 12 | 32(4.2) a | x | x | x | x | | | x | x | x | | x | | x | | | |
| 144 | D147 | To what extent has your country or organization participated in South–South collaboration between the developing countries and the pharmaceutical industries? If so, please explain. [4.4.3] | 4.4.3 | Action | D | L2/O | 12 | 32(4.2) a | x | x | x | x | | | x | x | x | | x | | x | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 145 | D148 | To what extent has your country or organization facilitated local networks for collaboration on R&D and transfer of technology? If so, please describe them and their effects. [4.4.4] | 4.4.4 | Action | C | L10 | 12 | 32(4.2) b | x | x | x | x | | | x | x | | | | | | | | |
| 146 | D149 | To what extent has your country or organization facilitated regional networks for collaboration on R&D and transfer of technology? If so, please describe them and their effects. [4.4.5] | 4.4.5 | Action | C | L10 | 12 | 32(4.2) b | x | x | x | x | | | x | x | | | | | | | | |
| 147 | D150 | To what extent has your country promoted technology transfer to least developed country members of WTO (consistent with Article 66.2 of the Agreement on Trade-Related Aspects of Intellectual Property Rights)? If so, please explain and with what effects. ¹² [4.4.6] | | Action | C | L10 | 12 | 32(4.2) c | | x | | | | | | | | | | | | | | |
| 148 | D151 | To what extent has your country or organization promoted the necessary training to increase absorptive capacity for technology transfer? If so, please describe how and with what effects. [4.4.7] | 4.4.7 | Action | C | L10 | 13 | 32(4.2) d | x | x | | | | | | x | x | | | | | | | |
| 149 | D152 | To what extent has your country or institution examined feasibility of voluntary patent pools of upstream and downstream health-related technologies? If so, please describe how and with what effects. [4.5.2] | 4.5.2 | Action | C | L10 | 13 | 32(4.3) a | x | x | x | x | | | x | x | x | | | | x | | | |
| 150 | D153 | To what extent has your country promoted the (other) developing countries' access to technologies related to Type II and III diseases? If so, please describe how and with what effects. ¹³ [4.5.3] | 4.5.3 | Action | C | L10 | 13 | 32(4.3) b | x | x | | | | | x | | | | | | x | x | | |

¹² FOOTNOTE (Source: https://www.wto.org/english/tratop_e/trips_e/t_agm7_e.htm): Article 66, Least-Developed Country Members

¹³ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|-------|-----------------|--|-------------|-------|-------------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 151 | D154 | To what extent has your country promoted the (other) developing countries' access to the specific R&D needs related to Type I diseases? If so, please describe how and with what effects. ¹⁴ [4.5.5] | 4.5.5 | Action | C | L10 | 13 | 32(4.3) b | x | x | | | | | x | | | | | | x | x | | |
| 152 | D155 | How many national collaboration initiatives did your country create between 2008-2015 to increase and facilitate the transfer of health-related technologies? If so, which ones? [4.1.1] | 4.1.1 | Indicator | D | L3/O | 28 | Ind 1st bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 153 | D156 | How many national collaboration initiatives did your country create to increase and facilitate the transfer of health-related technologies between public and private entities? If so, which ones? [4.1.2] | 4.1.2 | Indicator | D | L3/O | 28 | Ind 1st bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 154 | D157 | Has your country participated in the creation of regional collaboration initiatives aimed at increasing and facilitating transfer of health-related technology, including between public and private entities? If so, please explain them and their effects. [4.1.3] | 4.1.3 | Indicator | C | L10 | 28 | Ind 1st bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 155 | D158 | Has your country participated in regional technology transfer initiatives? If yes, please list them and indicate their effect. [4.1.4] | 4.1.4 | Indicator | C | L10 | 28 | Ind 1st bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 156 | D159 | Has your country participated in the creation of global collaboration initiatives aimed at increasing and facilitating transfer of health-related technology, including between public and private entities? If so, please explain and with what effects. [4.1.5] | 4.1.5 | Indicator | C | L10 | 28 | Ind 1st bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

¹⁴ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|-------|-----------------|--|-------------|-------|----------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 157 | D160 | Did your country create technology transfer strategies during 2008-2015 that include health-related technologies and relevant capacity- building components? If so, please explain them and their effects. [4.1.7] | 4.1.7 | Indicator | C | L10 | 28 | Ind 2nd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 158 | D161 | To what extent has your country promoted production of health products in the (other) developing countries through technology transfer? If so, please explain and describe their effects. [4.3.1] | 4.3.1 | Sub-element | C | L10 | 12 | 32(4.1) | x | x | x | x | | | x | x | | | | | x | x | | x |
| 159 | D162 | To what extent has the collaboration of technology transfer for health products between countries of different levels of development changed since 2008? Please explain. [4.4.1] | 4.4.1 | Sub-element | D | L2/O | 12 | 32(4.2) | x | x | x | x | | | x | x | | | | | x | | | |
| 160 | D163 | To what extent has your country or institution developed new mechanisms to promote access to key health-related technologies? If so, please describe how and with what effects. [4.5.1] | 4.5.1 | Sub-element | C | L10 | 13 | 32(4.3) | x | x | x | x | | | x | x | | | | | x | x | | |
| 161 | D164 | To what extent has your country or organization supported North–South and South–South development cooperation to build and improve transfer of technology related to health innovation? If so, please explain your efforts and their effects. [4.2.1] | 4.2.1 | Statement | C | L10 | 12 | 31 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 162 | D165 | Does your country comply with the Article 7 of the Agreement on Trade-Related Aspects of Intellectual Property Rights, which states that the protection and the enforcement of intellectual property rights should contribute to the promotion of technological innovation and the transfer and dissemination of technology, to the mutual advantage of producers and users of technological knowledge and in a manner conducive to social and economic welfare, and to the balance of rights and obligations? If so, | 4.2.2 | Statement | N | L11 | 12 | 31 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | please explain. ¹⁵ [4.2.2] | | | | | | | | | | | | | | | | | | | | | | |
| 163 | D166 | In summary, to what extent has technology been transferred? [4] | 4 | Element | D | L2 | | | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 164 | D167 | Please elaborate in respect to health innovation technology transfer. [4] | 4 | Open | D | O | | | | | | | | | | | | | | | | | | |
| | | ELEMENT 5: APPLICATION AND MANAGEMENT OF INTELLECTUAL PROPERTY TO CONTRIBUTE TO INNOVATION AND PROMOTE PUBLIC HEALTH | | | | | | | | | | | | | | | | | | | | | | |
| 165 | E168 | To what extent has the application and management of Intellectual Property in your country maximized health-related innovation and promoted access to health products? If so, please describe how and with what effects. [5.3.3] | 5.3.3 | Action | C | L10 | 13 | 34(5.1) a | x | x | | | | | | x | x | | x | | x | x | | x |
| 166 | E169 | To what extent has the application and management of Intellectual Property in your country met the specific R&D needs of (other) developing countries? If so, please describe the needs and how your intervention helped. [5.3.4] | 5.3.4 | Action | N, C | L11/ L10 | 13 | 34(5.1) a | x | x | | | | | | x | x | | x | | x | x | | x |
| 167 | E170 | To what extent has your country or organisation supported international efforts to manage and apply intellectual property in the (other) developing countries? If so, please describe how and with what effects. [5.3.5] | 5.3.5 | Action | C | L10 | 14 | 34(5.1) b | x | x | | | | | | x | x | | x | | x | x | | x |

¹⁵ FOOTNOTE: Please consult Article 7 here: https://www.wto.org/english/tratop_e/trips_e/t_agm2_e.htm [4.2.2]

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|--------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 168 | E171 | To what extent has your organization or country facilitated widespread access to administrative status of health-related patents? If so, please describe how and with what effects. [5.3.6] | 5.3.6 | Action | C | L10 | 14 | 34(5.1) c | x | x | | | | | | x | x | | x | | x | x | | x |
| 169 | E172 | To what extent has your organization or country stimulated collaboration between national institutions and government departments to promote information sharing relevant to public health needs? If so, please describe how and with what effects. [5.3.7] | 5.3.7 | Action | C | L10 | 14 | 34(5.1) d | x | x | x | x | | | x | x | x | | x | | | | | |
| 170 | E173 | To what extent has your organization or country stimulated collaboration between regional institutions and government departments to promote information sharing relevant to public health needs? If so, please describe how and with what effects. [5.3.8] | 5.3.8 | Action | C | L10 | 14 | 34(5.1) d | x | x | x | x | | | x | x | x | | x | | | | | |
| 171 | E174 | To what extent has your organization or country stimulated collaboration between global institutions and government departments to promote information sharing relevant to public health needs? If so, please describe how and with what effects. [5.3.9] | 5.3.9 | Action | C | L10 | 14 | 34(5.1) d | x | x | x | x | | | x | x | x | | x | | | | | |
| 172 | E175 | To what extent has your country or organization strengthened education and training in the application and management of Intellectual Property from a public health perspective? If so, please describe how and with what effects. [5.3.10] | 5.3.10 | Action | C | L10 | 14 | 34(5.1) e | x | x | | | | | | x | x | | x | | x | x | | x |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|--------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 173 | E176 | To what extent has the provided training and education taken into account the provisions and the flexibilities contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights? ¹⁶ [5.3.11] | 5.3.11 | Action | N | L11 | 14 | 34(5.1) e | x | x | | | | | | x | x | | x | | x | | | x |
| 174 | E177 | To what extent has your organization or country facilitated access to traditional medicinal knowledge for use as <i>prior art</i> in examination of patents? If so, please describe how and with what effects. ¹⁷ [5.3.12] | 5.3.12 | Action | C | L10 | 14 | 34(5.1)f | | x | x | | | | | | | | | | | | | |
| 175 | E178 | To what extent has your organization or country facilitated the inclusion of the traditional medicinal knowledge information in digital libraries? If so, please describe how? If so, please describe how and with what effects. [5.3.13] | 5.3.13 | Action | C | L10 | 14 | 34(5.1)f | | x | x | | | | | | | | | | | | | |
| 176 | E179 | To what extent has your country or institution promoted active and effective participation of health representatives in intellectual property-related negotiations reflecting public health needs? If so, please describe how and with what effects. [5.3.14] | 5.3.14 | Action | C | L10 | 14 | 34(5.1) g | | x | | | | | | | | | | | | | | |
| 177 | E180 | To what extent has your country or institution coordinated work related to Intellectual Property and public health among the secretariats and governing bodies of relevant regional organizations to disseminate information to countries? If so, please describe how and with what effects. [5.3.15] | 5.3.15 | Action | C | L10 | 14 | 34(5.1) h | x | x | | | | | | | | | | | x | x | | x |

¹⁶ FOOTNOTE: Please refer to Doha Agreement, including the flexibilities recognized by the Doha Declaration on the TRIPS Agreement and Public Health and other WTO instruments related to the Agreement on Trade-Related Aspects of Intellectual Property Rights: https://www.wto.org/english/thewto_e/minist_e/minist01_e/mindecl_trips_e.htm

¹⁷ FOOTNOTE: Prior art is any evidence that your invention is already known.

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|--------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 178 | E181 | To what extent has your country or institution coordinated work related to Intellectual Property and public health among the secretariats and governing bodies of relevant international organizations to disseminate information to countries? If so, please describe how. [5.3.16] | 5.3.16 | Action | C | L10 | 14 | 34(5.1) h | x | x | | | | | | | | | | | x | x | | x |
| 179 | E182 | Has your country adapted national legislation to fully use the flexibilities contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights, including those recognized by the Doha Declaration on the TRIPS Agreement and Public Health and the WTO decision of 30 August 2003? If so, please describe how and with what effects. ¹⁸ [5.4.3] | 5.4.3 | Action | C | L10 | 15 | 34(5.2) a | x | x | | | | | | | | | | | x | x | | x |
| 180 | E183 | To what extent has your country taken into account the impact on public health when adopting or implementing more extensive Intellectual Property protection than is required by the Agreement on Trade-Related Aspects of Intellectual Property Rights? If so, please describe how. [5.4.4] | 5.4.4 | Action | D | L2/O | 15 | 34(5.2) b | x | x | | | | | | | | | | | x | x | | x |
| 181 | E184 | To what extent has your country taken into account in trade agreements the flexibilities contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights? If so, please describe how. [5.4.5] | 5.4.5 | Action | N | L11 | 15 | 34(5.2) c | | x | | | | | | | | | | | | | | |
| 182 | E185 | Does your country have manufacturing capacity? If so, please describe. [5.4.6A] | 5.4.6A | Action | D | L1/O | 15 | 34(5.2) d | | x | | | | | | | | | | | | | | |
| 183 | E186 | If your country has manufacturing capacity, to what extent has your country taken necessary measures to facilitate, through export, access to pharmaceutical products in countries with insufficient or no manufacturing capacity in the pharmaceutical sector in a manner consistent with | 5.4.6B | Action | C | L10 | 15 | 34(5.2) d | | x | | | | | | | | | | | | | | |

¹⁸ FOOTNOTE: Please refer to Doha Agreement here: https://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | the Agreement on Trade- Related Aspects of Intellectual Property Rights? If so, please describe how and with what effects. [5.4.6B] | | | | | | | | | | | | | | | | | | | | | | |
| 184 | E187 | To what extent has your country or institution considered legislative measures to help to prevent misappropriation of health-related traditional knowledge and with what effects? If so, please describe. [5.4.7] | 5.4.7 | Action | C | L10 | 15 | 34(5.2) e | x | x | x | | | | | | | | | | x | x | | |
| 185 | E188 | To what extent has your country or organization promoted possible incentive schemes for R&D on Type II and Type III diseases? If so, please describe how and with what effects. ¹⁹ [5.5.3] | 5.5.3 | Action | C | L10 | 15 | 34(5.3) a | x | x | x | x | | | x | x | x | | x | | | | | |
| 186 | E189 | To what extent has your country or organization promoted possible incentive schemes for R&D on developing countries' specific research and development needs in relation to Type I diseases? If so, please describe how and with what effects. ²⁰ [5.5.4] | 5.5.4 | Action | C | L10 | 15 | 34(5.3) a | x | x | x | x | | | x | x | x | | x | | | | | |
| 187 | E190 | To what extent has your country or organization promoted a range of incentive schemes for delinking of the costs of R&D and the price of health products, for example through the award of prizes, with the objective of addressing diseases that disproportionately affect (other) developing | 5.5.5 | Action | C | L10 | 15 | 34(5.3) a | x | x | x | x | | | x | x | x | | x | x | x | x | x | x |

¹⁹ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

²⁰ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|-------|-----------------|--|-------------|-------|---------------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | countries? If so, please describe and with what effects. [5.5.5] | | | | | | | | | | | | | | | | | | | | | | |
| 188 | E191 | To what extent has your country been engaged in initiatives to strengthen the capacities to manage and apply intellectual property rights in order to contribute to innovation and promote public health? If so, please describe how and with what effects. [5.1.1] | 5.1.1 | Indicator | C | L10 | 29 | Ind 1st bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 189 | E192 | To what extent has your country been supporting efforts to strengthen capacities in the management and application of Intellectual Property rights in a manner oriented to public health needs of (other) developing countries? If so, please describe how and with what results. [5.1.2] | 5.1.2 | Indicator | C | L10 | 29 | Ind 2nd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 190 | E193 | To what extent has your country been integrating flexibilities for protection of public health of the WTO Agreement on Trade-Related Aspects of Intellectual Property Rights into national legislation? If so, please elaborate on the effects. [5.1.3] | 5.1.3 | Indicator | N, C | L11/ L10 | 29 | Ind 3rd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 191 | E194 | To what extent has your organization participated in initiatives aimed at coordinating work relating to intellectual property and public health? If so, please describe the initiatives and their effects. [5.1.4] | 5.1.4 | Indicator | C | L10 | 29 | Ind 4th, 5th bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 192 | E195 | To what extent has your country shared information and built capacity in the field of Intellectual Property with respect to the promotion of public health in (other) developing countries? If so, please describe how and with what effects. [5.3.1] | 5.3.1 | Sub-element | C | L10 | 13 | 34(5.1) | x | x | x | x | | | x | x | | | | | x | x | | x |
| 193 | E196 | To what extent has your country shared information and built capacity in the field of Intellectual Property with respect to health-related innovation? If so, please describe how and with what effects. | 5.3.2 | Sub-element | C | L10 | 13 | 34(5.1) | x | x | x | x | | | x | x | | | | | x | x | | x |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|-------|-----------------|--|-------------|-------|---------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | [5.3.2] | | | | | | | | | | | | | | | | | | | | | | |
| 194 | E197 | To what extent has your country or institution provided technical support to countries that intend to make use of the provisions contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights, in order to promote access to pharmaceutical products? If so, please describe how and with what effects. [5.4.1] | 5.4.1 | Sub-element | C | L10 | 14 | 34(5.2) | x | x | x | | | | | | | | | | x | x | | x |
| 195 | E198 | To what extent has your country or institution provided technical support to policy processes to the countries that intend to make use of the provisions contained in the Agreement on Trade-Related Aspects of Intellectual Property Rights, in order to promote access to pharmaceutical products? If so, please describe how and with what effects. [5.4.2] | 5.4.2 | Sub-element | C | L10 | 14 | 34(5.2) | x | x | x | | | | | | | | | | | | | |
| 196 | E199 | To what extent has your country, institution or organization promoted possible incentive schemes for R&D on Type II and Type III diseases? If so, please describe and explain what were their effects. ²¹ [5.5.1] | 5.5.1 | Sub-element | C | L10 | 15 | 34(5.3) | x | x | x | x | | | x | x | | | | | | | | |
| 197 | E200 | To what extent has your country, institution or organization promoted possible incentive schemes for R&D in (other) developing countries' specific research and development needs in relation to Type I diseases?[5] If so, please elaborate on your efforts and their effects. [5.5.2] | 5 | Sub-element | C | L10 | 15 | 34(5.3) | x | x | x | x | | | x | x | | | | | | | | |
| 198 | E201 | Have the international regulations on Intellectual | 5.2.1 | Statement | C | L10 | 13 | 33 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

²¹ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|-------|-----------------|--|-------------|-------|---------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | Property created incentives to develop new health products in your country? If so, which ones? If so, please describe them and their effects. [5.2.1] | | | | | | | | | | | | | | | | | | | | | | |
| 199 | E202 | To what extent have the international incentive schemes for research and development on Type II and Type III diseases been explored and implemented in your country? If so, please elaborate with what effects. ²² [5.2.2] | 5.2.2 | Statement | C | L10 | 13 | 33 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 200 | E203 | To what extent has your country explored and implemented the international incentive schemes for R&D needs of (other) developing countries in respect of Type I diseases? If so, please describe how and with what effects. ²³ [5.2.3] | 5.2.3 | Statement | C | L10 | 13 | 33 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 201 | E204 | To what extent has your country or organization strengthened innovation capacity in (other) developing countries? If so, please describe how and with what effects. [5.2.4] | 5.2.4 | Statement | C | L10 | 13 | 33 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 202 | E205 | To what extent has your country or organization assisted to manage and apply intellectual property in (other) developing countries? If so, please describe how and with what effects. [5.2.5] | 5.2.5 | Statement | C | L10 | 13 | 33 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 203 | E206 | To what extent has your country or organization complied with the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights and instruments related to that agreement, which provide flexibilities to take measures to protect public health? If so, please describe them | 5.2.6 | Statement | N, C | L11/ L10 | 13 | 33 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

²² FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

²³ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

The publication version, December 2010

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | and their effects. [5.2.6] | | | | | | | | | | | | | | | | | | | | | | |
| 204 | E207 | In summary, to what extent have the application and management of intellectual property contributed to innovation and the promotion of public health? [5] | 5 | Element | D | L2 | | | a | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 205 | E208 | Please elaborate in respect to the intellectual property and how it contributed to innovation and the promotion of public health. [5] | 5 | Open | D | O | | | | | | | | | | | | | | | | | | |
| | | ELEMENT 6: IMPROVING DELIVERY AND ACCESS | | | | | | | | | | | | | | | | | | | | | | |
| 206 | F209 | To what extent has your country or organization invested in developing health delivery infrastructures? If so, please describe your investments and their effects and the extent to which they have contributed to efficiency. [6.3.3] | 6.3.3 | Action | C | L10 | 16 | 37(6.1) a | x | x | x | | | | x | | | | x | | | | | |
| 207 | F210 | To what extent have your country developed effective and sustainable mechanisms in the least developed countries (LDCs) in order to improve access to existing medicines, acknowledging the transitional period until 2016? If so, please elaborate how and with what effects. [6.3.4] | 6.3.4 | Action | C | L10 | 16 | 37(6.1) b | x | x | | | | | | | | | | | | x | | |
| 208 | F211 | To what extent has your country prioritized health care in national agendas? If so, please elaborate on the effects. [6.3.5] | 6.3.5 | Action | C | L10 | 16 | 37(6.1) c | | x | | | | | | | | | | | | | | |
| 209 | F212 | To what extent has your country or organization encouraged health authorities to improve domestic management capacities in order to improve delivery of and access to medicines and other health products with quality, efficacy, safety and affordability? If so, please elaborate on the extent of improvement of these capacities. [6.3.6] | 6.3.6 | Action | C | L12 | 16 | 37(6.1) d | x | x | | | | | | | | | | | | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|--------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 210 | F213 | To what extent has your country or organization developed strategies to promote rational use of medicines? If so, describe how and with what effects. [6.3.7] | 6.3.7 | Action | C | L10 | 16 | 37(6.1) d | x | x | | | | | | | | | | | | | | |
| 211 | F214 | To what extent has the investment by your country or organization in human resource development changed in the health sector? Please elaborate on these investments and their effects. [6.3.8] | 6.3.8 | Action | C | L10 | 16 | 37(6.1) e | x | x | x | x | | | | | | | x | | | | | |
| 212 | F215 | To what extent has your country developed effective country poverty reduction strategies that contain clear health objectives? If so, please bring examples and show their effects. [6.3.9] | 6.3.9 | Action | C | L10 | 16 | 37(6.1)f | | x | | | | | | | | | x | | | | | |
| 213 | F216 | To what extent has your country or organization pooled procurement mechanisms for health products and medical devices? If so, please describe these mechanisms and their effects. [6.3.10] | 6.3.10 | Action | C | L10 | 16 | 37(6.1) g | x | x | | | | | | | | | | | | | | |
| 214 | F217 | To what extent has your country or organization developed and/or strengthened the capacity of national regulatory authorities to monitor the quality, safety and efficacy of health products? If so, please describe how and with what effects. [6.4.2] | 6.4.2 | Action | C | L10 | 17 | 37(6.2) a | x | x | | | x | | | | | | x | | | | | |
| 215 | F218 | To what extent has your country or organization sustained ethical review standards? If so, please describe. [6.4.3] | 6.4.3 | Action | D | L2 | 17 | 37(6.2) a | x | x | | | x | | | | | | x | | | | | |
| 216 | F219 | To what extent has your country or organization promoted operational research to maximize the appropriate use of new and existing products? If so, please describe your efforts and their effects. [6.4.4] | 6.4.4 | Action | C | L2 | 17 | 37(6.2) b | x | x | x | x | | | | x | x | | x | | | | | |
| 217 | F220 | To what extent has your country or organization promoted operational research to maximize the appropriate use of cost- effective and affordable products? If so, please describe how and with what results. [6.4.5] | 6.4.5 | Action | C | L2 | 17 | 37(6.2) b | x | x | x | x | | | | x | x | | x | | | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|--------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 218 | F221 | To what extent has your country or organization promoted operational research in settings with a high disease burden? If so, please describe. [6.4.6] | 6.4.6 | Action | C | L10 | 17 | 37(6.2) b | x | x | x | x | | | | x | x | | x | | | | | |
| 219 | F222 | To what extent has your country or organization complied with good manufacturing practices for safety standards, efficacy and quality of health products? If so, please describe them and their effects [6.4.7] | 6.4.7 | Action | C | L10 | 17 | 37(6.2) c | x | x | | | x | | x | | | | x | | | | | |
| 220 | F223 | To what extent has your organization or a country strengthened the WHO prequalification programme? If so, please describe your efforts and their effects. [6.4.8] | 6.4.8 | Action | C | L10 | 17 | 37(6.2) d | x | x | | | | | | | | | x | | | | | |
| 221 | F224 | To what extent has your country or organization harmonized the processes by the regulatory authorities for drug marketing approvals? If so, please describe, and their effects. [6.4.9] | 6.4.9 | Action | C | L10 | 17 | 37(6.2) e | x | x | | | x | x | | | | | x | | | | | |
| 222 | F225 | To what extent has your country or organization promoted ethical principles for clinical trials involving human beings as a requirement of registration of medicines and health-related technologies? If so, please describe how and with what results. [6.4.10] | 6.4.10 | Action | C | L10 | 17 | 37(6.2)f | x | x | | | x | | | | | | | | | | | |
| 223 | F226 | To what extent has your country or organization made reference to the Declaration of Helsinki, and other appropriate texts, on ethical principles for medical research involving human subjects, including good clinical practice guidelines? If so, please describe these documents. ²⁴ [6.4.11] | 6.4.11 | Action | N | L11 | 17 | 37(6.2)f | x | x | | | x | | | | | | | | | | | |

²⁴ FOOTNOTE: The Declaration of Helsinki is a set of ethical principles regarding human experimentation developed for the medical community by the World Medical Association (WMA). It is widely regarded as the cornerstone document on human research ethics. Please consult the full text here: <http://www.wma.net/en/30publications/10policies/b3/>

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|--------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 224 | F227 | To what extent has your country or organization supported collaborative efforts to strengthen the regulation and implementation of clinical trials using appropriate standards for evaluation and approval of medicines? If so, please describe how and their effects. [6.4.12] | 6.4.12 | Action | C | L10 | 17 | 37(6.2) g | x | x | | | x | x | | x | x | | x | | | | | |
| 225 | F228 | To what extent has your country supported the production and introduction of generic versions of essential medicines, in developing countries? If so, please describe how and with what results. [6.5.2] | 6.5.2 | Action | C | L10 | 17 | 37(6.3) a | | x | | | | | | | | | | | | | | |
| 226 | F229 | To what extent has your country developed national legislation and/ or policies that encourage generic production and entry, including a “regulatory exception” or “Bolar”-type provision, and that are consistent with the Agreement on Trade-Related Aspects of Intellectual Property Rights and instruments related to that agreement? If so, please describe these policies and their effects. [6.5.3] | 6.5.3 | Action | C | L10 | 17 | 37(6.3) a | | x | | | | | | | | | | | | | | |
| 227 | F230 | To what extent has your country or organization framed policies to improve access to safe and effective essential medicines at affordable prices, consistent with international agreements? If so, please list them. [6.5.4] | 6.5.4 | Action | N, D | L11/ L2 | 17 | 37(6.3) b | x | x | | | | | | | | | | | x | x | | |
| 228 | F231 | To what extent has your country or organization implemented policies to improve access to safe and effective essential medicines at affordable prices, consistent with international agreements? If so, please list them. [6.5.5] | 6.5.5 | Action | N, D | L11/ L2 | 17 | 37(6.3) b | x | x | | | | | | | | | | | x | x | | |
| 229 | F232 | To what extent has your country reduced or eliminated import tariffs on health products and medical devices during 2008-2015? If yes, please describe the change and their effects. [6.5.6] | 6.5.6 | Action | C | L10 | 17 | 37(6.3) c | | x | | | | | | | | | | | | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|--------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 230 | F233 | To what extent has your country monitored supply and distribution chains and procurement practices to minimize cost and increase access? If so, please describe them and their effect. [6.5.7] | 6.5.7 | Action | C | L10 | 17 | 37(6.3) c | | x | | | | | | | | | | | | | | |
| 231 | F234 | To what extent has your country or organization encouraged pharmaceutical companies and health-related industries to consider policies, including differential pricing policies, that are conducive to promoting access to quality, safe, efficacious and affordable health products in developing countries, consistent with national law? Please elaborate and indicate the effect. [6.5.8] | 6.5.8 | Action | N, C | L11/ L10 | 17 | 37(6.3) d | x | x | | | | | x | | | | | | | | | |
| 232 | F235 | To what extent has your country developed policies to monitor pricing? Please list them and elaborate on their effect. [6.5.9] | 6.5.9 | Action | C | L10 | 17 | 37(6.3) e | | x | | | | | | | | | | | | | | |
| 233 | F236 | To what extent has your country improved affordability of health products? Please describe how and with what effects. [6.5.10] | 6.5.10 | Action | C | L10 | 17 | 37(6.3) e | | x | | | | | | | | | | | | | | |
| 234 | F237 | To what extent has your country supported WHO's ongoing work on pharmaceutical pricing? Please share your experience. [6.5.11] | 6.5.11 | Action | D | L2/O | 17 | 37(6.3) e | | x | | | | | | | | | | | | | | |
| 235 | F238 | To what extent has your country prevented the abuse of Intellectual Property rights by right holders? Please share your experience. [6.5.12] | 6.5.12 | Action | D | L2/O | 18 | 37(6.3)f | | x | | | | | | | | | | | | | | |
| 236 | F239 | To what extent has your country restrained trade or affected the international transfer of technology, in the field of health products? Please describe. [6.5.13] | 6.5.13 | Action | D | L2/O | 18 | 37(6.3)f | | x | | | | | | | | | | | | | | |
| 237 | F240 | To what extent has your country or organization increased information among policy-makers, users, doctors and pharmacists regarding generic products? Please describe your efforts. [6.5.14] | 6.5.14 | Action | D | L2/O | 18 | 37(6.3) g | x | x | | x | | | x | | | | | | | | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|-------|-----------------|--|-------------|-------|----------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 238 | F241 | Has your country formulated official national policies on access, quality and use of essential medical products and technologies, during 2008-2015? If so, please list these policies. [6.1.1] | 6.1.1 | Indicator | D | L1/O | 32 | Ind 1st bullet | | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 239 | F242 | Is your country implementing its official national policies on access, quality and use of essential medical products and technologies? If so, please describe how and with what results. [6.1.2] | 6.1.2 | Indicator | C | L10 | 32 | Ind 1st bullet | | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 240 | F243 | Has your country designed or strengthened new comprehensive national procurement and supply systems? If so, please describe how and with what results. [6.1.3] | 6.1.3 | Indicator | C | L10 | 32 | Ind 2nd bullet | | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 241 | F244 | How many priority health products in your country have been assessed and prequalified for procurement by the UN? If so, please state how many and describe these products. [6.1.4] | 6.1.4 | Indicator | D | L3/O | 32 | Ind 3rd bullet | | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 242 | F245 | How many priority diagnostic tools have been assessed and prequalified in your country for procurement by the UN? If so, please state how many and describe these tools. [6.1.5] | 6.1.5 | Indicator | D | L3/O | 32 | Ind 3rd bullet | | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 243 | F246 | Does your country possess national strategic plans for the health workforce and related professionals including policies and management practices on incentives, regulation and retention? If so, please describe these plans [6.1.6] | 6.1.6 | Indicator | D | L1/O | 32 | Ind 4th bullet | | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 244 | F247 | Is your country fully implementing its policies and management practices on incentives, regulation and retention? If so, please describe how and with what results. [6.1.7] | 6.1.7 | Indicator | C | L10 | 32 | Ind 4th bullet | | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 245 | F248 | Does your country have an adequate number of qualified or trained health-related regulatory professionals? If so, please elaborate. [6.1.8] | 6.1.8 | Indicator | D | L1/O | 32 | Ind 5th bullet | | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 246 | F249 | To what extent are there gaps in staffing in some specific areas of specialization? If so, please | 6.1.9 | Indicator | D | L2/O | 32 | Ind 5th bullet | | x | x | x | x | x | x | x | | | | x | x | x | x | x |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|-------|-----------------|--|-------------|-------|---------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | elaborate. [6.1.9] | | | | | | | | | | | | | | | | | | | | | | |
| 247 | F250 | To what extent has your country increased investment in the health delivery infrastructure in order to strengthen the health system? If so, please elaborate and indicate with what effects. [6.3.1] | 6.3.1 | Sub-element | C | L10 | 16 | 37(6.1) | x | x | x | x | | | x | | | | | | | x | | |
| 248 | F251 | To what extent has your country financed health products in order to strengthen the health system? If so, please describe your investments and whether they have contributed to effectiveness and efficiency. [6.3.2] | 6.3.2 | Sub-element | C | L10 | 16 | 37(6.1) | x | x | x | x | | | x | | | | | | | x | | |
| 249 | F252 | To what extent are the mechanisms to improve ethical review and regulate the quality, safety and efficacy of health products and medical devices established and strengthened in your country or organization? If so, please describe them and their effects. [6.4.1] | 6.4.1 | Sub-element | C | L10 | 16 | 37(6.2) | x | x | x | x | x | x | x | x | | | | | | | | |
| 250 | F253 | To what extent has your country or organization promoted competition to improve availability and affordability of health products consistent with public health policies and needs? If so, please describe how and with what effects. [6.5.1] | 6.5.1 | Sub-element | C | L10 | 17 | 37(6.3) | x | x | | x | | | x | | | | | | x | x | | |
| 251 | F254 | To what extent are the pricing and taxation policies for health products in your country appropriate in order to guarantee strong health systems? If so, please elaborate. [6.2.1] | 6.2.1 | Statement | D | L2/O | 16 | 35 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 252 | F255 | To what extent is there competition in the field of health products in your country? If so, please elaborate. [6.2.2] | 6.2.2 | Statement | D | L2/O | 16 | 35 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 253 | F256 | To what extent are there functioning mechanisms to regulate the safety, quality and efficacy of medicines and other health products? If so, please describe them. [6.2.3] | 6.2.3 | Statement | D | L2/O | 16 | 35 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|---|------|---|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 254 | F257 | To what extent does your country adhere to good manufacturing practices and effective supply chain management? If so, please elaborate. [6.2.4] | 6.2.4 | Statement | D | L2/O | 16 | 35 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 255 | F258 | To what extent has your country monitored the International agreements that have an impact on access to health products in developing countries, with respect to their development and application? If so, please elaborate. [6.2.5] | 6.2.5 | Statement | N | L11 | 16 | 36 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 256 | F259 | ²⁵ To what extent has your country monitored the impact of the Agreement on Trade-Related Aspects of Intellectual Property Rights and of the Doha Declaration on the TRIPS Agreement and Public Health that permit improved access? If so, please elaborate. [6.2.6] | 6.2.6 | Statement | N | L11 | 16 | 36 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 257 | F260 | In summary, to what extent have delivery and access been improved? [6] | 6 | Element | D | L2 | | | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 258 | F261 | Please elaborate on the delivery and access. [6] | 6 | Open | D | O | | | | | | | | | | | | | | | | | | |
| ELEMENT 7: PROMOTING SUSTAINABLE FINANCING MECHANISMS | | | | | | | | | | | | | | | | | | | | | | | | |
| 259 | G262 | To what extent has your country or organization established a results-oriented and time-limited expert working group under the auspices of WHO to examine current financing and coordination of research and development? Please elaborate and comment of the effects. [7.3.3] | 7.3.3 | Action | C | L10 | 18 | 40(7.1) a | x | x | | | | | | | | | | | | | | |
| 260 | G263 | To what extent has your country or organization linked this expert working group with other relevant groups to examine current financing and coordination of research and development? If so, | 7.3.4 | Action | D | L2/O | 18 | 40(7.1) a | x | x | | | | | | | | | | | | | | |

²⁵ REFERENCE: The Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) is an international agreement administered by the World Trade Organization (WTO) that sets down minimum standards for many forms of intellectual property (IP) regulation as applied to nationals of other WTO Members. Full text can be found here: https://www.wto.org/english/tratop_e/trips_e/t_agm1_e.htm.

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| | | please elaborate. [7.3.4] | | | | | | | | | | | | | | | | | | | | | | |
| 261 | G264 | To what extent has your country or organization created proposals for new and innovative sources of financing to stimulate R&D related to Type II and Type III diseases? If so, please list them and comment on their effects. ²⁶ [7.3.5] | 7.3.5 | Action | C | L10 | 18 | 40(7.1) a | x | x | | | | | | | | | | | | | | |
| 262 | G265 | To what extent has your country or organization created proposals for new and innovative sources of financing to address the specific research and development needs of developing countries in relation to Type I diseases? If so, please list them and comment on their effects. ²⁷ [7.3.6] | 7.3.6 | Action | C | L10 | 18 | 40(7.1) a | x | x | | | | | | | | | | | | | | |
| 263 | G266 | To what extent has your country considered channelling additional funds to health-oriented research organizations, in both the private and public sector of developing countries? If so, please elaborate. [7.3.7] | 7.3.7 | Action | D | L2/O | 18 | 40(7.1) b | x | x | x | | | | x | x | x | | x | | | | | |

²⁶ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries

²⁷ FOOTNOTE: Type I diseases are incident in both rich and poor countries, with large numbers of vulnerable populations in each. Type II diseases are incident in both rich and poor countries, but with a substantial proportion of the cases in poor countries. Type III diseases are those that are overwhelmingly or exclusively incident in developing countries.

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|---|-------|-----------------|--|-------------|-------|-------------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 264 | G267 | To what extent has your country promoted good financial management to maximize the effectiveness of these health-oriented research organizations, in both the private and public sector of (other) developing countries (as recommended by resolution WHA58.34)? Please share your experience and comment on their effects. ²⁸ [7.3.8] | 7.3.8 | Action | C | L10 | 18 | 40(7.1) b | x | x | x | | | | x | x | x | | x | | | | | |
| 265 | G268 | Has your country or organization created a database of possible sources of financing for R&D? If so, please describe it. [7.3.9] | 7.3.9 | Action | D | L1/O | 19 | 40(7.1) c | x | x | | | | | | | | | | | | | | |
| 266 | G269 | To what extent has your country or organization documented and disseminated the best (good) practices in public-private and product development partnerships? Please describe your efforts. [7.4.3] | 7.4.3 | Action | D | L2/O | 19 | 40(7.2) a | x | x | | | | | | x | x | | | x | | | | |
| 267 | G270 | To what extent has your country or organization developed tools during 2008-2009 for periodic assessment of performance of public-private and product development partnerships? Please comment on their effects. [7.4.4] | 7.4.4 | Action | D, C | L2/L1 0 | 19 | 40(7.2) b | x | x | x | | | | x | x | x | | | x | | | | |
| 268 | G271 | To what extent has your country or organization supported public-private and product development partnerships in (other) developing countries? Please describe your efforts and comment on their effects. [7.4.5] | 7.4.5 | Action | D, C | L2/L1 0 | 19 | 40(7.2) c | x | x | x | x | | | x | x | x | | x | | | | | |
| 269 | G272 | Has your organization or country supported other appropriate research and development initiatives in (other) developing countries? If so, which? [7.4.6] | 7.4.6 | Action | D | L1/O | 19 | 40(7.2) c | x | x | x | x | | | x | x | x | | x | | | | | |
| 270 | G273 | Has your country or organization, during 2008-2010, submitted reports of expert working group on R&D and financing? Please list them. [7.1.1] | 7.1.1 | Indicator | D | L1/O | 35 | Ind 1st bullet | | x | x | x | x | x | x | x | | | | x | x | x | x | x |

²⁸ Footnote: Please find the resolution here: http://www.wpro.who.int/health_research/policy_documents/ministerial_summit_on_health_research_may2005.pdf

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|-------|-----------------|--|-------------|-------|----------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 271 | G274 | How many new sustainable financing initiatives, including public–private initiatives, has your country or organization created? Please list them. [7.1.2] | 7.1.2 | Indicator | D | L3/O | 35 | Ind 2nd bullet | | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 272 | G275 | To which extent has the sustainable health-related R&D funding increased during 2008-2015? Please elaborate. [7.1.3] | 7.1.3 | Indicator | D | L2/O | 35 | Ind 3rd bullet | | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 273 | G276 | To what extent has your country or organization secured adequate financing for R&D in order to address the health needs of (other) developing countries? If so, please describe your approach. [7.3.1] | 7.3.1 | Sub-element | D | L2/O | 18 | 40(7.1) | x | x | x | | | | x | x | | | | | | | | |
| 274 | G277 | To what extent has your country or organization improved coordination of the use of R&D financing in order to address the health needs of (other) developing countries? [7.3.2] | 7.3.2 | Sub-element | D | L2/O | 18 | 40(7.1) | x | x | x | | | | x | x | | | | x | | | | |
| 275 | G278 | To what extent has your country or organization facilitated the maximum use of existing financing in order to develop and deliver safe, effective and affordable health products and medical devices? Please describe your efforts. [7.4.1] | 7.4.1 | Sub-element | D | L2/O | 19 | 40(7.2) | x | x | x | x | | | x | x | | | | x | | | | |
| 276 | G279 | To what extent has your country or organization used financing through public– private and product development partnerships to develop and deliver safe, effective and affordable health products and medical devices? Please describe your efforts. [7.4.2] | 7.4.2 | Sub-element | D | L2/O | 19 | 40(7.2) | x | x | x | x | | | x | x | | | | x | | | | |
| 277 | G280 | To what extent has your country secured further funding on a sustainable basis to support a long-term R&D effort for products to meet the health needs of (other) developing countries? Please describe your efforts. [7.2.1] | 7.2.1 | Statement | D | L2/O | 18 | 38 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|---|------|---|-------|-----------------|--|-------------|-------|--------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 278 | G281 | Has your country identified and analysed the most serious gaps in financing for health products and R&D to meet the health needs of (other) developing countries? Please share how and with what effects. [7.2.2] | 7.2.2 | Statement | C | L10 | 18 | 38 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 279 | G282 | To what extent has your organization or country made maximum use of, or complemented the current initiatives – by contributing to the flow of resources into innovation and implementation? Please comment on their effects. [7.2.3] | 7.2.3 | Statement | C | L10 | 18 | 39 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 280 | G283 | In summary, to what extent have sustainable financing mechanisms been promoted? [7] | 7 | Element | D | L2 | | | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 281 | G284 | Please elaborate in respect to the sustainable financing mechanisms [7] | 7 | Open | D | O | | | | | | | | | | | | | | | | | | |
| ELEMENT 8: ESTABLISHING MONI-TORING AND REPORTING SYSTEMS | | | | | | | | | | | | | | | | | | | | | | | | |
| 282 | H285 | To what extent has your country or organization, during 2009-2015, established systems to monitor performance and progress of the implementation of each element of the global strategy and plan of action? Please describe your efforts. [8.2.3] | 8.2.3 | Action | D | L2/O | 19 | 42(8.1) a | x | x | | | | | | | | | | | | | | |
| 283 | H286 | To what extent has your country or organization, during 2009-2015, monitored and reported periodically to WHO's governing bodies on the gaps and needs related to health products and medical devices in your country? Please list the reports. [8.2.4] | 8.2.4 | Action | D | L2/O | 19 | 42(8.1) b | x | x | | | | | | | | | | | | | | |
| 284 | H287 | To what extent has your country or organization monitored the impact of Intellectual Property rights on the development of, and access to, health care products, during 2009-2015? If so, please explain how. [8.2.5] | 8.2.5 | Action | D | L2/O | 19 | 42(8.1) c | x | x | | | | | | | | | | | x | x | | |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|-------|-----------------|--|-------------|-------|-------------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 285 | H288 | To what extent has your country or organization reported on the impact of Intellectual Property rights on the development of, and access to, health care products, to the Health Assembly, during 2009-2015? If so, please list the reports. [8.2.6] | 8.2.6 | Action | D | L2/O | 19 | 42(8.1) c | x | x | | | | | | | | | | | x | x | | |
| 286 | H289 | To what extent has your country or organization monitored and reported on the impact of incentive mechanisms on innovation of health products and medical devices, during 2009-2015? If so, please list the reports. [8.2.7] | 8.2.7 | Action | D | L2/O | 19 | 42(8.1) d | x | x | | | | | | | | | | | x | x | | |
| 287 | H290 | To what extent has your country or organization monitored and reported on the impact of incentive mechanisms on access to health products and medical devices, during 2009-2015? If so, please list the reports. [8.2.8] | 8.2.8 | Action | D | L2/O | 19 | 42(8.1) d | x | x | | | | | | | | | | | x | x | | |
| 288 | H291 | To what extent has your country or organization monitored and reported on investment in research and development to address the health needs of (other) developing countries, during 2009-2015? If so, please list the reports. [8.2.9] | 8.2.9 | Action | D | L2/O | 19 | 42(8.1) e | x | x | | | | | | | | | | | | | | |
| 289 | H292 | Has your country reported regularly on progress towards the implementation of the strategy during 2009-2015? Please list the titles of these reports. [8.1.1] | 8.1.1 | Indicator | D | L1/O | 36 | Ind 1st bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 290 | H293 | To what extent has your country or organization created new or strengthened existing initiatives at national level to promote the implementation of the strategy, during 2009-2015? Please describe your efforts and indicate the effects. [8.1.2] | 8.1.2 | Indicator | C | L10 | 36 | Ind 2nd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 291 | H294 | To what extent has your country or organization created new or strengthened existing initiatives at regional level to promote the implementation of the strategy, during 2009-2015? Please describe your efforts and indicate the effects. [8.1.3] | 8.1.3 | Indicator | C | L10 | 36 | Ind 2nd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |

| Q# | SRV# | QUESTIONS | Node | Question source | C = Cause & Effect D= Descriptive N= Normative | Answer type | Page# | Section | WHO | Government | Civil Society | NGOs | Regulatory | Regional | Health & Private | National R&D | International R&D | Donor agencies | Dev Partners | Partnerships | WIPO | WTO | OECD | UNCTAD |
|-----|------|--|-------|-----------------|--|-------------|-------|----------------|-----|------------|---------------|------|------------|----------|------------------|--------------|-------------------|----------------|--------------|--------------|------|-----|------|--------|
| 292 | H295 | To what extent has your country or organization created new or strengthened existing initiatives at global level to promote the implementation of the strategy, during 2009-2015? Please describe your efforts and their effects [8.1.4] | 8.1.4 | Indicator | C | L10 | 36 | Ind 2nd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 293 | H296 | Has your country or organization submitted reports on the compliance with Element 8, during 2009-2015? Please list the titles of these reports. [8.1.5] | 8.1.5 | Indicator | D | L1/O | 36 | Ind 3rd bullet | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 294 | H297 | To what extent has your country or organization measured performance and progress towards objectives contained in the strategy and plan of action, during 2009-2015? Please explain. [8.2.2] | 8.2.2 | Sub-element | D | L2/O | 19 | 42(8.1) | x | x | | | | x | | | | | | | x | x | | |
| 295 | H298 | Has your country or organization been subject to comprehensive evaluation of the strategy, during 2009-2015? Please explain. [8.2.1] | 8.2.1 | Statement | D | L1/O | 19 | 41 | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 296 | H299 | In summary, to what extent have monitoring and reporting systems been established? [8] | 8 | Element | D | L2 | | | x | x | x | x | x | x | x | x | | | | x | x | x | x | x |
| 297 | H300 | Please elaborate on the established monitoring and reporting systems. [8] | 8 | Open | D | O | | | | | | | | | | | | | | | | | | |
| 298 | H301 | Do you have any other information you wish to contribute? [L] | L | | | | | | x | x | x | x | x | x | x | x | x | x | x | x | | | | |